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Abstract
Foot-and-mouth disease (FMD) is caused by the foot-and-mouth disease virus
(FMDV), genus Aphthovirus, family Picornaviridae. It is a highly contagious disease
of cloven-hoofed animals, has a worldwide distribution and plays an important role in
the limitation of international trade in livestock and livestock products.
The main objectives of this project were to provide an accurate quantitative
description, and develop a mathematical model, of FMDV dynamics in infected pigs.
Time-course studies were set up and the viral load in serum, nasal swabs and tissue
samples were determined. Time after infection, mode of infection, inoculation dose
and housing conditions were examined as possible determinants of viral load.
Similar results were obtained from pigs infected with FMDV by the intravenous,
intradermal or oro-nasal route, i) A strong relationship between inoculation dose and
incubation period of FMDV was evident: the higher the inoculation dose, the shorter
the incubation period, and vice versa, ii) The higher the inoculation dose, the more
predictable and consistent was the incubation period and time-course of infection. The
lower the inoculation dose, the more variable was the incubation period and the
probability of subclinical infections, iii) Housing pigs in a group (rather than
individually) resulted in synchronous infections and reduced the variance in the
incubation period.
Initial models of the early viral dynamics of FMDV disagreed with the experimental
data. Experimental data showed larger effects of dose on the temporal distribution of
viraemia than was predicted by the models. This disagreement could be resolved by:
i) limiting the rate of infection of epithelial cells at low FMDV concentrations; ii)
converting the virus removal system (such as the mononuclear phagocyte system) into
one of limited capacity; or iii) the addition of a virus removal system of limited
capacity, such as non-specific binding ofFMDV into the models.
A hypothesis in which the rate of infection of epithelial cells was limited at low
FMDV concentration could be supported by the literature. For FMDV to successfully
infect and replicate within a cell, host protein synthesis has to be inhibited and anti¬
viral defences inactivated. The probability of a successful infection of a cell increases
as the number of infecting viruses increases, suggesting that the rate of infection of
cells at low FMDV concentrations is indeed limited.
The experimental work has highlighted the strong relationship between inoculation
dose and dynamics of FMDV in vivo and the modelling exercise has highlighted
important determinants of viral dynamics, as well as areas where further research
should be directed. This has lead to a deeper understanding of the dynamics of, not
only FMDV, but virus infections in general.
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biodegradable. But householders in Cardiff, having drunk deep of the
recycling message, have been ordered to keep their used teabags well
away from the city council's compost collections.
An EU directive of the straight banana variety has obliged officials
in the city of Cardiff to classify the teabag, a simple assembly of
paper and dried leaves, as an animal by-product, and therefore the
potential source of a future foot-and-mouth outbreak.
The reason, according to the EU's Animal By-Products Order 1999, is
that teabags, and indeed used coffee filters, could have come into
contact with contaminated milk."
Alan Hamilton, Sunday Times (UK) , January 7th, 2005
Introduction Chapter 1
1.1. Literature review
Foot-and-mouth disease (FMD) affects wild and domestic cloven-hoofed animals and
is caused by the foot-and-mouth disease virus (FMDV), genus Aphthovirus (which it
shares with equine rhinitis A virus), family Picornaviridae (Belsham, 1993; van
Regenmortel et al., 2000). The disease has a worldwide distribution with an endemic,
sporadic or epidemic occurrence.
FMD is one of the most contagious diseases of animals, as a result of the wide host
range affected, the numerous routes of infection, the small amounts needed to infect
animals, the rapid replication of the virus within its host and the large quantities of
virus excreted by infected animals (Alexandersen et al., 2001; Alexandersen et al.,
2003a).
FMD plays an important role in the limitation of international trade in livestock and
livestock products (Alexandersen et al., 2003a). In addition, the cost of eradication
may be enormous. The FMD outbreak in the United Kingdom in 2001 was estimated
to have incurred losses of £3.1 billion to the agricultural sector and the food chain,
with a similar amount lost by the tourism industry (Thompson et al., 2002), while the
total economic cost to Taiwan's pig industry after a FMD outbreak in 1997 was
estimated to be about US$1.6 billion (Yang et al., 1999). Worldwide sales of FMD
vaccines represent a major cost to the livestock industry, e.g. US$284 million in 2000
(Gay et al., 2002).
1.1.1. History of FMDV
FMD is one of the most important diseases of livestock, with a significant economic
impact and a worldwide distribution. The first possible reference to FMD was in 1514
(Fracastorius, 1546) - when herdsmen looked into the mouths of cattle they saw 'a
sort of roughness and small pustules on the palate and the whole mouth, and the
infected animal had to be removed at once from the herd, or the whole herd became
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infected. Gradually this distemper descended to the shoulders and thence to the
feet...' (translated in Wright, 1930).
In 1780, 'klowsiekte', a disease of cattle was described, which 'attacked the feet of
oxen causing them to swell prodigiously, and often producing suppuration; sometimes
the hoofs dropped off. It was not attended with any danger and generally terminated
within a fortnight' (Le Vaillant, 1795, in Thomson, 1994). There were no other
references to FMD until the first appearance of the disease in England in August
1839, at Stratford, near London (Anonymous, 1884). Subsequently, RG Cumming,
while travelling through South Africa, made reference to a 'tongue or hoof sickness'
that affected his oxen. His oxen 'had been looking very spare, and fallen off in
condition', with many suffering from lameness. The disease was known amongst the
Hottentots, who had said that an ox required months to recover from the disease and
that the disease was often fatal (Cumming, 1850).
During the latter half of the 19th century, there was more awareness of the disease
with numerous reports in the literature. Research into the disease had started when
FMDV was the first animal agent discovered that was small enough to pass through
Berkfeld filters. It was concluded that the agent was beyond the resolution of light
microscopy (Loeffler & Frosch, 1898).
In the following 25 years, the epidemiological characteristics of FMD were
established. The disease spread rapidly, most frequently through animal-to-animal
contact, but also indirectly through the movement of farm products and people
(Brooksby, 1982).
It was soon observed that cattle that had recovered from FMD were resistant to the
disease. Occasionally, this was not the case, and the problem was solved when the
first two immunological types of FMDV were discovered (Vallee & Carre, 1922). The
serotype prevalent in France was designated type O as it originated from the Oise
valley. The virus that reinfected type O recovered animal was called type A, for
Allemand, as it had come from East Prussia, Germany (Vallee & Carre, 1928). A third
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type was discovered soon afterwards (Waldmann & Trautwein, 1926). It was named
type C, as the authors wanted to rename the serotypes A, B and C. The Southern
African Territories (SAT) 1, 2 and 3 serotypes were classified in 1948 by the British
Animal Virus Research Institute (Cottral & Gailiunas, 1971; Brooksby, 1982). The
final serotype, Asia 1 was typed from a sample from Pakistan in 1954, so-named as
the British Laboratory anticipated further types to be discovered in the region
(Brooksby & Rogers, 1957).
1.1.2. Physical characteristics of FMDV
FMDV virions are spherical in shape (icosahedral symmetry), have a diameter of
around 25-30 nm and are composed of a protein shell (capsid) surrounding the naked
RNA (Knipe et al., 2001). The capsid is formed of 60 protomers and each protomer is
composed of four capsid proteins VP1, VP2, VP3 & VP4 (Wild et al., 1969). The
external capsid surface is made up from VP1-VP3, while VP4 is buried within the
virion.
FMDV is insensitive to organic solvents, as the virus lacks a lipid envelope. The virus
(like rhinovirus) is acid-labile (< pH 6.8) (Randrup, 1954), which is in contrast to
other genera (viz. cardio-, entero-, hepato- and parechovirus) in the same family. The
difference in pH stability is reflected in the different sites of replication for the viruses
- FMDV and rhinovirus replicate in the upper respiratory tract and do not need to pass
through the gastric intestinal tract (Knipe et al., 2001).
1.1.3. Molecular characteristics of FMDV
This topic has been reviewed by Belsham (1993), Mason et al. (2003) and Belsham &
Martinez-Salas (2004).
Contained within each FMDV particle is a single, positive sense RNA genome
approximately 8400 nucleotides in length (Forss et al., 1984; Zibert et al., 1990). The
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genome contains a single open reading frame with a poly(A) tail at the 3' terminus
and an untranslated region (UTR) at the 5' terminus. FMDV genomes do not contain
the 5' 7-methyl-G cap structures that are critical for translation of cellular mRNA.
Instead, a small virus encoded protein, VPg, is covalently attached to the 5' UTR
(Figure 1.1).
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Figure 1.1 Genome organization of FMDV (reproduced from Belsham & Martinez-Salas,
2004)). The genome contains a 5' untranslated region (UTR), a single open reading frame
that encodes a polyprotein which is co-translationally cleaved by viral proteases into the
products indicated, and a 3' UTR.
The genome functions as mRNA and encodes a viral polyprotein that is co-
translationally processed by virus encoded proteases into 15 mature proteins (Belsham
& Martinez-Salas, 2004). The genome also functions as a template for RNA
replication: negative strand viral RNA is produced from the positive strand RNA
template and used to generate numerous copies of positive strand RNA's, which are
packaged into viral capsids to give rise to a new generation of infectious virus
particles.
The FMDV genome is infectious and no viral proteins are required to initiate the
replication cycle. Replication takes place in the cytoplasm of cells (Follett et al.,
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1975) and begins with the translation of viral proteins which are needed for the
formation of the viral replication complex and the viral capsid. At some stage, there
appears to be a block in translation and a switch to viral replication. Replication
involves various viral proteins, such as RNA-dependent RNA polymerase (3Dpo1) and
VPg (3B), which acts as a primer for RNA synthesis.
1.1.3.1. FMDV5' UTR
The 5' UTR of the FMDV RNA is about 1300 nt in length and can be considered to
be composed of various regions (Figure 1.1). From the 5' end, these are the S-
fragment, a poly(C) tract, several pseudoknots, the cA-acting replication element (ere)
and the internal ribosomal entry site (IRES) (Belsham & Martinez-Salas, 2004).
The S-fragment is about 360 nt in length and is predicted to form a large hairpin
structure (Clarke el a/., 1987; Escarmis et a/., 1992; Witwer et al, 2001). The
function of the S-fragment has not been characterised, but it may facilitate replication
and/or translation, play a role in the switch from translation to replication or protect
the RNA from degradation (Belsham & Martinez-Salas, 2004).
The poly(C) tract of FMDV may, through a predicted association with Cellular
Poly(C) Binding Protein (PCBP), play a role in genome circularization and the switch
from translation to replication (Barton et al., 2001; Herold & Andino, 2001).
The ere (McKnight & Lemon, 1996; Mason et al., 2002) serves as the template for
3Dpol-mediated uridylylation of 3B (Paul et al., 2000; Ricder et al., 2000), a critical
step in RNA replication, since the pUpU-3B serves as the primer for RNA synthesis.
In FMDV, it appears that the ere can be complemented in trans and that this element
should rather be called a 3B-uridylylation site (BUS) (Tiley et al., 2003).
The IRES of FMDV is a highly structured region that initiates translation through a
cap-independent mechanism (Belsham & Brangwyn, 1990; Kuhn et al., 1990;
Martinez-Salas et al., 1993). In contrast, eukaryotic mRNA translation is cap-
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dependent and depends on the recognition of the 7-methyl-G cap structure at the 5'-
end of the mRNA and the initiation factor eIF4F (composed of eIF4E, eIF3 and
eIF4G) (Prevot et al., 2003).
The IRES is important as it provides an alternative to cap-dependent translation and a
mechanism for FMDV to inhibit host protein synthesis and switch the cell's
translational capacity from cellular to viral protein synthesis. The mechanism involves
the cleavage of the translation initiation factor eIF4G by the leader (or L) (Devaney et
al., 1988; Medina et al., 1993) and 3C protease (Belsham et al., 2000) of FMDV.
With capped mRNA, eIF4G serves as a bridge between the mRNA and the small
ribosomal subunit. Intact eIF4G is not necessary for IRES-mediated translation and a
cleaved portion of eIF4G maintains its activity in recruiting IRES-containing mRNA
to the small ribosomal subunit. The result is that cap-dependent translation is
inactivated while cap-independent translation is not.
1.1.3.2. FMDVpolyprotein
The FMDV polyprotein is encoded by a region of approximately 7 000 nt but is never
observed as it is co-translationally cleaved by virus-encoded proteases into various
precursors or products, such as the leader protease, the capsid precursor P1-2A, the P2
proteins and the P3 proteins (Figure 1.1).
Two distinct forms of the leader protease (Lab and Lb) are produced due to the
presence of two separate initiation codons 84 nt apart (Sangar et al., 1987). It appears
that the FMDV IRES may direct ribosome attachment either up or downstream of the
Lab initiation site. Ribosomes that attach upstream of the Lab initiation site may fail
to recognise the Lab initiation site and are able to scan along the RNA until the Lb
initiation site is reached, whereas ribosome that attach downstream of the Lab
initiation site initiate translation at the Lb site (Belsham & Martinez-Salas, 2004).
The L protein is a protease that has been shown to cleave the L/Pl junction, induce
cleavage of the translation initiation factor eIF4G (that results in the inhibition of host
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protein synthesis) (Devaney et al., 1988; Medina et a/., 1993) and stimulate the
activity of certain picornavirus IRES elements (Borrnan et al., 1997; Roberts et al.,
1998; Hinton et al., 2002). The primary advantage for FMDV to inhibit host protein
synthesis may be that the ability of the cell to mount an anti-viral response is
diminished. Interferon production is induced within FMDV-infected cells, but these
interferons are suppressed by FMDV leader protease (Sellers, 1963; Chinsangaram et
al., 1999; Zhang et al., 2002). Interferons trigger various responses within a cell,
including the activation of the dsRNA-activated protein kinase PK.R (Kaufman,
2000). This kinase phosphorylates the a-subunit of eIF2 and hence blocks the
initiation step of both host and viral protein synthesis, to the obvious detriment of
FMDV.
The capsid precursor P1-2A is cleaved by the 3C protease into 1AB, 1C and ID (the
viral capsid precursors VP1, VP2, VP3 and VP4). The 2A sequence 'cleaves' the
linkage between 2A and 2B through a translational effect (Donnelly et al., 2001; Ryan
et al., 2002). One copy of 1AB, 1C and ID form a protomer, five protomers assemble
into a pentamer and twelve pentamers can assemble into an RNA-containing particle,
called a provirion (Guttman & Baltimore, 1977), or an empty capsid lacking the RNA
genome (Grubman et al., 1985). A mature virion is formed when 1AB is cleaved by
an unknown mechanism and in the presence of viral RNA into 1A and IB.
The P2 precursor is processed to 2B and 2C by the 3C protease. The functions of
these proteins are poorly understood but have been implicated in virus-induced
cytopathic effects (Mason et al., 2003).
The P3 precursor is processed by the 3C protease to 3A, three copies of the 3B
peptide (VPg), the 3C protease and the 3D RNA-dependent, RNA polymerase:
• It is thought that the 3A protein serves to localise the FMDV RNA to membrane
vesicles and also plays a role in delivering the 3B protein to sites of RNA
replication (Bienz et al., 1983; 1987).
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• The FMDV RNA encodes three copies of 3B (VPg). VPg is covalently linked to
the 5'-terminal of the FMDV genome and may play a role in priming RNA
synthesis. There appears to be a strong selective pressure to maintain three copies
of the protein, as this redundancy may be related to the pathogenic potential and
broad host range of FMDV (Mason et al., 2003).
• The 3C protease is responsible for most of the cleavages within the polyprotein. In
addition, it can also cleave host proteins, such as histone H3 (Falk et al., 1990)
and the translation initiation factors elF4A and elF4GI (Belsham et al., 2000).
1.1.3.3. FMDV3' UTR
The 3' UTR of FMDV is composed of two regions: a heterogeneous sequence and the
poly(A) tail. The heterogeneous sequence may play a role in infectivity (Saiz et al.,
2001) and has been shown to stimulate IRES activity (Lopez de Quinto et al., 2002),
indicating possible RNA-RNA or RNA-protein 'bridging' interactions between the 5'
and 3' UTR's. Unlike cellular mRNAs, where the poly(A) tract is added post-
transcriptionally, the poly(A) tract of picornaviruses is encoded by the genome
(Dorsch-Hasler et al., 1975). The length of the poly(A) tract may be important for
RNA stability or for a possible interaction between the 3' and 5' termini of the RNA
(Belsham & Martinez-Salas, 2004). In poliovirus, which is closely related to FMDV,
the length of the poly(A) tail was shown to affect the infectivity of the virus (Spector
& Baltimore, 1974).
1.1.4. FMDV pathogenesis
The pathogenesis of FMDV has been reviewed by Alexandersen et al., (2003a) and
described in cattle (Burrows et al., 1981; Brown et al., 1992; Hofner, 1995), sheep
(Alexandersen et al., 2002c) and pigs (Donaldson et al., 1970; Terpstra, 1972; Brown
et al., 1995; Alexandersen et al., 2001).
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1.1.4.1. Routes of infection & minimum infectious dose
Animals can be infected by various natural routes, such as the oral (e.g. ingestion of
virus in food products such as swill), respiratory (e.g. aerosol infection) and
intradermal (e.g. infection through cuts, scratches or bites) route, or via fomites (an
inanimate object that can transmit infectious agents from one person/animal to
another). Experimental routes of infection include subcutaneous (Henderson, 1952;
Graves & Cunliffe, 1960), intradermal (Henderson, 1949; 1952; Burrows, 1966),
intramuscular (Cottral et at, 1966; Donaldson et al., 1984) and intravenous
inoculation (Quan et al., 2004), intranasal (McVicar & Sutmoller, 1976; Hughes et
al., 2002a) and conjunctival (Sutmoller & McVicar, 1973) instillation, and exposure
to artificially created aerosols (McVicar & Eisner, 1983).
The respiratory tract is the usual route of infection in species other than pigs
(Alexandersen et al., 2003a). Cattle and sheep have been infected experimentally with
as little as 10 TCID50 (Gibson & Donaldson, 1986; Donaldson et al., 1987) and under
natural conditions, as far as 270 km away from a source of FMDV (Gloster et at,
1982) under exceptional circumstances. Pigs are very resistant to aerosol infection and
may need more than 1 000 TCID50 (Alexandersen & Donaldson, 2001; Donaldson &
Alexandersen, 2001; Alexandersen et al., 2002a; Alexandersen & Donaldson, 2002;
Alexandersen et al., 2002c) delivered at a high concentration (Alexandersen et at,
2003a) to be infected. Although pigs are resistant to aerosol infection, they play an
important role in the airborne spread of FMDV as they excrete up to 3 000 times more
virus than cattle or sheep (Donaldson et al., 1970; Donaldson, 1983; Alexandersen et
al., 2002a; Alexandersen & Donaldson, 2002). Cattle and sheep, on the other hand,
excrete relatively low quantities of the virus, but are very sensitive to aerosol infection
(Gibson & Donaldson, 1986; Donaldson et al., 1987; Alexandersen et al., 2002c).
The intradermal route is the most reliable route of infection (Bedson et at, 1925;
Aramburu, 1949; Henderson, 1952; Alexandersen et at, 2003a) and as little as 100
TCID50 may initiate an infection (Alexandersen et al., 2003a). By comparison, the
subcutaneous route has been reported to require the same amount of virus to 250 000
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times more, and the intravenous route 600 times more than the intradermal route to
establish an infection (Henderson, 1952). Animals are relatively insensitive to
infection by the oral route, requiring about 104 - 105 (in pigs) or 10^ - 106 (in
ruminants) TCIDso (Sellers, 1971). For the intranasal and intramuscular route, the
minimum infectious dose is lower: 104 to 105 TC1D?0 (McVicar & Sutmoller, 1976;
Burrows et al., 1981; Donaldson et al., 1984).
1.1.4.2. Sites ofprimary infection
In domestic animals infected with FMDV by the aerosol or oral route, the pharynx, in
particular the dorsal naso-pharynx and dorsal surface of the soft palate, is a
predilection site of primary infection (Garland, 1974; McVicar & Sutmoller, 1976;
Burrows et al., 1981; Zhang & Kitching, 2000; Alexandersen et al., 2001;
Oleksiewicz et al., 2001), as the epithelium in this area is non-cornified and contains
live cells throughout its cross-section. In contrast, the rest of the respiratory tract
consists of respiratory or cornified stratified squamous epithelium that does not appear
to be susceptible to infection (Alexandersen et al., 2003a). In animals infected by
direct inoculation in the skin (through bites or scratches for example), FMDV
replication takes place at the site of entry and from there spreads to regional lymph
nodes and then to the general circulation.
1.1.4.3. Dissemination and replication ofFMDV
Dissemination of the virus to the rest of the body is thought to occur via the lymphatic
and circulatory system (Burrows et al., 1981; Alexandersen et at, 2001). Replication
of FMDV takes place within cornified stratified squamous epithelia of the skin and
mouth, and in the myocardium of young animals, but not in lymphoid tissue (Cottral
et al., 1963; Alexandersen et al., 2002b). It has been suggested that precursors of
Langerhans cells might play a role in the transport of virus from the circulatory
system to predilection sites, such as epithelium (di Girolamo et al., 1985). FMDV
infects epithelial cells by binding to integrin receptors on the cell surface (Berinstein
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et al., 1995; Neff et al., 1998; Jackson et a/., 2000; Jackson et al., 2002; Jackson et
ah, 2004). The integrins recognise the Arg-Gly-Asp (RGD) sequence found in the
G-H loop (ID) of FMDV (Pierschbacher & Ruoslahti, 1984; Mason et al., 1994;
McKenna et al., 1995; Leippert et ah, 1997).
Infected cells undergo ballooning degeneration and show increased eosiniphilic
staining (Alexandersen et ah, 2003a). Bullae develop by lysis of swollen cells and the
release of intracellular fluid, or by the formation of areas of focal intercellular oedema
(Yilma, 1980) and this is followed by mononuclear cell and granulocyte infiltration.
1.1.4.4. FMDV excretion and clearance
FMDV may be detected in nasal and mouth swabs before the development of clinical
signs or onset of viraemia (Garland, 1974; Alexandersen et ah, 2003c), although all
secretions and excretions may contain FMDV during the course of the disease
(Alexandersen et ah, 2003a). The maximum amount of FMDV is excreted in the
breath of sheep before the detection of clinical signs, while in pigs and cattle this
occurs about 2 days after the onset of clinical signs (Sellers & Parker, 1969;
Donaldson et ah, 2001; Alexandersen et ah, 2002c).
Immunity to FMDV is mediated primarily by the humoral immune response
(McCullough & Sobrino, 2004) and circulating antibodies can be detected from 3 to 4
days after the onset of clinical signs and (Alexandersen et ah, 2003a). The virus is
cleared rapidly from the circulation and at a slower rate from more peripheral sites,
such as the pharynx and skin, by the immune system. In some cases virus may not be
cleared from the pharynx with the result that up to 50% of ruminants become carrier
animals (van Bekkum et ah, 1959; Zhang & Kitching, 2001; Alexandersen et ah,
2002b). Carrier animals are defined as an animal in which virus can be detected in
oesophageal-pharyngeal fluid for at least 28 days after exposure to FMDV (Sutmoller
et al., 1968). The carrier state has not been demonstrated in pigs and FMDV is cleared
within 3-4 weeks (Alexandersen et ah, 2003a).
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1.1.5. Clinical signs in pigs
Clinical disease in pigs infected with FMDV is usually severe. The first clinical signs
are non-specific in nature and include depression, anorexia and fever. This is followed
by lameness and feet may be warm to the touch 1-2 days before the appearance of
vesicular lesions. Lesions develop in areas affected by persistent local irritation or
friction (Thomson, 1994), such as the coronary band of the digits (Figure 1.2a and b),
interdigital space, pressure points (such as the knees and hocks), snout, buccal mucosa
(Figure 1.2c), tongue and teats (in suckling animals or dairy cows in lactation). In
severely affected pigs, the hooves may slough off ("thimbling") (Figure 1.2d),
exposing the corium. Lesions are visible as blanched areas of epithelium, which fill up
with clear fluid to become vesicles. The vesicles rupture within a few days to leave
exposed, red erosions that are susceptible to secondary bacterial infection. Wound
healing is by secondary intention.
Mortality in adults is generally low, but can be high in young piglets. Piglets may die
without developing vesicles and deaths in these animals may be the first indication
that a herd is infected (Donaldson et al., 1984). Death is attributed to severe, acute
necrotising myocarditis, which may present as marcroscopic yellow streaks in the
myocardium and is commonly referred to as "tiger heart" (Figure 1.2e).
1.1.6. Mathematical modelling
The development ofmathematical models to describe the spread of infectious diseases
(Anderson & May, 1991) has united what used to be two distinct disciplines:
mathematical and biological sciences. Models were first developed to describe and
understand human diseases but have since been applied to various animal diseases
(Hudson et al., 2001).
An advantage of modelling infectious diseases is that diseases have inherently





Figure 1.2 Clincal signs of FMDV in pigs: a) multifocal vesicles in buccal mucosa; b) and c)
foot lesions; d) sloughing of hoof and e) tiger heart.
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rules. These rules constitute a theory which provides a logical link between
assumption and conclusion. This clarifies thinking and allows for the formulation and
testing of hypotheses.
1.1.6.1. FMDV in the atmosphere
Models that describe the spread of FMDV plumes through the atmosphere have been
examined (Gloster et at, 1981; Donaldson et at, 1982; Baldock, 1993; Durand &
Mahul, 1999; Sorensen et at, 2000; Sorensen et at, 2001; Gloster et al., 2003;
Gloster & Alexandersen, 2004). These models use meteorological data to predict the
direction, distance and extent of a plume of FMDV excreted by infected animals into
the atmosphere.
1.1.6.2. FMDV in populations
Models to describe the spread of FMDV in a population of animals/herds may be
deterministic or stochastic. Deterministic models generate a single set of results for a
given set of parameters (Haydon et al., 1997; Durand & Mahul, 1999; Ferguson et al.,
2001a; b; Gerbier et al., 2002; Dexter, 2003) while stochastic model incorporate
chance into the models and therefore generate numerous results for a given set of
parameters (Garner & Lack, 1995; Keeling et al., 2001; Morris et al., 2001; Bates et
al., 2003; Schoenbaum & Terry Disney, 2003; Carpenter et al., 2004).
All of the state-transition models referred to in the previous paragraph make use of
some form of a Susceptible, Latent, Infected and infectious, Recovered (SL1R) model,
in which all animals or herds in a population belong to one state (e.g. Susceptible) and
move from one state to the other (e.g. from Susceptible to Latent) at certain rates.
These models have been very useful to describe microparasite infections (Anderson &




One assumption is that all the animals in a certain state, e.g. Infected, are regarded as
a homogenous group, i.e. all the animals in the Latent group are latent for the same
period, or animals in the Infected state are equally infectious. This is an over¬
simplification as latency (or incubation period) has been shown to be strongly
dependent on the inoculation dose (McVicar & Sutmoller, 1976; Sutmoller &
McVicar, 1976; French et a/., 2002; Hughes et al., 2002a) and for FMDV can vary
from 1 to 14 days (Alexandersen et al., 2003a). Infectiousness of an animal is not
constant over time, but rather increases over the course of the infection, peaks and
then decrease as an adaptive immune response is mounted. Not only is infectiousness
not constant over time, but the amount of FMDV excreted by a pig can vary over six
orders ofmagnitude (Donaldson et al., 2001; Alexandersen & Donaldson, 2002).
In many models, the epidemiological unit of interest is a farm, rather than the
individual animal (Garner & Lack, 1995; Durand & Mahul, 1999; Keeling et al,
2001; Gerbier et al., 2002; Bates et al., 2003; Schoenbaum & Terry Disney, 2003).
Similar to the reason mentioned above, farms in one state are considered as a
homogenous group, which may be regarded as an over-simplification. For example, a
farm in which one animal on it is infected is considered as infectious as a farm in
which all the animal on it are infected.
The other important components of models, apart from variables, are parameters.
Parameters describe the rate the variables change over time. The parameters in models
need to be estimated, either from experimental data, previous epidemics or from the
epidemic being modelled. It is important that the parameter values make biological
sense. Transmission experiments which have described the spread of FMD on a
temporal and spatial scale (Alexandersen & Donaldson, 2001; Donaldson &
Alexandersen, 2001; Aggarwal et al., 2002; Alexandersen et al., 2002a; Alexandersen
& Donaldson, 2002; Alexandersen et al., 2002c; Hughes et al., 2002b) have been
useful to estimate parameter values.
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1.1.6.3. FMDV in individual animals
Although models have been able to accurately describe the spread of FMDV in a
population (Ferguson et al., 2001b; Keeling et a/., 2001), there is room for refinement
and improvement of these models. An important area of FMDV dynamics that has
received little attention is the viral dynamics and a mathematical description of
FMDV within a host. Quantitative descriptions of FMD viraemia have been reported
(Cottral & Bachrach, 1968; Sutmoller & McVicar, 1976; Alexandersen et al, 2001;
Alexandersen et al., 2002c) and clearance of the virus from the circulation has been
studied (Sutmoller & McVicar, 1976). Dose-dependant studies (McVicar &
Sutmoller, 1976; Sutmoller & McVicar, 1976; French et al., 2002; Hughes et al.,
2002a) have looked at the relationship between virus dose and in vivo viral dynamics.
The focus of modelling within-host viral dynamics has been directed at diseases of
humans. Models of the viral dynamics (Nowak & Bangham, 1996; Bonhoeffer et al.,
1997) of human/simian immunodeficiency virus (Le Corfec et al., 2000; Nowak &
May, 2000), hepatitis B virus (Herz et al., 1996; Nowak et al., 1997; Nowak & May,
2000; Perelson, 2002) and human T-cell leukaemia virus (Wodarz et al., 1999) have
been described. These models have focussed on the chronic nature of these diseases,
as well as chemotherapeutic interventions.
In published reports of models that describe within-host viral dynamics, the life-cycle
of the described viruses takes place within the circulation or in organs closely
associated the circulation, i.e. there are no physical barriers between the circulation
and organ. No reports of models that describe the process of viral replication in organs
not closely associated with the circulation and hence the process of how a virus moves
from the circulation to the organ in which it replicates, have been published. On the
other hand, pharmacokinetic models to describe movement of drugs between different




In order to assess the infectiousness of animals, assumptions have to be made on the
amount of virus excreted by individual animals. General differences between species
have been reported (Donaldson et al., 1970), but relatively little on the determinants
of viral excretion in individual animals are known. Although previous studies have
reported on the pathogenesis of FMDV infection in pigs (Donaldson et al., 1970;
Terpstra, 1972; Brown et al., 1995; Alexandersen et al., 2001), a more thorough
understanding of the pathogenesis and kinetics of FMDV infection in individual
animals is warranted.
The two main objectives of this project are:
i) to provide an accurate quantitative description of FMDV infection in pigs, and
ii) develop a working quantitative model of FMDV infection in pigs.
Recent developments in quantitative RT-PCR (Alexandersen et al., 2001; Oleksiewicz
et al., 2001; Reid et al., 2001a; b; Alexandersen et al., 2002c; Reid et al., 2002;
Alexandersen et al., 2003c; Reid et al., 2003; Zhang & Alexandersen, 2003) have
made it possible to measure virus quantities directly. More established quantitative
methods, such as titration of samples in various laboratory animals (ID50) or tissue
culture systems (TCIDso), provide an indirect measurement of virus quantities. In
addition, many different laboratory animals and tissue culture systems have been used
in these assays, and this has made it difficult to quantitatively compare results from
different assays.
Modelling techniques will be used to fit a model to experimental data and
assumptions will initially have to be made. This should lead to testable hypotheses,
which will be tested experimentally and the results generated used to refine the model.
A working quantitative model of FMD infection in pigs will enable a virus production
model to be developed, which may be used for prediction of on-farm spread and
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subsequently temporal models of FMD spread. This will result is refinement of these
models, making for more accurate predictions of FMD spread in an epidemic.
1.3. Experimental approach
The experimental approach will be to obtain quantitative data from experiments,
construct a mathematical model of FMDV dynamics in vivo, compare the model to
the experimental data, formulate hypotheses if there are discrepancies between the
model and the data, and design experiments to test these hypotheses and refine the
model.
The determinants of viral load that will be looked at are:
• time after infection
• mode of infection
• housing conditions
• inoculation dose
Time-course studies will be set up, and the total viral load in serum, nasal swabs and
other tissues, such as epithelium will be determined by RT-PCR. Experiments
described in this thesis were not necessarily designed around the objectives of this
project. Samples were collected from experiments designed for related projects to
reduce the amount of animals used in experiment work.
1.4. Overview of thesis
Following on from a chapter detailing the materials and methods used in this thesis
(Chapter 2), quantitative data are presented: the first quantitative chapter describes the
distribution of FMDV in various tissues of pigs naturally infected with FMDV over
time (Chapter 3). The following three chapters (Chapters 4-6) explore how
inoculation dose and housing conditions influence the dynamics of FMDV in vivo,
such as the length of time between inoculation and i), the start of active viraemia or
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ii), onset of clinical signs. A different route of inoculation was used to infect the pigs
in each of these three chapters. These were the intravenous (Chapter 4), intradermal
(Chapter 5) and direct contact (Chapter 6) route of inoculation.
Mathematical modelling results are introduced by a chapter that details experimental
work used to calculate parameters used in the models (Chapter 7). This is followed by
a chapter that details these models (Chapter 8). Four different models are presented
and compared to experimental data of pigs inoculated by the intravenous route (taken
from Chapter 4).
The thesis concludes with how different routes of inoculation affect viral dynamics




General Materials & Methods
General materials and methods Chapter 2
2.1. Disease security
2.1.1. Animal Unit
Animal experimentation was performed under project licence PPL70/4997, the
Animals (Scientific Procedures) Act, 1986 (Home Office, UK).
Animals were housed in a category 4 bio-containment animal unit (Specified Animal
Pathogens Order, DEFRA 1998) consisting of five boxes in a row connected by a
"clean" corridor on one side and a "dirty" corridor on the other (Figure 2.1). The
entrance to any box was from the "clean" corridor through double doors with a
shower unit between the doors. Before leaving the box to go back to the clean
corridor, personnel disinfected outerwear with FAM R (Evans Vanodine International,
UK), followed by showering. There was no cross-contamination between the boxes as
the ventilation for each box was self-contained by high efficiency particulate air
(HEPA) filtration.
2.1.2. Laboratory
All laboratory work was carried out in a category 4 bio-containment laboratory
approved to handle live foot-and-mouth disease.
All procedures in the laboratory involving live virus was carried out in a laminar flow
hood (Microflow Class 11), while wearing polyvinyl chloride (PVC) proofed nylon
protective clothing. The hood, its contents and protective gear were all disinfected
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2.2. FMDVO UKG 34/01
Epithelial tissue was collected from a pig at Chealc Meats Abattoir, Brentwood, Essex
on 20th February 2001 (Alexandersen & Donaldson, 2002; Alexandersen et al., 2002;
Alexandersen et al., 2003b; Alexandersen et al., 2003c) and placed into sterile 50%
M25 phosphate buffer/glycerol (Appendix A). An inoculum was prepared from the
suspension by grinding up the epithelial tissue with a sterile pestle and mortar. Sterile
sand (BDH Laboratory Supplies, UK) was added to the mortar to aid maceration. The
mixture was centrifuged at 4 500 rpm for 10 min (Denley BR401 Refrigerated
Centrifuge; ThermoQuest, UK) and the supernatant diluted in M25 phosphate buffer
to make a 10% solution [ 107 2 TCID50 in primary bovine thyroid cells (BTY)/ml],
The inoculum was diluted in HEPES tissue culture medium (Appendix A) just before
use. After inoculation, the dilutions were tested by fluorogenic RT-PCR and viral
titration in BTY cells to confirm genome quantity and infectivity.
2.3. Clinical examination, sample collection
A subjective scoring system was used to evaluate the progression of disease in pigs
(Quan et al., 2004). Individual clinical signs were scored as follows: lameness, 1;
lesions on one foot, 1; lesions on two feet, 2; lesions on three feet, 3; lesions on four
feet, 4; lesions on tongue, mouth or snout, 1 . A pig with lesions on any foot other than
the one used for inoculation was taken to be lame. The individual scores were added
up and a pig could score a maximum of 6 points. The score was scaled to fit the
graphs on which it was plotted.
Serum samples were collected by venipuncture (anterior vena cava/brachiocephalic
vein) into plain serum tubes with no additive (Vacutainer™; Becton Dickinson, UK).
Nasal swabs were collected with cotton buds and placed in 2.0 ml screw cap micro
tubes (Sarstedt, Germany) containing 1 ml Trizol (Invitrogen, USA).
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If clinical disease in a pig was judged to be severe, the animal was humanely killed by
injection of an overdose of pentobarbitone (Merial Animal Health, France) followed
by exsanguination.
2.4. Quantitative measurement of viral genomes in
serum
This method has been described in Alexandersen et al. (2001), Oleksiewicz et al.
(2001), Reid et al., (2001a; b), Alexandersen et al. (2002), Reid et al. (2002),
Alexandersen et al. (2003c), Reid et al. (2003), Zhang & Alexandersen (2003) and
Quan et al. (2004).
2.4.1. Sample preparation
Blood samples were left to clot at room iemperature for at least an hour and then
centrifuged (Denley BR401 Refrigerated Centrifuge) at 3000 rpm for 10 mins at 4°C.
Serum and nasal swab samples were stored in 2.0 ml screw cap micro tubes at -80°C.
For analysis, serum or nasal swab samples were defrosted at room temperature and
200 pi serum added to 300 pi lysis/binding buffer containing guanidium
thiocyanate/Triton X-100 (MagNA Pure I C total nucleic acid isolation kit, Roche
UK) to denature proteins and simultaneously release and stabilise DNA and RNA.
2.4.2. Total nucleic extraction
RNA was extracted with a MagNA Pure LC Total Nucleic Acid Isolation Kit, using a
MagNA Pure LC instrument (Roche Diagnostics, UK) and the Total NA
ExternaMysis protocol. The protocol included the following steps:
• Proteinase K was added to the sample to digest proteins in the sample.
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• Magnetic glass particles (MGP) were added to bind nucleic acids under chaotropic
salt conditions and the high ionic strength of the Lysis/Binding Buffer (Vogelstein
& Gillespie, 1979).
• Wash Buffer 1 was added to remove unbound substances such as denatured
protein (nucleases), cellular membranes and PCR inhibitors such as heparin or
haemoglobin.
• Wash Buffer II was added to remove impurities (cellular debris) and reduce the
chaotropic salt concentration.
• Wash Buffer III was added to remove impurities and reduce the salt concentration.
Purified total nucleic acids were eluted at elevated temperature (Anonymous, 2001) to
a total volume of 50 pi in elution buffer (MagNA Pure LC Total Nucleic Acid
Isolation Kit).
If required, the RNA concentration of the MagNA Pure elution was determined by
measuring the optical absorbance at 260 nm (OD260) with a Genova MK3
spectrophotometer (Jenway, UK). The machine was blanked with elution buffer
(MagNA Pure LC Total Nucleic Acid Isolalion Kit) before use.
2.4.3. Reverse transcription (RT)
A post-elution programme (RT 64 well) was developed to enable automated pipetting
of RT mixture (9 pl/well) and nucleic acid samples (6 pl/well) into 96-well PCR
plates (ABgene®, UK) by the MagNA Pure LC instrument. A FMDV standard
dilution series (6 pl/well) (see 2.4.5 Quantitation of FMDV genomes) was included on
the plate for RT. Taqman® reagents (Applied Biosystems, UK) were used for the
reverse transcription reaction in the following concentrations:
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Table 2.1 Concentration of reagents used for a reverse transcription reaction
Per reaction (pil)
10XRT buffer 1.50
MgCI2 (25 mM) 3.30
dNTP mix (with dTTP) (2.5 mM each) 3.00
Random hexamers (50 pM) 0.75
RNase Inhibitor (20 U/pl) 0.30
MultiscribeTM reverse transcriptase (50 U/pil) 0.38
Sample 6.00
Total volume per reaction 15.23
Reactions were carried out in Thermo-Fast® 96, non-skirted PCR plates (ABgene,
UK) in a thermal cycler (PTC-100™ Programmable Thermal Controller; MJ Research
Inc., USA) at 48°C for 45 mins and then 95" for five minutes.
2.4.4. Fluorogenic 5' Nuclease Polymerase Chain Reaction (PCR)
This method has been described by Alexandersen et al. (2001), Oleksiewicz et al.
(2001), Alexandersen et al. (2002) and Reid et al. (2002).
A TaqMan® probe, SAmulti2-P-lR-292-269R (5' - CCT CGG GGT ACC TGA AGG
GCA TCC - 3') specific in sequence to the internal ribosomal entry site (IRES) was
designed on Primer Express™ Software (Applied Biosystems). A reporter dye, 6-
carboxyfluoroscein (6-FAM™), was covalently linked to the 5' end, while a non-
fluorescent quencher dye, carboxytetramethylrhodamine (TAMRA), was covalently
linked to the 3' end.
Redundant primers, SA-1R-219-246F (5' ~ CAC YTY AAG RTG ACA YTG RTA
CTG GTA C - 3') and SA-IR-315-293R (CAG ATY CCR AGT GWC 1CI TGT TA -
3'), able to detect all seven serotypes of FMD virus, were designed on Primer
Express™ Software (Reid et al., 2002).
The above primers and probe set was not used to analyse all samples. Where different
primer and probe set have been used, they are described in detail elsewhere (Chapters
5, 6 and 7).
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TaqMan® Universal PGR Master Mix (Applied Biosystems) was used for the PCR
reactions in the following concentrations:
Table 2.2 Concentration of reagents used in a polymerase chain reaction
Per reaction (pi)
Forward primer (SA-IR-219-246F) 2.25
Reverse primer (SA-IR-315-293R) 2.25
Probe (Samulti2-P-IR-292-269R) 1.25
TaqMan® Universal PCR Master Mix 12.50
Nuclease-free H20 2.00
Sample 5.00
Total volume per reaction 25.25
After manual preparation of a 'stock' solution, a post-elution programme (PCR 64
well) was developed to enable the MagNA Pure LC instrument to plate the samples
and reagents into a MicroAmp® optical 96-well reaction plate with optical caps
(Applied Biosystems).
Fluorogenic PCR was performed in a GeneAmp® 5700 Sequence Detection System
(Applied Biosystems). Samples were heated to 50°C for two min, for optimal
AmpErase® uracil-N-glycosylase (UNG) enzyme activity, before the temperature was
increased to 95°C for 10 min to activate the AmpliTaq Gold DNA polymerase. Fifty
cycles of 15 sec at 95°C- and 60 sec at 60°C were used for DNA amplification.
The PCR Master Mix contains a passive reference dye (ROX™) that does not
participate in the 5' nuclease assay. This provides an internal reference to which the
reporter-dye signal can be normalised during data analyses. Fluorescence
normalisation was achieved by dividing the emission intensity of the probe
flourophore by the emission intensity of the passive reference to give a ratio, Rn
(normalised reporter) for a given reaction well.
A ARn = Rn+ - Rn" value was calculated, where Rn+ is the Rn value of a reaction
containing all components, including the template and Rn" is the Rn value of an
unreacted sample. The Rn" value was obtained from the early cycles of a real-time run,
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before an increase in fluorescence was detected. This baseline was set at a default
cycle 6 (start) to cycle 15 (stop). To allow the automatic exposure of the instrument
time to stabilise, a cycle setting lower than 6 was not chosen.
A manual threshold value of ARn = 0.1 was selected, as this value intersects the linear
phase of a log scale ARn/cycle number amplification plot. A threshold cycle, Cj, was
calculated for each sample, and was defined as the cycle number where the ARn value
crosses the threshold value (0.1). Samples that did not have a detectable fluorescence
above threshold after 50 cycles were taken to be negative.
2.4.5. Quantitation of FMDV genomes
2.4.5.1. FMDVO Kaufbeuren
Partial genome of FMDV O Kaufbeuren (from the 5' untranslated region to 1C) was
synthesised in vitro from a plasmid pT73S containing full-length FMDV type O
Kaufbeuren (kindly provided by Dr AMQ King, Institute for Animal Health, UK).
The Not I restriction enzyme (New England Biolabs, UK) was used to linearise the
plasmid, which was transcribed using T7 RNA polymerase (Ambion, UK) according
to the manufacturer's instructions, to produce positive RNA standard. The DNA
template was removed by treatment with DNase I (Ambion). The RNA transcripts
were purified by using precipitation with lithium chloride and ethanol and then
dissolved in DEPC-treated water, and quantified by a PU8720 UV/visible
spectrophotometer (Philips, UK). A 10-fold dilution series (1 x 101 - lxlO7 genome
copies/pl) was aliquoted and stored at -80°C until needed.
2.4.5.2. FMDVO UKG
FMDV O UKG RNA standard was synthesized in vitro from a plasmid (pT7Blue,
Novagen, Madison, USA) containing a 500 base pair insert of the internal ribosomal
entry site (IRES) of FMDV O UKG 34/01 (kindly provided by Dr G Belsham,
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Institute for Animal Health, UK). The enzyme Bgl II (Promega, Madison, USA) was
used to linearize the plasmid, which was transcribed with a MEGAScript T7 kit
(Ambion, USA) used according to the manufacturer's instructions. The DNA template
was removed by treatment with DNase I. The RNA transcripts were purified with acid
(pH 4.7) phenokchloroform 5:1 (Sigma-Aldrich, England), precipitated with
ammonium acetate and ethanol and washed with 70% ethanol. The pellet was
resuspended in TE buffer (Ambion) and quantified with a Genova spectrophotometer
(Jenway, England). A 10-fold dilution series (lxlO1 - lxlO7 genome copies/pl) was
aliquoted and stored at -80°C until needed.
2.4.5.3. Parallel analysis ofstandard and samples
RT-PCR of the standard dilution series was performed in the same plate as the test
samples. A standard curve of Ct against log copy number was generated by the
GeneAmp® 5700 SDS software and used to calculate genome copy numbers per
reaction. The following formula was used to calculate the genome copies/ml serum:
copies/reaction , . , ,xTNA /ml serum = copies/ml serum
TNAd/reaction
copies/reaction ,,4 _c . . , .,
—- g—x50x5 = copies/ml serum (2.1)6 h- 15 x5
copies/reaction x 125 = copies/ml serum
Defined as the volume (pi) of total nucleic acid (TNA) extracted by the MagNA Pure LC.
b Six volumes of TNA were converted into 15 volumes of cDNA and 5 volumes of cDNA
used/reaction.
c
From 200 volumes serum, 50 volumes TNA were extracted.
2.4.6. Samples containing small concentrations of virus
PCR positive samples that contained < 1 virus copy per PCR reaction were taken to
be negative. Samples that contained small concentrations of virus were reanalysed and
if > 80% of the retests were negative (PCR negative or PCR positive but < 1 virus
copy/PCR reaction) they were taken to be negative. An exception to this rule applied
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if more than 80% of the results for a sample were PCR positive and contained < 1
virus copy/PCR reaction. In this case, the values < 1 were not taken to be negative and
were used to calculate the concentration of FMDV in the sample.
2.5. Viral titrations
This method has been described in Donaldson et ol. (1970), Gibson & Donaldson
(1986) and Donaldson et al. (1987).
2.5.1. Preparation of primary bovine thyroid (BTY) cell culture tubes
BTY cell culture tubes were kindly prepared by Elaine Lea Fitzgerald as follows:
Thyroid glands from bovines were placed in a beaker containing 100 ml calcium and
magnesium free phosphate buffered saline (PBS) and WRL field antibiotics (see
Appendix A). The glands were trimmed free of fat and washed with Ca-Mg free PBS,
after which they were chopped as finely as possible using scissors. They were
transferred into 500 ml indented flasks and then washed 10 times with Ca-Mg free
PBS, before being covered by growth medium A [Glasgow minimum essential media,
10% adult bovine serum, L-glutamine (all Sigma-Aldrich Co. Ltd., UK) and WRL
field antibiotics]. The flasks were left overnight at +4°C.
The following day, the medium from the flasks was decanted off and the cells washed
three times with Ca-Mg free PBS and field antibiotics. One hundred millilitres of 0.3
% Dispase (Roche Diagnostic, UK) and a sterile magnet was added to the flask and
then placed on a magnetic stirrer (502 series 111, LH Engineering Co. Ltd., UK) for
one hour at 37°C. The supernatant was decanted into 50 ml polypropylene conical
tubes (Becton Dickinson Labware, USA) and centrifuged at 2 000 rpm for 10 min.
Fresh Dispase was added to the remaining tissue and the process repeated three times.
Once centrifuged, the cell pellet was resuspended in approximately 200 ml growth
medium A.
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The cells were counted by adding 0.5 ml of cell suspension to 9.5 ml 0.5 % trypan
blue vital stain and loading a modified Fnch Rosenthal chamber (Arnold R Horwell
Ltd., UK). The dilution factor was determined by dividing the total count of cells in
10 large squares by the count (100) required. The cell suspension was diluted to give a
final concentration of 1 x 106 cells/ml. Two millilitres of diluted cell suspension was
aliquoted into Nalge Nunc™ tissue culture flat-sided tubes (Scientific Laboratory
Supplies, UK) and placed at 37°C for 4 - 5 days. If the cells were confluent, the
growth medium A was changed to maintenance media (Glasgow minimum essential
media, 2% adult bovine serum, L-glutamine and field antibiotics) and tubes kept at
32°C until needed. If the cells were not confluent, the growth medium was replaced
with fresh growth medium, tubes kept at 37°C and cells observed until they were
confluent.
2.5.2. Preparation of IB-RS-2 cell culture tubes
1B-RS-2 cells culture tubes were kindly prepared by Elaine Lea-Fitzgerald as follows:
IB-RS-2 cells are a continuous cell line stored in liquid nitrogen at -196°C. The cells
were grown in flasks containing growth medium B [Glasgow minimum essential
media, 10% adult bovine serum, L-glutamine (all Sigma-Aldrich Co. Ltd.), penicillin-
G sodium (100 IU/ug per ml), streptomycin sulphate (0.1 mg/ml)] for 24 h at 37°C.
The growth medium was discarded, 5 ml of trypsin (Sigma-Aldrich Co. Ltd.) added,
swirled around the flask and then discarded. Another 5 ml of trypsin was added and
left in the flasks for 5 - 10 min at 37°C. New growth medium was added to the flasks,
the contents mixed by inversion, and 2 ml of the mixture aliquoted into Nalge Nunc™
tissue culture flat-sided tubes (Scientific Laboratory Supplies, UK). The flat-sided
tubes were kept at 37°C and used once the cell layer was confluent.
2.5.3. Viral titration of serum on BTY cells
Viral titrations of serum samples from animals infected with the FMD O UKG
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34/2001 strain were performed on BTY cells. BTY tubes were prepared by discarding
the cell culture maintenance media and washing the cells with 2.0 ml of warm (37°C),
PBS. Two ml of Glasgow Eagle's Medium (see Appendix A, CSU 001 - MED 004),
to which penicillin-G sodium (100 lU/ug per ml), streptomycin sulphate (0.1 mg/ml)
and Fungizone® (2.5 |ig/ml) had been added, was then added to the BTY tubes.
Viral titrations were performed by making a 10-fold (logio) dilution series of the test
serum in M25 phosphate buffer (see Appendix A, CSU 001 - MED 008), by adding
0.1 ml of the neat or previous dilution to 0.9 ml M25 phosphate buffer in bijoux
bottles. Starting at the lowest dilution, 0.2 ml of sample was added to a BTY tube.
Three BTY tubes per dilution were prepared.
Tubes were rolled (The Matburn Roller Tissue Culture Apparatus, Matburn Surgical
Equipment Ltd., UK) continuously at 35 - 39°C. The BTY tubes were observed for
evidence of cytopathic effect (CPE) after three days, using an inverted microscope
(Zeiss 47 12 02 - 9901, Microscope Service and Sales, UK).
The titrc (estimated quantity of virus in sample, expressed as tissue culture infectious
doses, TCID.so/ml) was calculated according to methods described by (Karber, 1931).
Media from BTY culture tubes that showed CPE were randomly tested by an antigen
ELISA (Hamblin et ol., 1984; Roeder & Le Blanc Smith, 1987; Ferris & Dawson,
1988; Ferris et al., 1988) to confirm presence of FMDV.
2.5.4. Viral titration of serum on IB-RS-2 cells
Viral titrations of serum samples from animals infected with SVDV were performed
on IB-RS-2 cells. Viral titration of serum on IB-RS-2 cells was essentially the same as
for viral titration of serum on BTY cells, with the following differences:
34
General material and methods Chapter 2
IB-RS-2 cells are more sensitive to the growth properties of serum than BTY cells.
With the neat and 10"' dilution samples, it was necessary to discard the cell culture
maintenance media, wash the cells with 2.0 ml warm (37°C) PBS, add 0.2 ml of
sample, incubate the tubes at 37°C for half an hour, pour off the sample, wash the
cells with 2 ml warm (37°C) PBS, and then add 2 ml maintenance medium, before
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The distribution of FMDV in pig tissues Chapter 3
3.1. Summary
• The temporal distribution of FMDV in various tissues of pigs infected by limited
(2 hours) direct contact with FMDV infected pigs is described.
• High levels of FMDV were detected in tissues of the upper respiratory tracts (soft
palate and pharynx) and draining lymph nodes (mandibular and retro-pharyngeal
lymph nodes) of pigs two hours after exposure to FMDV infected pigs.
• As viraemia levels increased, virus levels in tissues tended to mimic levels in the
general circulation.
• In the latter stage of infection, FMDV was cleared more rapidly from the
circulation than from tissues.
• The extraction efficiency of RNA varied between tissues samples: liver, tongue
and soft palate provided the lowest yields and lymph nodes the most.
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3.2. Introduction
The exact mechanisms and sites of initial FMDV infection, multiplication and
dissemination of the virus through the host have not been fully characterized, but
descriptions of the pathogenesis of the disease in cattle (Burrows et al., 1981; Brown
et al., 1992; Hofner, 1995), sheep (Alexandersen et al., 2002c) and pigs (Donaldson et
al., 1970; Terpstra, 1972; Brown et al., 1995; Alexandersen et al., 2001) have been
published, and the topic has been reviewed by Alexandersen et al., (2003a).
Cattle and sheep are most commonly infected with FMDV by the aerosol route and
pigs, which are resistant to aerosol infection, are commonly infected by either eating
contaminated swill or through cuts and abrasions in the skin. Infection can also take
place through the conjunctiva of the eye (Sutmoller & McVicar, 1973).
The upper respiratory tract has been identified as the primary site of infection in cattle
(Garland, 1974; McVicar & Sutmoller, 1976; Burrows et al., 1981; Zhang &
Kitching, 2000; Alexandersen et al., 2001; Oleksiewicz et al., 2001). FMDV could be
recovered from pharyngeal samples up to five days in cattle and sheep, and ten days
in pigs before the onset of clinical signs (Burrows, 1968; Sellers et al., 1968). In-situ
hybridization and RT-PCR techniques have confirmed the importance of the pharynx
in the establishment of FMDV infection in animals (Zhang & Kitching, 2000;
Alexandersen et al., 2001).
Dissemination of the virus to the rest of the body is thought to occur via the lymphatic
and circulatory system (Burrows et al., 1981; Alexandersen et al., 2001). It has not
been established whether replication occurs in lymphoid tissue, but this appears
unlikely (Alexandersen et al., 2002b). Replication takes place in stratified squamous
epithelial cells, but has also been reported to take place in mammary gland tissue
(Burrows, 1968; Burrows et al., 1971). FMDV is able to replicate in vitro in a number
of cells, such as bovine kidney, lung and heart tissue cultures (Melendez et al., 1957).
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This report provides a temporal distribution of FMDV in various tissues of pigs
infected by direct contact with FMDV infected pigs. This report has extended the
report by Alexandersen et al., (2001), which described the early pathogenesis of FMD
in pigs infected by contact, by lengthening the time course of the experiment and
providing better quantitative data.
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3.3. Materials and methods
3.3.1. Inoculum
The FMDV O UKG 34/2001 inoculum, as described in Quan et a!., (2004) and
Chapter 2, contained 1072 TCIDso/ml, as measured in primary BTY cells.
3.3.2. Experiment DEFRAexp2-Oct-2002
Twenty-four female Landrace x Large White pigs, weighing between 20 - 30 kg were
divided into two groups; Group A with 8 pigs (donor and direct contact pigs) and
Group B with 14 pigs (recipient pigs) were placed in two separate boxes of an
isolation unit. The two unassigned pigs were killed to serve as controls. Tissue
samples were collected and placed in RNA/a/er® (Ambion, USA), left overnight at
4°C and stored at -20°C for further analysis.
In Group A, 4 of the pigs (donor pigs) were inoculated by intra/sub-dermal injection
in the left fore heel bulb (Burrows, 1966) of 0.5 ml of a 1 in 10 dilution of the
inoculum (equal to 105 9 TCIDjo/animal). The remaining 4 pigs were kept in direct
contact with the inoculated pigs (unlimited direct contact pigs) for the duration of the
experiment.
The pigs were monitored for clinical signs of disease and temperatures recorded daily.
Serum and nasal swab samples were collected before the start of the experiment (to
serve as control samples) and approximately 1 - 5 min after inoculation. Thereafter,
samples were collected twice a day, reducing in frequency to daily after 4 days and
every second day after 8 days.
Two days after the inoculations took place, the four donor pigs from Group A were
moved into the box containing pigs from Group B, so that direct contact was possible
between all the pigs. After 2 hours of exposure (2 h PE), the donor pigs were moved
40
The distribution of FMDV in pig tissues Chapter 3
back to their own box. At the same time (2 h PE), two of the recipient pigs were
selected at random, killed and tissue samples collected. Thereafter, two recipient pigs
were killed daily and tissue samples collected until 6 days after the exposure to the
donor pigs.
3.3.3. Analysis of serum and nasal swab samples for FMDV
RNA extraction, reverse transcription and PCR of serum and nasal swab samples were
performed, as described in Quan et a/., (2004), with a SA-IR-219-246F/SA-1R-315-
293R primer and SAmulti2-IR292-269R probe set (Reid et a/., 2002). Viral quantities
were determined by comparison to a FMDV O Kaufbeuren RNA standard (Zhang et
a/., 2002; Alexandersen et al., 2003c; Zhang & Alexandersen, 2003; Quan et a/.,
2004)
3.3.4. Analysis of tissue samples for FMDV
Approximately 20 mg of tissue was weighed and placed together with 700 pi Tissue
Fysis Buffer [MagNA Pure FC RNA Isolation Kit III (Tissue), Roche, Mannheim,
Germany] in Fysing Matrix D tubes (Q-Biogene, Carlsbad, USA). The tubes were
placed in a FastPrep" FP120 instrument (Q-Biogene) and the instrument run on a
setting of 6.5 m/sec for 2 x 45 sec (with intermediate cooling of samples on ice for 2
min). The tissue samples were homogenised by the ceramic spheres in the tubes and
the vertical, angular motion of the sample holder of the FastPrep" machine.
Homogenization was repeated for samples that were still visible in the lysing matrix.
The lysate was incubated for 30 min at 15° to 25°C and then centrifuged for 2 min at
13 000 g (Centrifuge 5415C, Eppendorf, Hamburg, Germany). 350 pi of the
supernatant was transferred to sample cartridges (Roche) and stored overnight at 4°C.
A MagNA Pure FC instrument (Roche), together with the RNA III Tissue
Fresh_frozen protocol was used to extract RNA from the tissue samples. Samples
were eluted to a total volume of 100 pi in elution buffer [MagNA Pure FC RNA
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Isolation Kit III (Tissue), Roche], Reverse transcription and quantitative PCR were
performed, as above.
3.3.5. RNA quantitation of tissue samples
The RNA quantity of the tissue samples was determined with the use of RiboGreenR
RNA quantitation kit (Molecular Probes, USA). The assay was performed on
microplates according to the manufacturer's instructions and fluorescence was
detected with a Mx4000™ Multiplex Quantitative PCR System (Stratagene, USA).
Samples were diluted with TE buffer (Ambion, USA) until the fluorescence fell
within the linear region of the high range assay.
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3.4. Results
The time course of infection in donor and direct contact pigs, as determined by serum
and nasal swab samples are tabulated in Tables 3.1 and 3.2 respectively.
Supplementary data, such as body temperatures and clinical scores, can be found in
Appendix B (Tables B-l and B-2).
Table 3.1 Log FMDV genomes/ml serum in donor pigs (UR91 - UR94) and direct contact pigs
(UR95 - UR98). Days and hours indicate time after inoculation of donor pigs with FMDV.
a morning b afternoon
f pig died, no sample taken ... pig killed, no sample taken
NVD no virus detected
Days 0 0a 1a 2a 2b 3a 3b
Hours 0.0 0.1 23.5 47.5 54.5 72.0 78.5
UR91 NVD 4.23 8.02 9.11 9.25 8.25
UR92 NVD 3.57 6.54 8.93 8.53 6.22
UR93 NVD 2.75 7.46 9.32 9.18 t t
UR94 NVD 3.43 7.29 9.57 9.41 t t
UR95 NVD NVD 6.68 7.65 8.73 9.28
UR96 NVD NVD 3.38 3.67 5.86 5.50
UR97 NVD NVD 7.46 7.75 9.06 9.44
UR98 NVD NVD NVD 1.88 5.02 4.62
Day 4a 4b 5a 6a 7a 8a 10a
Hours 96.0 102.5 120.0 144.0 168.0 192.0 240.0
UR95 8.77
UR96 6.31 7.42 6.03 3.64 NVD NVD NVD
UR97 7.72 6.61 2.66
UR98 5.66 5.91 6.71 6.73 6.33 3.09 NVD
Table 3.2 Log FMDV genomes/ml in nasal swabs of donor pigs (UR91 - UR94) and direct
contact pigs (UR95 - UR98). Days and hours indicate time after inoculation of donor pigs with
FMDV. Numbers in italics indicate virus quantities recipient pigs were exposed to.
a morning b afternoon
f pig died, no sample taken ... pig killed, no sample taken
NVD no virus detected
Days 1a 2a 3a 4a 5a 6a 7a 8a 10a
Hours 23.5 47.5 72.0 96.0 120.0 144.0 168.0 192.0 240.0
UR91 3.09 5.81 6.70
UR92 2.18 7.09 7.24
UR93 4.53 8.15 t t t t t t t
UR94 2.81 7.34 t t t t t t t
UR95 NVD 7.43 6.39 5.21
UR96 NVD 6.43 5.45 4.75 3.90 5.41 2.95 4.01 4.53
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Days 1a 2a 3a 4a 5a 6a 7a 8a 10a
Hours 23.5 47.5 72.0 96.0 120.0 144.0 168.0 192.0 240.0
UR97 NVD 5.55 6.20 6.54 5.31
UR98 1.94 6.21 6.14 5.18 5.39 5.09 4.92 5.40 3.74
9 27
Donor pigs (UR91-94) reached a geometric mean peak viraemia of 10 ' (95% CI:
10901 - 10953) FMDV genomes/ml serum, which occurred approximately 2 days after
inoculation in 3 out of the 4 pigs. The maximum clinical score of these pigs coincided
with the peak of viraemia (results not shown). Two days post inoculation, the
geometric mean concentration of FMDV in the nasal swabs of donor pigs was 10710
(95% CI: 106 15 - 10s05) genomes/ml. It was at this time that the donor pigs were
introduced to the recipient pigs and they were exposed to high levels of virus over a 2
hour period. The time course of infections in recipient pigs, as determined by serum
and nasal swab samples are tabulated in Tables 3.3 and 3.4 respectively.
Table 3.3 Log FMDV geriomes/ml serum in recipient pigs (UR99 - US12) exposed for a
limited time (2 hours) to FMDV infected donor pigs (UR91 - UR94). Days and hours indicate
time after donor pigs were first introduced to recipient pigs.
a morning b afternoon
NVD no virus detected ... pig killed, no sample taken
Days 0 0a 1a 1b 2a 2b 3a 4a 5a
Hours 0.0 2.0 24.5 31.0 48.5 54.0 72.5 96.5 120.5
UR99 NVD NVD 5.39 5.46 7.69 8.16 9.60 8.02 4.96
usoo NVD NVD 6.38 5.96 8.79 9.09 9.86 7.26 3.11
US01 NVD NVD 4.20 4.96 8.84 8.66 9.28 5.33 1.30
US02 NVD NVD NVD 2.40 4.82 5.54 6.92 8.11 5.47
US03 NVD NVD 7.77 8.02 9.32 9.50 5.80 0.00
US04 NVD NVD NVD 2.83 6.17 6.81 8.27 9.12
US05 NVD NVD NVD NVD 2.36 2.72 5.77
US06 NVD NVD 6.70 7.42 9.20 9.33 7.32
US07 NVD 2.71 7.54 8.40 9.45
US08 NVD 2.25 8.52 8.92 9.79
US09 NVD NVD 5.70
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Table 3.4 Log FMDV genomes/ml in nasal swabs of recipient pigs (UR99 - US12) exposed
for a limited time (2 hours) to FMDV infected donor pigs (UR91 - UR94). Day and hours
indicate time after donor pigs were first introduced to recipient pigs,
a morning b afternoon ... pig killed, no sample taken
Days Oa 1a 2a 3a 4a 5a
Hours 2.0 24.5 48.5 72.5 96.5 120.5
UR99 5.27 5.24 6.80 7.86 7.14 5.39
USOO 5.15 4.04 6.83 7.09 5.29 5.35
US01 4.68 3.69 6.06 6.53 5.41 4.88
US02 6.06 4.14 6.15 6.30 7.50 7.71
US03 5.68 4.31 8.21 6.73 5.38
US04 5.04 3.03 5.92 6.07 5.18
US05 5.02 3.42 6.35 5.24
US06 4.52 3.86 6.85 6.57
US07 4.97 4.44 6.49





Two hours after exposure to donor pigs, there were comparable amounts of FMDV in
the nasal swabs of the recipient pigs, the geometric mean concentration of FMDV was
105 35 (95% CI: 105 08 - 105'63) genomes/ml. The maximum clinical score of the
recipient pigs occurred at, or just after the peak of viraemia (results not shown).
Rectal temperatures showed a general increase as viraemia reached a peak, but did not
closely parallel viraemia or presence of clinical signs.
Even though the recipient pigs were exposed to the donor pigs at the same time and
received similar doses of FMDV (as judged by nasal swab samples), the range when
active viraemia was first detected in the recipient pigs varied between 2 and 49 hours
(Table 3.3). In order to place the pigs on a similar timescale of disease progression,
the pigs were divided into different groups: pigs that were killed before or at the time
they became actively viraemic (group i), pigs that were killed after they were actively
viraemic but before they had reached a peak in viraemia (group ii), and pigs that were
killed after they had reached a peak in viraemia (group iii). The pigs were sorted
according to: time after exposure to donor pigs (group i), time after the start of active
viraemia (group ii) and time after the viraemia peak (group iii) the pigs were killed.
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To put the different groups of pigs on the same timescale, the largest time value in
group i (24.5 h) was added to all the time values in group ii. Thereafter, the largest
time value in group ii was added to all the time values in group iii. The re-ordering
and grouping of the pigs is shown in Table 3.5.
Table 3.5 Geometric mean (for n > 1) viraemia (log FMDV genomes/ml serum) of pigs
grouped and sorted according to either the time after exposure to donor pigs, time after the
start of active viraemia or time after the peak of viraemia they were killed. The timescale was
determined by the grouping of the pigs and calculated according to the order each pig













The reordering and grouping of pigs, as shown in Table 3.5, was used to construct
manipulated time courses of virus distribution in various organs of pigs infected by
limited direct contact with donor pigs (Table 3.6 and Figure 3.1).
Table 3.6 Log FMDV genomes/mg RNA of tissue samples from pigs exposed to FMDV by
limited contact with donor pigs. Flours indicate time after donor pigs were first introduced to
recipient pigs. CLN - cervical lymph node, MLN - mandibular lymph node, NVD - no virus
detected, RPLN - retropharyngeal lymph node.
Animal US14 US13 US12 US11 US10 US09 US08 US07
Flours 0.0 0.0 2.0 2.0 24.5 24.5 48.5 48.5
Liver NVD NVD NVD NVD NVD NVD 7.96 7.84
Spleen NVD NVD NVD NVD 4.13 3.68 7.70 7.35
CLN NVD NVD NVD 4.07 4.53 NVD 7.31 8.64
MLN NVD NVD 4.02 4.15 NVD NVD 6.29 6.84
RPLN NVD NVD NVD 4.61 3.83 NVD 6.90 7.06
S. palate NVD NVD 5.64 4.31 6.12 4.90 8.10 7.09
Pharynx NVD NVD 4.70 4.99 7.08 5.07 7.89 8.13
Tonsil NVD NVD NVD NVD 3.88 5.03 7.60 8.49
Tongue NVD NVD 4.06 6.31 7.39 6.48 9.11 11.85
Skin NVD NVD 5.20 6.98 6.06 4.82 10.79 8.82
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Animal US06 US05 US04 US03 US02 US01 usoo UR99
Hours 72.5 72.5 96.5 96.5 120.5 120.5 120.5 120.5
Liver 6.03 NVD 8.51 4.93 7.10 4.77 NVD NVD
Spleen 7.52 5.06 8.40 6.91 6.79 7.33 6.10 6.05
CLN 7.45 5.73 7.84 7.99 6.41 6.81 6.35 7.18
MLN 6.36 NVD 6.96 6.18 8.42 7.10 6.42 5.98
RPLN 8.33 5.23 8.32 5.59 6.65 7.52 5.74 5.58
S. palate 8.72 5.67 8.50 NVD 6.92 6.07 5.65 6.27
Pharynx 7.92 5.06 8.22 6.35 8.00 7.06 6.12 7.80
Tonsil 5.50 4.19 7.02 6.99 7.77 6.47 6.53 8.14
Tongue 7.97 5.62 9.09 7.51 8.60 9.68 9.32 7.57
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Figure 3.1 A manipulated time course of FMDV distribution in a) liver and spleen, b) lymph
nodes, c) tissues of the throats and d) tongue and skin epithelium of pigs infected by limited
(2 hours) contact with donor pigs. Symbols indicate the virus concentration in individual pigs
and the line the average of the data. The data was obtained by sampling 2 pigs daily for 6
days and then sorted according to what stage of infection the pigs were killed. For each time
point, the virus concentrations in the organs are plotted in relation to the mean (when n > 1)
viraemia (solid grey) of the animals sampled.
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Virus quantities in tissues were expressed on a per mg RNA basis and results were
influenced by the extraction efficiency of RNA from the samples (as measured by the
Ribogreen" assay). The quantities of RNA extracted per unit weight of a range of








1.5 2.0 2.5 3.0
mg RNA/g tissue
Figure 3.2 Box plots of the extraction efficiency of RNA from various tissue types (n = 16).
CLN - cervical lymph node, MLN - mandibular lymph node, RPLN - retropharyngeal lymph
node.
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3.5. Discussion
Donor pigs (UR91-94) were inoculated with a relatively high dose of FMDV (10x)
TCID50, equivalent to 1081 genomes/animal). The progression of disease was uniform
in these pigs (Table 3.1), as in other studies where similar inoculation doses have been
used (Alexandersen et al., 2001; Alexandersen et al., 2003c; Quan et al., 2004). An
inverse relationship between inoculation dose and, i) variability in the progression of
disease, and ii) the time taken for an animal to become actively viraemic, has been
shown (Quan et al., 2004).
The nasal swab samples reflected the route of FMDV infection. In the donor pigs,
viraemia preceded FMDV positive nasal swab samples. In the unlimited direct contact
pigs (UR95-98), nasal swab and serum samples were positive for FMDV at roughly
the same time. In the recipient pigs, FMDV could be detected in nasal swabs before
serum samples. The nasal swabs also reflected the limited contact between the donor
and recipient pigs, as swabs taken from the recipient pigs immediately after exposure
were approximately 1.75 logs lower than the donor's and after 24 hours viral level in
the nasal swabs of recipients had fallen by a further 1.33 logs before increasing at 48
and 72 hours after exposure (Table 3.4).
FMDV could be detected for a longer period in nasal swab samples compared to
serum samples (Tables 3.1 and 3.2) as the virus was detected in nasal swabs after it
had been eliminated from the circulation by the immune system or levels had fallen
below the detection threshold for the assay. The assay quantifies viral genomic
material and does not provide any indication of infectiousness. It is likely that in the
latter stage of the disease, the virus in nasal swabs was, at least in part, non-infectious
due to neutralisation by antibody. Removal of genomic material in the respiratory
tract is mainly a mechanical process and more inefficient that removal of opsinized
virus in the circulation. It follows that to detect FMD in an animal, a nasal swab
sample is preferable to a serum sample, as the window for detection of genomic
material by RT-PCR is longer (Alexandersen et al., 2003c).
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At the peak of infection, the donor pigs were introduced to the recipient pigs
(UR99/US00-12). There was no relationship between the amount of virus in the nasal
swab of a recipient pig at the end of the contact period and the start of active viraemia
in the same pig (Table 3.3 and 3.4). Even though all recipient pigs were exposed to
the same donor pigs, at the same time and had similar amounts of virus in nasal swab
samples, the variability in the progression of disease necessitated that the pigs were
sorted according to the time after the start of active viraemia they were killed, and not
according to when they were killed. The pigs were split into those that had reached a
peak in viraemia before they were killed and those that had not. This was done as two
different processes were dominant before and after the peak in viraemia: viral
replication before the peak and elimination of virus by the immune system after. Both
these processes could influence the distribution of FMDV in tissues.
FMDV concentrations in tissue were expressed on a per mg RNA basis (Figure 3.1),
as well as on a per gram [wet (RNA/ater®, Ambion, USA) mass] basis (results not
shown). On a log scale, the quantitative and qualitative differences between the two
methods were slight, with the biggest differences seen in hard to homogenise and
tough tissue such as tongue and skin epithelium. As a result, only FMDV
concentrations/mg RNA are shown. This was biologically more relevant since the
quantity of RNA is proportional to the number of cells in the extracted sample, while
a unit mass of a tissue sample is made up of cells as well as connective tissue and
influenced by variable extraction efficiency in different tissues.
The amount of RNA extracted from the different tissue types varied between 0.02 to
4.80 mg RNA/g tissue. Results from tissues that were tough and difficult to
homogenise occupied the low end of the range whilst soft tissues were at the high end.
It was unexpected to find that the concentration of RNA in the liver was low, but it
was possible that the RNases present in liver tissue were not adequately inactivated
and had degraded the RNA or that a large proportion of the liver weight was due to
accumulation of blood in this organ during euthanasia.
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Degraded RNA may also explain why no virus was isolated from the liver samples 24
and 48 hours post inoculation (Figure 3.1). Otherwise, FMDV concentrations in liver
(and spleen) samples paralleled viraemia levels quite closely. FMDV concentrations
in the lymph nodes that drain the head (e.g. mandibular, retro-pharyngeal lymph
nodes), as well as tissues of the upper respiratory tract (soft palate and pharynx)
reflected the route of infection in the recipient pigs. Virus concentrations in these
tissues were high after the period of contact with the donor pigs, but then
concentrations either levelled off or dropped for 24 - 48 hours. Thereafter,
concentrations increased and paralleled viraemia levels. A similar pattern was seen in
tongue and skin tissue samples, as high concentrations of FMDV were detected in
samples collected 2 h PE. Surface contamination of the tissue samples by FMDV
could not be excluded, so it is unclear whether the virus present represented virus in
the tissue that had been filtered out from the circulation into the epithelium.
FMDV could be detected in the cervical lymph node of one of the animals (US 11)
two hours after the contact period with infected donor pigs. This lymph node is
interlinked by afferents with other cervical lymph nodes and FMDV does not need to
enter the general circulation to gain access to this lymph node.
FMDV persisted in most of the tissues for a longer period compared to serum. This
difference indicated that the virus was efficiently and quickly removed from the
circulation by the immune system, while this process in tissues was slower or even
non-effective, as the decrease of virus could also have been due to viral decay. FMDV
genetic material persists for the longest time in epithelium and has been detected in
skin epithelium samples up to 19 days PE (unpublished data).
The data from this study describe the distribution of FMDV in organs of pigs exposed
through direct contact with infected pigs: In recipient pigs, FMDV is taken up by the
upper respiratory tract and rapidly spreads to the local lymph nodes and skin
epithelium. By 2 hours post contact, high concentrations of FMDV can be found in
tissues such as soft palate, pharynx, tonsil, tongue and skin epithelium. From these
sites and the local lymph nodes, FMDV spreads throughout the rest of the body.
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FMDV replicates within 2.5 - 3.5 hours after infection of an epithelial cell
(Cartwright et al., 1957), so virus soon appears in the circulation. As the concentration
of virus increases, presentation ofFMDV antigen to the cells of the immune system in
the circulation, spleen and lymph nodes elicits a response which is responsible for
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FMDV dynamics in pigs infected by intravenous inoculation Chapter 4
4.1. Summary
• The effects of dose and exposure intensity on the replication of the FMDV in vivo
and the development of disease after intravenous inoculation were studied.
• Dose-dependent, time course studies of FMDV load in serum were performed by
inoculating pigs by the intravenous route and housing them together in groups or
individually.
• It was shown that the higher the dose, the shorter was the time to the start of active
viraemia and to the onset of clinical signs.
• Inoculation dose had no significant influence on the maximum rate of increase of
FMDV in the circulation.
• Increasing the exposure intensity, by increasing the number of infected pigs
housed together, had the effect of synchronizing the infection and reducing the
variance in the start of active viraemia.
• Increasing the number of pigs housed together also increased the interaction
between the pigs and the activity of individual pigs, which had the effect of
shortening the time to the onset of clinical signs such as vesicle formation.
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4.2. Introduction
The highly contagious nature of FMD reflects the wide host range, the numerous
possible routes of infection, the small amounts of virus needed to infect, rapid
replication in vivo, and the large quantities of virus excreted (Alexandersen et al.,
2001; Alexandersen et al., 2003a). These determinants of transmission play important
roles in the dynamics of the disease, and the influence of virus dose, route of infection
and exposure intensity on early viral dynamics is explored in this paper.
In vitro, it was shown that the time to detection of FMDV growth decreased as the
inoculation dose increased (Brooksby & Wardle, 1954). Under field conditions, the
incubation period of FMD is highly variable and depends on the strain and dose of
virus, the route of transmission, animal species, individual susceptibility, husbandry
and environmental conditions (Kitching & Alexandersen, 2002; Alexandersen et al.,
2003b; Alexandersen et al., 2003a). When exposed to a low dose of vims, pigs may
only develop a sub-clinical infection (Alexandersen et al., 2003c). The incubation
period of FMD in pigs ranges from 24 h (Yang et al., 1999; Sims et al., 2000) to 14
days (Alexandersen et al., 2003a). Data from the 1967-8 FMD epidemic in the UK
indicated that the incubation period in pigs was 4-9 days, younger pigs taking
somewhat longer than older animals to show clinical signs (Hugh-Jones & Tinline,
1976). Under experimental conditions, the mean incubation period ranged from 1 - 3
days, and was dependent on the intensity of direct contact (Alexandersen et al.,
2003c). An inverse relationship between inoculation dose and incubation period was
shown in cattle (Henderson, 1952; McVicar & Sutmoller, 1976), pigs (Alexandersen
et al., 2003c) and sheep (Hughes et al., 2002).
Alexandersen et al., (2003c) has shown that in pigs the intensity of FMDV exposure
affected the incubation period and efficiency with which the disease spread. When
two inoculated pigs were kept together with four "direct contact" pigs, the incubation
period in the direct contact pigs was shorter than when a single inoculated pig was
kept together with a single direct contact pig ("one-on-one"), even though the area per
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pig was less for the latter group. This may have been due to a smaller effective dose in
'one-on-one' pigs as a result of less social interaction or fighting.
This report describes the early infectious process in pigs experimentally infected with
FMDV. Pigs were inoculated by the intravenous route with FMDV and housed
together in groups or individually. The effects of inoculation dose, inoculation route
and exposure intensity on the replication of the FMDV in vivo and the development of
disease were studied, the ultimate aim being the development of a quantitative model
of FMD in pigs for use in predicting the temporal and spatial spread of the virus in an
epidemic.
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4.3. Materials and Methods
4.3.1. Inoculum
The FMDV strain used (O UKG 34/01) contained 1072 TCID50, as measured in
primary BTY cells or 109 4 FMDV genomes/ml.
4.3.2. Experiment minl3
Twelve female Landrace x Large White pigs, weighing 20 - 30 kg, were divided into
three groups of four pigs, each group being placed in a different box of the isolation
unit. Because the pigs in each box were not physically separated from each other,
direct contact between them was possible. The pigs in each of the three groups were
inoculated intravenously (via the anterior vena cava/brachiocephalic vein) with 0.5 ml
of either a 1 in 10, 1 in 100 or 1 in 1000 dilution of the inoculum (equal to 10s 1, 1071
or 1061 FMDV genomes/animal). The most dilute inoculum was given first and the
least dilute last.
Serum samples were collected before the start of the experiment (to serve as controls)
and approximately 1-5 min after inoculation. Thereafter, they were collected every
day at 7 to 8 am and 3 - 4 pm. After 4 days the frequency of sampling was reduced to
once daily/every second day.
4.3.3. Experiment minl4
Experiment min 14 was similar to Experiment min 13, except that samples were
collected more frequently (every 8 hours) and the distribution of the pigs within the
animal isolation unit differed. The low dose inoculation group (four pigs receiving the
1 in 1000 dilution of inoculum) was distributed between two boxes, with two pigs per
box. The pigs in each box were physically separated from each other by double (30
cm apart), solid, watertight, wooden partitions, so that no direct contact between the
pigs could take place (Alexandersen et al., 2002a). Likewise the medium dose
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inoculation group (pigs receiving the 1 in 100 dilution of inoculum) was distributed
between two boxes. Due to the design of the isolation unit, the pigs in the high dose
inoculation group were kept together in one box without any physical separation
between them.
4.3.4. Statistics
Only data up to the time of euthanasia of the first pig in a treatment group were used
for analysis. Homogeneity of variance and Kruskal-Wallis tests were performed by
means of Minitab® for Windows, release 12.31 (Minitab Inc., State College, USA).
Due to the small sample sizes for the Kruskal-Wallis test, an exact distribution was
used to calculate a P-value (Kruskal & Wallis, 1952; Siegel, 1956). The Jonckheere-
Terpstra test was performed with SPSS for Windows, release 11 (SPSS Inc., Chicago,
USA).
The start of active viraemia was defined as the time of the first sampling viraemia was
above the threshold detection level (approximately 102 FMDV genomes/ml serum)
and due to viral replication.
'kyx was defined as the maximum rate of increase of FMDV in the circulation and
was calculated by fitting an log-linear regression equation through the steepest part of
the viraemia curve over a 24 h period, with a minimum of three data points.
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4.4. Results
The FMDV concentrations in serum samples, temperature and clinical scores of
individual pigs are shown in Appendix B, Tables B-3 to B-6 and Figures B-2 to B-3.
8 1
In Experiment mini3, pigs were inoculated intravenously with either 10'" (high dose
inoculation group), 1071 (medium dose inoculation group) or 1061 (low dose
inoculation group) FMDV genomes/animal. The onset of active viraemia in pigs
varied from 6 to 96 h, depending on the inoculation dose received, and reached a peak
of 10*3 FMDV copies/ml of serum (n = 4, other animals being killed before reaching
a peak viraemia). The time courses of viraemia in infected pigs are shown in Table
4.1. The data are summarized in Figure 4.1, which shows the geometric mean of
viraemia, as well as mean clinical scores, for each sampling time point, as well as for
each inoculation group. Clinical signs were noted 24 to 96 h after inoculation and the
peak clinical score (not shown for individual animals) occurred at, or just after, the
peak of viraemia. Rectal temperatures (for all experiments) showed a general increase
as viraemia reached a peak, but did not closely parallel viraemia nor presence of
clinical signs (Tables B-3 and B-4, Figure B-2).
Table 4.1 Experiment min13: FMDV copies (expressed in log™ values) per ml of serum at
intervals after infection.
a morning b afternoon ... pig killed NVD no virus detected
0 hours indicate time of intravenous inoculation
FMDV copies determined by RT-PCR
FMDV copies (log-|0)/ml serum in pigs (nos UP50 - UP61) of groups
Low dose (10®1) Medium dose (ICC1) High dose (1081)
UP UP UP UP UP UP UP UP UP UP UP UP
50 51 52 53 54 55 56 57 58 59 60 61
0 (0.0) NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD
0a (0.1) 2.10 2.57 2.88 2.80 4.29 4.92 2.10 4.11 5.28 5.06 5.11 5.24
0b (5.5) NVD NVD NVD NVD NVD NVD NVD NVD NVD 2.10 NVD NVD
1a (23.5) NVD NVD NVD NVD NVD 4.33 NVD 5.57 3.14 7.42 NVD 6.49
1b (30.0) NVD NVD 3.88 NVD 2.40 3.38 NVD 6.59 4.43 7.91 3.48 6.13
2a (47.5) NVD NVD 5.13 2.08 2.91 4.46 NVD 7.71 5.12 8.03 3.75 8.54
2b (54.0) NVD NVD 5.10 NVD 2.29 6.17 3.33 7.90 6.05 2.91 8.65
3a (71.5) NVD NVD 7.68 2.42 6.01 8.20 8.45 8.46 8.00 5.78 8.52
3b (78.0) NVD NVD 8.11 2.28 7.16 8.21 8.33 7.83 5.34
4a (95.5) 7.11 7.95 8.89 6.33 8.62 7.93 8.88 8.03 6.76
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5a (119.0) 9.17 8.67 ... 7.61 6.20
7a (167.0) 5.36 NVD
8a (191.0) NVD NVD
9a (215.0) NVD NVD
10a (239.0) NVD NVD
Viraemia - low dose inoculation group
Viraemia - medium dose inoculation group
Viraemia - high dose inoculation group
Clinical score - low dose inoculation group
Clinical score - medium dose inoculation group
Clinical score - high dose inoculation group
0 24 48 72 96
Hours post inoculation
Figure 4.1 Experiment mini 3. Viraemia curves of the low, medium and high dose inoculation
groups, showing geometric mean values (n = 4 per treatment group) and standard error bars.
Mean clinical scores (with standard error bars) of the inoculation groups scaled to a 10-point
scale (secondary y-axis). Only the data up to the time at which the first pig in each group was
killed are shown.
The three treatment groups (low, medium and high dose inoculation) of Experiment
mini 3 were compared with each other, in respect of the start of active viraemia, time
to onset of clinical signs and kyx (maximum rate of increase of FMDV in the
circulation). An exact one-tailed Jonckheere-Terpstra test (a nonparametric procedure
for testing the equality of k location parameters against an ordered alternative
hypothesis) produced significant results for the start of active viraemia (P = 0.004)
and time to onset of clinical signs (P = 0.002), but not for kyx (P = 0.216). Mean kyx
(kyx) was calculated to be 0.33 (95% CI of 0.24 - 0.41)
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Experiment mini4 was similar to Experiment mini3, except that pigs were housed
separately instead of being kept together as a group. The start of active FMDV
viraemia in pigs varied from 15 to 192 h, depending on the inoculation dose received,
and reached a peak of 10s '1 FMDV copies/ml of serum (n = 6, other animals being
killed before reaching a peak viraemia). The time courses of viraemia in infected pigs
are shown in Table 4.2 and summarized in Figure 4.2. The latter shows for each
inoculation group the geometric mean of viraemia, as well as mean clinical scores, for
each sampling time point. Clinical signs were noted 48 to 264 h after inoculation and
the peak clinical score (not shown for individual animals) occurred at, or just after, the
peak of viraemia (Tables B-5 and B-6, Figure B-3).
Table 4.2 Experiment min14: FMDV copies (expressed in log10 values) per ml of serum at
intervals after infection
a morning b afternoon ... pig killed NVD no virus detected
0 hours indicate time of intravenous inoculation




FMDV copies (log10)/ml serum in pigs (nos UQ10 - UQ21) of groups
Low dose (10B1 ) Medium dose (10A1) High dose (1081)
UQ UQ UQ UQ UQ UQ UQ UQ UQ UQ UQ UQ
10 11 12 13 14 15 16 17 18 19 20 21
0 (0.0) NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD
0a (0.1) 2.00 1.43 2.41 3.54 4.81 4.25 4.25 3.77 5.09 5.27 5.27 5.43
Ob (7.0) NVD NVD 1.75 NVD NVD NVD NVD NVD 4.75 5.02 NVD 3.41
0c (15.0) NVD NVD NVD NVD NVD NVD NVD NVD 3.63 4.84 NVD NVD
1a (23.5) NVD NVD NVD NVD NVD 2.75 NVD NVD 7.08 6.50 4.50 3.55
1b (31.0) NVD NVD NVD 2.93 2.10 3.55 NVD NVD 7.08 6.65 4.41 3.62
1c (39.0) NVD NVD 3.65 4.04 4.68 2.74 NVD NVD 7.92 6.96 5.70 5.02
2a (47.5) NVD 1.97 5.05 5.00 5.64 3.85 2.81 NVD 9.00 7.44 7.59 6.79
2b (55.0) NVD NVD 5.44 6.00 6.51 4.47 4.17 NVD 9.59 7.65 8.37 6.79
2c (63.0) 3.59 NVD 6.45 6.48 7.64 4.63 4.71 3.72 8.30 8.56 6.84
3a (71.5) NVD NVD 6.71 7.14 8.53 4.25 5.08 NVD 8.66 8.31 7.52
3b (79.0) NVD NVD 6.31 7.02 8.18 4.27 5.95 NVD 8.08
3c (87.0) 3.38 NVD 6.82 7.43 8.83 3.76 6.90 NVD 8.68
4a (95.5) 5.14 NVD 7.92 7.80 8.99 3.49 7.66 NVD 8.72
4b (103.0) 5.68 NVD 8.22 7.69 7.72 5.66 7.50 NVD
4c (111.0) 6.28 NVD 8.67 7.11 6.92 6.14 7.61 NVD
5a (119.5) 6.94 3.42 6.59 7.74 NVD
6a (143.5) 8.22 NVD 7.24 5.30
7a (167.5) 6.95 NVD 5.99 7.48
8a (191.5) 4.07 5.02 4.34 8.09
9a (215.5) 3.63 6.01 NVD
10a (239.5) NVD 6.73 NVD
11a (263.5) NVD 6.43 NVD
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Viraemia - low dose inoculation group
Viraemia - medium dose inoculation group
Viraemia - high dose inoculation group
Clinical score - low dose inoculation group
Clinical score - medium dose inoculation group
Clinical score - high dose inoculation group
0 24 48 72 96
Hours post inoculation
Figure 4.2 Experiment min14. Viraemia curves of the low, medium and high dose inoculation
groups, showing geometric mean values (n = 4 per treatment group) and standard error bars.
Mean clinical score (with standard error bars) of the inoculation groups scaled to a 10-point
scale (secondary y-axis). Only the data up to the time at which the first pig in each group was
killed are shown.
As in Experiment mini3, the three treatment groups (low, medium and high dose
inoculation) of Experiment mini4 were compared with each other, in respect of the
start of active viraemia, time to onset of clinical signs and kyx. An exact one-tailed
Jonckheere-Terpstra test produced significant results for the start of active viraemia (P
= 0.003) and time to onset of clinical signs (P = 0.004), but not for kyx (P = 0.361).
kyx was calculated to be 0.26 (95% CI of 0.20 - 0.31).
The effect of housing pigs individually, or in groups, on (a) start of active viraemia,
(b) time to onset of clinical signs, and (c) kyx was examined by comparing the low and
medium inoculation groups of Experiment mini3 with the corresponding groups of
Experiment mini4 (the high inoculation groups of both experiments were housed
together). The median and range of start of active viraemia and time to onset of
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clinical signs for Experiments mini3 and mini4 are shown in Figure 4.3. A
randomization test for two independent samples (Siegel, 1956) detected a significant
difference in the time to onset of clinical signs for the medium inoculation group (P =
0.043). For the low dose inoculation group, the difference was weaker (P = 0.086).
No significant differences (P > 0.150) in the start of active viraemia, or kyx, between
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Figuro 4.3 Box plot showing modian (labelled) and 25th and 75th percentiles of start of active
viraemia and time to onset of clinical signs for low, medium and high dose inoculation groups.
Differences in kyx, between treatment groups (high, medium and low dose inoculation
groups) and between Experiments mini3 and mini4, were examined with a Kruskal-
Wallis and homogeneity of variance (Levene's) test. As no significant differences (P
> 0.05) were detected, data for kyx were combined to calculate a mean kyx (kyx = 0.29,
95% confidence interval of 0.25 to 0.34)) of FMDV O UKG 34/01. This equated to a
mean viral load doubling time of 2.4 h.
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4.5. Discussion
In this study, a relationship between dose and the early viral dynamics was shown: the
lower the inoculation dose by intravenous injection, the longer the time to start of
active viraemia and onset of clinical signs. These finding accord with those of
previous studies (Henderson, 1952; McVicar & Sutmoller, 1976; Hughes et al., 2002;
Alexandersen et al., 2003c), but provide additional quantitative data.
The viraemia curves obtained from Experiments mini3 and minl4 show that in some
cases the transition from onset of active viraemia to peak viraemia was not smooth
and that the main viraemia curve was preceded by smaller peaks (e.g., pigs UP53,
UP55, UQ10, UQ12, UQ17; see Tables 4.1 and 4.2). It is possible that the smaller
peaks represented contamination during sample analysis, but multiple repeat analyses
of these samples indicated that this was unlikely. It is therefore possible that the
smaller peaks represented waves of early synchronous viral multiplication. This study,
in addition to many other studies (unpublished data), showed that in the early stages
of FMDV infection virus levels tend to be higher in morning samples when compared
to afternoon samples (e.g., pigs UP54 and UP60; see Table 4.1). Morning and
afternoon samples were processed in the same manner, so whether this phenomenon
represented a physiological state of the host or some host influence on FMDV
replication is not known.
Experiments mini3 and minl4 differed in that pigs in the low and medium dose
groups in Experiment mini4 were kept separate from each other (and no direct
contact with other pigs was possible), while the pigs from similar treatment groups in
Experiment mini 3 were housed in groups. When pigs were housed together, it was
possible that animals could be re-infected by other ill pigs in the group and not
exclusively by the intravenous inoculation. It was unlikely that pigs housed
individually were infected by any other routes. Pigs are highly resistant to aerosol
infection (Alexandersen et al., 2000; Alexandersen et al., 2002a; Alexandersen &
Donaldson, 2002; Alexandersen et al., 2002c) and are unlikely to be infected by this
route. As the pigs still had to be handled to collect samples, the possibility of infection
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by indirect contact could not be excluded, but the risk was judged to be small and
certainly much less than in Experiment mini3. Due to limited space within the
isolation facility, the animals in the high dose inoculation group of Experiment mini 4
were kept together, as the progress of disease was more uniform, rapid and predictable
in this group.
The failure to detect any significant differences in the start of active viraemia between
pigs housed individually (Experiment mini4) or in groups (Experiment mini3)
(Figure 4.3) may have been because the animal numbers used were too small. When
the data for time to onset of clinical signs in the medium inoculation groups were
examined, a significant difference was found between pigs housed individually and in
groups. This association was weaker for the low inoculation groups and probably
because of the high variance of the data and the small numbers of animals used in the
experiment. There was also a significant difference (P = 0.014 - 0.043) in the time to
onset of clinical signs between the high dose inoculation groups of Experiments
mini3 and mini4, even though the groups were kept under similar conditions.
However, the difference in the medians was only 7 h (Figure 4.3), and considering
that observations were performed only twice a day, this result is not considered to be
significant.
There was no significant difference in respect of the start of active viraemia between
pigs housed individually and in groups, but such a difference occurred in respect of
the onset of clinical signs. This might be explained by examining the time difference
between the start of active viraemia and the onset of clinical signs in infected pigs.
This time difference was greater in pigs housed individually than as a group. FMD
lesions appear as a result of friction to the infected epithelium (Thomson, 1994;
Alexandersen et al., 2003a); an increase in activity will therefore result in the rapid
development of lesions, whereas an inactive animal will take longer to develop
clinical signs. Pigs kept together in a group interact socially and are therefore more
active than pigs housed individually; it is reasonable to assume therefore, that lesions
will appear more rapidly in the former group.
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Housing pigs together reduces the variation seen in the start of active viraemia and
onset of clinical signs when pigs are inoculated with lower doses of FMDV. With
such doses, stochastic variation will result in some pigs becoming viraemic early and
transmitting virus to other susceptible pigs in the group. Social interaction between
pigs housed as a group can result in bites and scratches from fighting over food,
establishing hierarchy, boredom etc. (Alexandersen et al, 2003a). Such interaction
would greatly favour transmission. The overall effect would be to reduce the variation
seen in the start of active viraemia and would tend to synchronize infection in the
group. Viraemia and clinical score curves would shift to the left (with time on the x-
axis) as a result and the observed start of active viraemia or onset of clinical signs
would be shorter than when pigs are kept alone.
No significant differences in kyx (the maximum rate of increase of FMDV) in vivo
between the inoculation groups were found. This was not unexpected since kyx
depends on viral and host factors and should be independent of dose. It would seem
that the same FMDV strain replicates at the same rate in pigs and cattle, since the O
UKG 34/01 strain gave similar results in cattle to those in the present study
(unpublished results). However, in pigs, O UKG 34/01 appeared to replicate more
rapidly than the O Taiwan 9/97 strain, even though the latter is a specific pig-adapted
strain (unpublished results). As the viral load can double every 2.4 h for FMDV O
UKG 34/01 (equivalent to a 1000-fold increase in 24 h), it is easy to see why the virus
can spread so rapidly in a population of susceptible animals.
This study showed that the higher the inoculation dose, the shorter the time to the start
of active viraemia and the onset of clinical signs. Exposure intensity and housing
conditions can influence the viral dynamics of FMDV. Increasing the exposure
intensity, by increasing the number of infected pigs housed together has the effect of
synchronizing the infection and reducing the variance in the start of active viraemia.
Increasing the number of pigs housed together also increases the interaction between
the animals and the activity of individual pigs, which has the effect of shortening the
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FMDV dynamics in pigs infected by intradermal inoculation Chapter 5
5.1. Summary
• Groups of pigs were inoculated with either 105 6, 1046, 103 6 or 102 6 TCID50
FMDV/pig.
• It was shown that the higher the inoculation dose, the shorter was the time to the
start of active viraemia and to the onset of clinical signs.
• Inoculation dose had no significant influence on the maximum rate of increase of
FMDV in the circulation (kyx= 0.28, 95% CI of 0.22 - 0.34).
• At high inoculation doses, the time of onset of active viraemia and clinical signs
was consistent within and between treatment groups. Similar results between
treatment groups indicate that a maximum replication threshold had been reached.
• The variance in the time of onset of active viraemia and clinical signs increased as
the inoculation dose was lowered. At the lowest inoculation dose (1026 TCID50
FMDV/pig), subclinical infections (viraemia with no clinical signs) were evident.
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5.2. Introduction
The experimental infection of animals with FMDV is commonly performed by the
intradermal route. The different inoculation procedures used to infect animals with
FMDV include scarification and inoculation by intradermal, subcutaneous,
intramuscular, intraperitoneal, intranasal and airborne routes. The intradermal route
has been shown to be the most reliable and required the least amount of virus (Bedson
et al., 1925; Aramburu, 1949; Henderson, 1952; Alexandersen et al., 2003a). By
comparison with the intradermal route, the subcutaneous route has been reported to
require the same amount of virus to 250 000 times more, and the intravenous route to
require 600 times more (Henderson, 1952).
The influence of inoculation dose by the intravenous route on in vivo FMDV
dynamics has been reported (Quan et al., 2004). In this study, we report on the
influence of inoculation dose by the intradermal route on FMDV dynamics, as
measured by the time of onset of active viraemia and clinical signs.
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5.3. Materials and methods
5.3.1. Inoculum
The FMDV strain used (O UKG 34/01) contained 1072 TCIDjo/ml, as measured in
primary BTY cells (Chapter 2).
5.3.2. Experiment minl9
Sixteen female Landrace x Large White pigs, weighing 20 - 30 kg, were divided into
four groups of four pigs and each group placed in a different box of the isolation unit.
Control samples were collected and two of the four pigs in the first box were given an
intradermal/subcutaneous injection into the left fore heel bulb of 0.25 ml of a 1 in
1000 dilution of FMDV inoculum (1036 TCID.Vpig); two of the four pigs in the
second box received a 1 in 100 dilution of FMDV inoculum (1046 TCIDso/pig)- Two
of the pigs in each of the third and fourth boxes were inoculated with a 1 in 10
dilution of FMDV inoculum (105 6 TCID^o/pig)- The most dilute inoculum was given
first and the least dilute last.
As the data from the pigs in direct contact with the inoculated pigs are not relevant for
the purposes of this paper, only data from the inoculated pigs will be discussed
further.
5.3.3. Experiment min22-dose
Nine female Landrace x Large White pigs, weighing 20 - 30 kg, were placed in one
of three boxes of an isolation unit. In a box, a pig was placed in each cubicle, as well
as the space outside the cubicles (3 pigs per box). Control samples were collected and
the pigs in one box were given an intradermal/subcutaneous injection into the left fore
heel bulb of 0.25 ml of a 1 in 1000 dilution of FMDV inoculum (10"'6 TCIDso/pig)-
The pigs in the other two boxes were inoculated with 0.25 ml of a 1 in 10 000 dilution
70
FMDV dynamics in pigs infected by intradermal inoculation Chapter 5
2 6 r*of FMDV inoculum (10 TCIDso/pig). The most dilute inoculum was given first and
the least dilute last.
5.3.4. PCR
Samples were analysed by using primers SA-UK-IRES-248F (5'-AAC CAC TGG
TGA CAG GCT AAG G-3')/SA-UK-IRES-308R (5-CCG AGT GTC GCG TGT
TAC CT-3') and a UK-IRES-271T (6-FAM-TGC CCT TTA GGT ACC C-MGB)
TaqMan" Minor Groove Binding probe (Applied Biosystems). This primer/probe set
was designed for optimum detection of the FMDV O UK.G 2001 virus. The PCR
reaction mixture contained the forward and reverse primers (0.9 pmol/pl of each),
probe (0.20 pmol/pl), and 1 x TaqMan " master mixture (total volume, 25 pl/well).
5.3.5. Statistics
Only data up to the time the first pig in a treatment group was euthanased was used
for analyses. The Jonckheere-Terpstra test was performed using SPSS for Windows,
release 11 (SPSS Inc., Chicago, USA).
The start of active viraemia was defined as the time of the first sampling where
viraemia was above the threshold detection level (approximately 102 FMDV
genomes/ml serum) and on, or at the beginning of, a positive slope of the viraemia
curve.
'kyx' was defined as the maximum rate of increase of FMDV in the circulation and
was calculated by fitting an exponential regression equation through the steepest part
of the viraemia curve over a 24 hour period, using a minimum of three data points.
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5.4. Results
Viraemia, clinical score and temperature of individual pigs are described in Appendix
B (Tables B-7 to B12 and Figures B-4 & B-5).
In Experiments mini9, the start of active viraemia in the pigs varied from 7 to 48 h,
reaching a mean peak viraemia of 109'7 FMDV copies/ml serum (Figure 5.1). Virus
concentrations in nasal swabs lagged levels in serum samples (Table 5.1). Clinical
signs were noted 24 to 72 h after inoculation and the peak clinical score occurred
around the peak of viraemia. The start of active viraemia and onset of clinical signs
were fairly uniform in all the pigs and no dose differences between treatment groups
were apparent. The exception was pig UW84, which was inoculated with 103ATCID5o
FMDV and became viraemic and showed clinical signs approximately 24 h after all
the other pigs in the experiment.
In Experiment min22-dose, the start of active viraemia in the pigs varied from 24 to
120 h, reaching a mean peak viraemia of 10l()0 FMDV copies/nil serum (Figure 5.1).
Virus was frequently detected in nasal swab samples before it was detected in serum
samples, but once an animal had become viraemic, virus concentrations in nasal
swabs lagged levels in serum samples (Tabic 5.2). Clinical signs were noted 72 to 120
h after inoculation and peak clinical scores occurred around the peak of viraemia. A
uniform time course of viraemia and clinical signs in pigs inoculated with 1036
TCID50 FMDV per pig was evident - viraemia was first detected at 48 h and clinical
signs 48 h later. In contrast, pigs inoculated with 102 6 TCID50 FMDV per pig showed
a wide range in the onset of active viraemia and clinical signs - detection of viraemia
ranged from 24 to 120 h and clinical signs from 72 to 120 h. Of the 6 pigs in this
group, 3 pigs (VC88 - VC90) developed clinical signs, VC91 was not infected
(although local replication of FMDV in the upper respiratory tract was evident), VC92
was subclinically infected (viraemia with no clinical signs). VC93 was killed at an
early stage of the experiment due to a rectal prolapse unrelated to FMDV infection
and was excluded from any statistical analyses.
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0 24 48 72 96 120 144 168 24 48 72 96 120 144 168
Time post inoculation (h)
Figure 5.1 Viraemia (solid lines) and clinical scores (dashed lines) of pigs in Experiments
mini9 (a & b) and min22-dose (c & d) inoculated with 1056 (red), 1046 (yellow), 10 6 (green)
or 1026 (blue) TCID50 FMDV intradermal^.
Table 5.1 Experiment mini9. FMDV copies (expressed in log-to values) per ml in nasal swabs
at intervals after infection. FMDV copies determined by RT-PCR.
a morning NVD no virus detected ... pig killed, no sample collected
Days (and
hours) post
FMDV copies (log10)/ml serum in pigs (UW84, 85, 88, 89, 92-97)
-^in / • ' a r\4.6 ~rI n\ * r\5 6 ~r r^\ p\103 6 TCIDso/pig 10"° TCID50/pig 10° ° TCIDso/pig
infection UW84 UW85 UW88 UW89 UW92 UW93 UW96 UW97
0(0) NVD NVD NVD NVD NVD 2.97 NVD NVD
0a (0.1) NVD NVD NVD NVD NVD NVD NVD 2.81
0b (7.0) NVD NVD 2.76 NVD NVD NVD NVD NVD
1a (23.5) NVD 4.58 3.60 NVD NVD 3.21 2.96 NVD
2a (47.5) 6.48 6.03 7.28 6.41 6.34 5.91 6.73 7.03
3a (71.5) 7.85 6.56 6.74 6.19 6.25 6.11 5.81 5.87
4a (95.5) 7.49 6.23
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Table 5.2 Experiment min22-dose. FMDV copies (expressed in log10 values) per ml in nasal
swabs at intervals after infection. FMDV copies determined by RT-PCR.




FMDV copies (logio)/ml serum in pigs (VC88 - VC96)
102 6 TCIDso/pig 1036 TCIDso/pig
VC88 VC89 VC90 VC91 VC92 VC93 VC94 VC95 VC96
0(0) NVD NVD NVD NVD NVD NVD NVD NVD NVD
0a (0.1) NVD NVD NVD NVD NVD NVD NVD NVD NVD
1a (24.0) NVD NVD NVD NVD NVD NVD NVD NVD NVD
2a (49.0) NVD NVD NVD NVD 3.73 NVD NVD NVD
3a (71.5) 5.34 4.96 6.90 NVD 4.60 3.58 4.11 4.73
4a (97.0) 5.29 5.60 6.00 4.01 4.38 8.13 4.67 5.00
5a (120.0) 6.34 7.14 3.52 NVD 6.34 5.87
6a (143.0) 5.34 7.51 NVD NVD
7a (167.5) 5.65 7.02 NVD NVD
8a (191.5) NVD NVD
9a (215.5) NVD NVD
10a (239.5) NVD NVD
11a (263.5) NVD NVD
The difference in the mean viraemia, FMDV concentration in nasal swabs and clinical
scores of the treatment groups can be seen in Figure 5.2. The treatment groups (10 A,
104'6, 103 6 and 102 6 TCID50 FMDV/pig) were compared with each other, in respect of
the start of active viraemia, time to onset of clinical signs and kyx (maximum rate of
increase of FMDV in the circulation). An exact one-tailed Jonckheere-Terpstra test
produced significant results for the start of active viraemia (P - 0.001) and time to
onset of clinical signs (P = 0.005), but not for kvx (P > 0.05). Mean kyx (kyx) was
calculated to be 0.28 (95% CI of 0.22 - 0.34) (Figure 5.3).
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• 1:10 inoculation (4/4)
1:100 inoculation (2/2)
■ 1:1000 inoculation (5/5)
♦ 1:10000 inoculation (3/5)
Figure 5.2 Geometric mean a) viraemia (± SE), b) FMDV concentrations in nasal swabs (±
SE), and c) clinical score (± SE) of pigs showing clinical signs of FMDV (the proportion in
each group indicated in legend).
I I Start of active viraemia

















Hours post inoculation (h)
144
Figure 5.3 Box plot showing median (indicated on graph) and 25th and 75th percentiles of start
of active viraemia (grey) and time to onset of clinical signs (grey hatched) for pigs inoculated
intradermally with 1056 (n = 4), 1046 (n = 2), 1036 (n = 5) and 10 6 (n = 5) TCID50 FMDV/pig.
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5.5. Discussion
In Experiment mini9, pigs were inoculated with either 1056, 1046 or 103 6 TCIDso
FMDV/pig by the intradermal/subcutaneous route. The pigs were part of a larger,
separate experiment and the animal numbers described in this report are small. This
limited the usefulness of the data for statistical purposes.
The viraemia curves and time to onset of clinical signs for most of the inoculated pigs
in Experiment mini9 were very similar, irrespective of the inoculation dose. For
intradermal/subcutaneous inoculation, there appears to be an inoculation dose
threshold at which FMDV replication is at a maximum. The similar viraemia curves
obtained for the medium and high dose inoculation groups (Figure 5.1) suggests that
this dose was exceeded. The data fit well with field data, from which the minimum
incubation period for FMDV in the field has been reported as 24 h (Yang et a/., 1999;
Sims et a/., 2000; Alexandersen et al., 2003b).
The exception to the time course of disease was pig UW84, which became viraemic
and showed clinical signs 24 h after all the other pigs in the experiment. This suggests
that at lower inoculation doses, a dose effect on the incubation period of FMDV is
possible, and that the onset if viraemia and clinical disease is more variable at low
doses.
Results from Experiment min22-dose were in agreement with the findings from
Experiment mini9. In Experiment min22-dose, pigs were inoculated with either 103A
2 6
or 10 TCID50 FMDV/pig by the intradermal/subcutaneous route. The onset of
viraemia and clinical disease appeared to occur at a later stage, but was also more
variable, in pigs inoculated with a lower amount of FMDV (Figure 5.1).
3 6
Pigs from both Experiment mini9 and min22-dose were inoculated with 10 TCID50
FMDV/pig. While the onset of viraemia was similar in these pigs, the onset of
clinical signs differed between the two experiments and occurred approximately 24 h
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later in Experiment min22-dose compared to Experiment mini9. The reason for this
difference may be natural variation or could be due to different housing conditions;
pigs in Experiment mini9 were housed as a group and pigs in Experiment min22-dose
housed individually. Pigs tend to be more active when kept together in a group than
when kept alone and because pigs develop FMD lesions in areas prone to friction
(Thomson, 1994; Alexandersen et al., 2003a), the more active pigs will develop
lesions sooner than less active pigs. Similar results were obtained in pigs inoculated
intravenously (Chapter 4).
When results from both experiments were combined, it was shown that the higher the
dose, the shorter was the time to the start of active viraemia and to the onset of
clinical signs, but inoculation dose had no significant influence on kyx, the maximum
rate of increase of FMDV in the circulation. These results are in agreement with
results reported by Quan et al., (2004), Chapter 4.
These results indicate that a high inoculation dose results in a consistent onset of
viraemia and clinical signs in pigs. As the inoculation dose is lowered, the variation in
the onset of viraemia and clinical signs increases and it becomes more difficult to
predict when pigs will have a detectable viraemia or show signs of FMD. In addition,
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FMDV dynamics in pigs infected by direct contact Chapter 6
6.1. Summary
• A minimum infectious dose appears to exist for FMDV transmitted by direct
contact with an infected pig.
• The incubation period of FMDV is related to the dose received by direct contact:
the lower the dose, the longer the incubation period.
• Local replication of FMDV in the upper respiratory tract can occur in the absence
of viraemia or clinical signs.
• Pigs can be subclinically infected (viraemia in the absence of clinical signs) with
FMDV.
• FMDV transmission is more efficient when susceptible pigs are exposed to a
group of infected pigs, rather than a single infected pig: transmission of FMDV
by direct contact is frequency-dependent.
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6.2. Introduction
The most common natural mode of transmission of FMDV from infected to
susceptible pigs is through direct contact, as pigs are very resistant to aerosol infection
(Alexandersen & Donaldson, 2001; Donaldson & Alexandersen, 2001; Alexandersen
et al., 2002a; Alexandersen & Donaldson, 2002; Alexandersen et al., 2002c). The
relationship between intravenous inoculation dose and the incubation period of
FMDV has already been demonstrated: the higher the dose, the shorter the incubation
period and the time from inoculation to onset of viraemia and clinical signs
(Alexandersen et a/., 2003c; Quan et al., 2004). In this study, natural exposure of pigs
to FMDV was simulated by placing susceptible pigs in direct contact with infected
pigs. The dose of FMDV transmitted to groups of uninfected pigs was controlled by
exposing these pigs to infected pigs at different stages of the infection process for a
set time period. The following question was addressed, "Is the incubation period of
FMDV in a susceptible pig related to the dose received from direct contact with a
FMDV infected pig?"
Previous work had suggested a difference in the transmission efficiency of FMDV in
pigs exposed one-on-one and as a group to FMDV-infected pigs (Alexandersen et al.,
2003c; Quan et al., 2004). This study added to this work by comparing the
transmission efficiency of one susceptible pig exposed to one infected pig (one-on-
one exposure) to a group of four susceptible pigs exposed to a group of four infected
pigs (group exposure).
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6.3. Materials and methods
6.3.1. Inoculum
The FMDV O UKG 34/2001 inoculum, as described in Quan et al., (2004) and
Chapter 2, contained 107 2 TCID50, as measured in primary BTY cells.
6.3.2. Experiment minl7
Twenty female Landrace x Large White pigs (UU82 - UU99, UV00 - UV01),
between 20 and 30 kg body weight, were divided into five groups of four pigs and
each group placed in an animal box of a biosecure isolation unit. Boxes 1 to 4 were
divided into 2 cubicles/box (see Chapter 2, Figure 2.1) and two 'recipient' pigs placed
in each cubicle. Blood and nasal swab samples were collected from all pigs to serve as
control samples before all pigs in Box 5 were inoculated by intradermal/sub-
cutaneous injection of the left fore heel bulb with 0.5 ml of a 1:10 dilution of
inoculum (105 9 TCID^o/animal). One day post inoculation (PI), the four pigs from
Box 5 were transferred to Box 4 and placed together with the pigs from Box 4, in the
space outside the cubicles of Box 4. The pigs from Box 4 were allowed to mix freely
with the inoculated pigs from Box 5 for two hours, and then the inoculated pigs were
taken back to Box 5. The pigs from Box 5 were transferred in a similar fashion to
Boxes 3, 2 and 1 two, three and four days PI respectively. Blood and nasal swab
samples were collected once to twice a day for 10 days. Pigs were monitored for
clinical signs of disease and temperatures recorded daily.
6.3.3. Experiment minl8
Twenty female Landrace x Large White pigs (UW27 - UW48), between 20 and 30 kg
body weight, were divided into four groups of three and two groups of four pigs. The
groups was placed in separate animal boxes of a biosecure isolation unit, the four
groups of three pigs in Boxes 1, 2, 3 and 4 respectively, one groups of four pigs in
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Box 5 and the other group of pigs in a holding pen of the Isolation Unit. In Boxes 1 to
4, one pig was placed in each cubicle and the third in the space outside the cubicles.
Blood and nasal swab samples were collected from all pigs to serve as control
samples before four of the pigs in Box 5 were inoculated by intradermal/sub-
cutaneous injection of the left fore heel bulb with 0.25 ml of a 1:10 dilution of
inoculum (1056 TCIDso/animal). One day PI, three of the inoculated pigs were
transferred to Box 4 from Box 5. The inoculated pigs were paired with the pigs in Box
4 (one-on-one exposure: one inoculated with one contact pig) for a period of two
hours and then moved back to Box 5. On day two, three and four days PI, the same
three inoculated pigs were transferred in a similar manner to Boxes 3, 2 and 1
respectively, for a two hour period. On day four, after the inoculated pigs had been
moved to Box 1 for two hours, all the inoculated pigs (the three from Box 1 and one
from Box 5; four in total) were then moved to the holding pen to expose the pigs in
that pen as a group for two hours. In that time, Box 5 was cleaned and when the two
hour period had passed, all the inoculated pigs were killed and the remaining pigs in
the holding pen moved into Box 5.
Blood and nasal swab samples were collected once to twice a day for 10 days. Pigs
were monitored for clinical signs of disease and temperatures recorded daily.
6.3.4. RNA isolation, reverse transcription, PCR and quantitation
RNA isolation and RT-PCR were performed as described in Quan et al., (2004),
Chapter 2.
Samples from Experiment mini7 were analysed with a SA-IR-219-246F/SA-IR-315-
293R primer and SAmulti2-IR292-269R probe set (Reid et al., 2002) and quantified
with a FMDV O Kaufbeuren (Zhang et al., 2002; Alexandersen et al., 2003c; Zhang
& Alexandersen, 2003) RNA standard.
Samples from Experiment mini8 were analysed with a SA-UK-IRES-248F/SA-UK-
IRES-308R primer and SAmulti2C-P-282T (5'-CCT CAG GGT ACC TAA AGG
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GCA TCC-3') probe set. The SAmulti2C-P-282T probe differed from the SAmulti2-
IR292-269R probe by two base changes, to enable more sensitive detection of the
FMDV O UKG34/2001 virus. Samples were quantified with a FMDV O Kaufbeuren
RNA standard.
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6.4. Results
6.4.1. Experiment minl7
FMDV concentrations in serum and nasal swab samples, temperature and clinical
scores of pigs in Experiment mini 7 are tabulated in Appendix B (Tables B-13 to B-
16; individual pig results are shown in Figure B-6).
Inoculated pigs showed uniform time courses of infection, with similar FMDV
concentrations present in serum samples 24 h PI (Figure 6.1). The peak in
temperatures and maximum clinical scores coincided with a peak in viraemia (Figure
6.1, Figure B-6, Tables B-13 to B-16).
FMDV concentrations in nasal swabs of the inoculated pigs lagged serum samples by
approximately 24 h and were used to estimate the dose of FMDV transmitted to
recipient pigs. The recipient pigs in contact with inoculated pigs on day 1 PI were
exposed to a dose below the detection threshold of the assay. On days 2 and 4 PI,
recipient pigs were exposed to similar doses (10440 and 104'80 FMDV copies/ml,
respectively) and on day 3 PI, recipient pigs were exposed to an approximately 100






UU98, UU99, UV00 & UV01
Clinical score:
UU98, UU99, UV00 & UV01
Nasal swabs:
UU98, UU99, UV00 & UV01
Figure 6.1 Geometric mean (± SE) FMDV concentration in serum, nasal swabs and clinical
score of inoculated pigs (UU98, UU99, UV00 and UV01) on days 1, 2, 3 and 4 post-
inoculation (Experiment min17). Clinical scores scaled to fit y-axis. Pigs inoculated with 105 9
TCID50 FMDV/animal intravenously.
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The maximum clinical score in relation to the peak of viraemia differed in pigs
inoculated by intradermal/subcutaneous injection and pigs infected by direct contact,
coinciding with the peak of viraemia in the former and occurring approximately 1 - 3
days after the peak of viraemia in the latter (Table B-16). The data suggested that the
lower the dose of FMDV, the longer the period between the timing of the peak of
viraemia and maximum clinical score.
Of the pigs exposed on day 1 PI (UU94 - UU97), neither UU94 nor UU95 became
infected with FMDV, as no viraemia nor clinical signs were detected in these pigs,
although low levels of FMDV in nasal swab samples were occasionally demonstrated
(Tables B-13, B-14, B-16). In contrast, UU96 and UU97 were infected with FMDV,
as both pigs developed clinical signs and viraemia, but it is highly likely that UU96
was infected by UU97 and not by the inoculated pigs, as both pigs shared a cubicle
and clinical disease in UU96 was preceded by clinical disease in UU97 2 days earlier.
In the group exposed day 1 PI, only one out of four pigs in Figure 6.2 was therefore
considered to have been infected with FMDV by the inoculated pigs.
All groups of pigs (4 pigs/group) exposed to inoculated pigs on days 2, 3 and 4 PI
were infected with FMDV (Figure 6.2) and developed similar disease characteristics,
with the exception of UU87 which presented with an abnormal infection characterised
by low level viraemia of < 104 FMDV copies/ml serum (mean peak viraemia of 1066°
FMDV copies/ml serum in other non-inoculated pigs) for a prolonged period of
approximately 7 days (mean of 4 days in other non-inoculated pigs) and onset of
clinical signs 8 days after viraemia was first detected (range of 2 - 5 days in other
non-inoculated pigs). UU87 only developed lesions on the hind feet and on the tip of
the tongue and therefore failed to register a maximum clinical score.
No significant differences in the time course of infection (evaluated by serum and
nasal swab samples) between groups of pigs exposed on day 2, 3 and 4 PI were
detected, but for pigs exposed on day 1 PI, the time course of infection (UU97) lagged
the other pigs by approximately 3 days (Figure 6.3).
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Clinical score: UU82 - UU85
Nasal swab: UU82 - UU85
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Figure 6.2 Viraemia, clinical score (± SE) and viral concentration in nasal swabs (± SE) of
pigs (UU82 - UU97) exposed for 2 hours to FMDV-inoculated pigs (Experiment mini7): a)
day 1 post-inoculation (PI) (no clinical signs, nor viraemia in UU94 and UU95, UU96 probably
infected by UU97), b) day 2 PI, c) day 3 PI and d) day 4 PI.
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—•— Viraemia: UU97 (Day 1 PI) —•— Nasal swab: UU97 (Day 1 PI)
Viraemia: UU90 - UU93 (Day 2 PI) Nasal swabs: UU90 - UU93 (Day 2 PI)
—•— Viraemia: UU86 - UU89 (Day 3 PI) —•— Nasal swabs: UU86 - UU89 (Day 3 PI)
—Viraemia: UU82 - UU85 (Day 3 PI) —Nasal swabs: UU82 - UU85 (Day 4 PI)
Time (h)
Figure 6.3 Temporal difference of FMDV in serum and nasal swabs (± SE) of pigs (UU94 -
UU97) exposed to inoculated pigs on day 1 post inoculation (PI) and pigs (UU82 - UU93)
exposed on day 2, 3 and 4 PI (no viraemia, nor clinical signs in UU94 and UU95, UU96 most
likely infected by UU97) (Experiment mini7). No significant differences detected between pigs
exposed on day 2, 3 and 4 PI.
6.4.2. Experiment minl8
Temperatures, clinical scores and FMDV concentrations in serum and nasal swabs of
pigs in Experiment mini 8 are tabulated in Appendix B (Tables B-17 to B-20, Figure
B-7).
Inoculated pigs showed a uniform time course of infection, as viraemia peaked 3 days
PI for all the pigs (Figure 6.4).
None of the pigs exposed on day 1, 2 and 3 PI to the inoculated pigs developed
clinical disease or viraemia (with the exception of a trace amount of FMDV in one
sample from UW42), even though nasal swabs from these pigs showed evidence for
local replication of FMDV in the upper respiratory tract (Figure 6.4).
On day 4 PI, pigs were either exposed one-on-one (UW46 - UW48) or as a group
(UW31 - UW34) to inoculated pigs. Only two out of the three one-on-one exposed
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Figure 6.4 FMDV concentrations in serum and nasal swabs of FMDV inoculated pigs (UW27
- UW30) and pigs exposed one-on-one (UW37 - UW48) and as a group (UW31 - UW34) to
the inoculated pigs (Experiment mini8). Values next to the legends indicate the FMDV
concentration in a nasal swab (log10 copies/ml) taken from the inoculated pig (e.g. UW27) at
the time of exposure to the recipient pig (e,g. UW37) and provides an estimate of the dose of




7.34 —•— Nasal swab: UW46
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0.00 t Nasal swab: UW41
0-00 —•— Nasal swab: UW42
d) 6.04 —•— Nasal swab: UW43
4.07 t Nasal swab: UW44





• Nasal swab: UW27
—t— Nasal swab: UW28
—■— Nasal swab: UW29
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0.00 —•— Nasal swab: UW37
0.00 —t— Nasal swab: UW38
0.00 —•— Nasal swab: UW39
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pigs (UW46 and UW47) developed clinical signs and viraemia, the time courses of
which varied greatly, as judged by the big difference in the time viraemia was first
detected (34 and 171 h). The other pig (UW48) did not develop clinical signs nor a
viraemia, even though nasal swabs from this pig were positive for FMDV (Figure
6.4). Three of the four pigs exposed as a group to inoculated pigs developed clinical
signs of FMDV, the other pig (UW32) was subclinically infected as it developed a
low level viraemia for 6 days but did not show any clinical signs.
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6.5. Discussion
A measure of transmission is the basic reproduction ratio R, defined as the average
number of secondary infections produced when one infected individual is introduced
into a host population (Anderson & May, 1991), which can be estimated in
transmission experiments by maximum likelihood estimates (Kroese & de Jong,
2001). The limits of FMDV transmission in pigs have been demonstrated in this
study, as it appears that transmission of FMDV is unlikely below a certain dose of
FMDV transmitted from infected to exposed pigs by direct contact. In Experiment
mini 7, only one of the four pigs exposed as a group on day 1 PI became infected (R =
0.47, 95% CI of 0.01-4.45), even though FMDV could be demonstrated in nasal
swabs of uninfected animals (Figure 6.2, Tables B-13, B-14 & B-16). In Experiment
mini8, none of the pigs exposed one-one-one on day 1, 2 or 3 PI became infected
with FMDV (upper CI of 4.84), as neither viraemia nor clinical signs in these pigs
could be demonstrated.
Results from Experiment mini7 suggested that the incubation period of FMDV is
related to the dose received from direct contact with an infected pig. The incubation
period of the pig (UU97) that was infected with FMDV on day 1 PI was at least 3
days longer than pigs infected on day 2, 3 and 4 PI, which were exposed to a greater
amount of FMDV (as judged by nasal swab samples of the inoculated and exposed
Pigs).
There was general agreement between the FMDV concentration in nasal swabs from
inoculated and susceptible pigs after these pigs were exposed to each other, which
suggests that there had been good transfer of FMDV from the inoculated to
susceptible pigs (Figures 6.1 and 6.2.).
No differences in the incubation period between pigs exposed on day 2, 3 and 4 PI
were seen (Figure 6.3), even though the FMDV concentration in nasal swabs of the
inoculated pigs or 'dose' was approximately 100-fold higher on day 3 than on days 2
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or 4 PI. There appears to be an inoculation dose threshold at which FMDV replication
is at a maximum, resulting in similar incubation periods between the pigs.
Results from Experiment mini8 suggested local replication of FMDV in the upper
respiratory tract in the absence of a concurrent viraemia or clinical signs (Figure 6.4).
In pigs exposed on day 1 and 2 PI, no FMDV was detected in nasal swab samples
collected straight after the exposure period to inoculated pigs but was detected in
relatively high concentrations at later time points (Figure 6.4b and c). Nasal swabs
taken from pigs exposed on day 3 PI showed initially high FMDV concentrations (at
levels similar to the nasal swabs of inoculated pigs taken at the same time), which
declined below detection levels and was followed by intermittent detectable
concentrations of FMDV (Figure 6.4d).
FMDV transmission was more efficient in group (Experiment mini7) than in one-on-
one (Experiment mini8) exposure. In both experiments similar amounts of FMDV
were excreted by the inoculated pigs as they were injected with same amounts of
FMDV and showed similar viraemia (and nasal swab) -time curves (Figures 6.1 and
6.4). With group exposure, one out of four pigs was infected with FMDV on day 1 PI
and four out of four pigs on days 2, 3 and 4. With one-on-one exposure, no pigs (out
of three) were infected on day 1, 2 or 3 PI and only two pigs on day 4 PI.
In Experiment mini8 on day 4 PI, pigs were exposed one-on-one as well as a group to
the same FMDV-infected pigs (Figure 6.4). The small number of animals used and the
high variance of the data precluded any significant conclusions but it appeared that
FMDV transmission was more efficient in pigs exposed as a group than one-on-one,
with a quicker onset of viraemia and higher peak levels of viraemia in the group
exposed pigs.
Pigs exposed as a group were exposed in Box 5 (without cubicles) and the area per
pig was therefore % of a box (n = 8). Pigs exposed one-on-one were exposed either in
the cubicles (% of a box) or in the space outside the cubicles (XA a box) (Alexandersen
et al., 2003c). The area per pig was therefore % (n = 2) to % (n = 1) of a box, which
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was the same or half the density of the group exposed pigs. FMDV transmission was
more efficient in the group-exposed pigs, indicating transmission was frequency-
dependent, rather than density-dependent (Begon et al., 2002). The difference in the
transmission efficiency between group and one-on-one exposed pigs may be due to
the fact that pigs are social animals and interact to a greater degree when in a group
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7.1. Summary
• Quantitative RT-PCR methods were used to estimate the rate of clearance of
FMDV and SVDV from the circulation in pigs after intravenous inoculation.
• Regression analysis of experimental data suggested an increasing (FMDV) or
constant (SVDV) instantaneous per capita rate of clearance of virus from the
circulation over time.
• The instantaneous per capita removal rates of FMDV (mean: -1.48 h"1 ± 0.29
95% CI, half life = 0.47 h) and SVDV (mean: -2.03 If1 ± 0.30 95% CI, half life =
0.34 h) from the circulation were calculated.
• The instantaneous per capita decay rate of FMDV in blood at 37°C was
calculated (-0.19 IT1 ±0.15 95% CI, half life = 3.72 h).
• SVDV was detected in liver and spleen samples as early as two hours post
inoculation. In contrast, no FMDV was detected in any tissue samples up to four
hours post-inoculation. Dose and receptor differences may explain these
differences
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7.2. Introduction
An understanding of the dynamics of FMDV in vivo requires an estimation of the
rates at which the various processes of infection occur. These issues have received
little attention in the literature, the exceptions being Sutmoller & McVicar, (1976),
who described the rate of clearance of FMDV in cattle and goats. The kinetics of cell
infection and replication in vitro have been well documented (Cartwright et al., 1957;
Thorne, 1962).
Data obtained from quantitative RT-PCR are used to estimate the rate of clearance
and decay of FMDV and SVDV from the circulation in pigs after intravenous
inoculation. The rate of clearance was defined as the instantaneous per capita loss of
virus from the central compartment (circulation) (h"'). The decay of virus was defined
as the decay of virus in whole blood at 37°C (h"1).
Clearance of virus from the circulation may be the result of various processes, such as
activity of the immune system, e.g. mononuclear-phagocyte system (MPS) (van Furth,
1992), non-specific binding to tissue proteins and other constituents, and infection of
target cells. To discriminate between these processes, dual inoculations of FMDV and
SVDV were compared to single inoculations of either virus. A high simultaneous dose
of SVDV relative to FMDV was used to saturate non-specific tissue binding and the
MPS. This allows the rate of infection of target cells by FMDV to be estimated, as
FMDV and SVDV share common structural features (they both belong to the
Picornaviridae family), yet employ different receptors to infect target cells: FMDV
has been reported to use integrin receptors (Berinstein et a/., 1995; Neff et a/., 1998;
Jackson et al., 2000; Jackson et al., 2002; Jackson et al., 2004), SVDV coxsackievirus
adenovirus (CAR) and CD55 (decay accelerating factor) receptors (Martino et al.,
2000). Both viruses are able to bind heparan sulphate (Jackson et al., 1996;
Escribano-Romero et al., 2004), although for FMDV this appears to only be the case
for cell culture adapted isolates.
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The rates of clearance and decay of FMDV and SVDV were determined for use in
mathematical models to describe viral dynamics in vivo (Chapter 8).
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7.3. Materials and methods
7.3.1. Inoculum
The FMDV O UKG 34/2001 inoculum contained 1072 TCIDso/ml, as measured in
primary BTY cells. The SVDV UKG 27/72 RS7 inoculum (7th passage) had a TCID50
of 108'°/ml, as measured in IB-RS-2 cells.
The FMDV inoculum was diluted in HEPES buffered tissue culture medium just
before inoculating the pigs and the SVDV inoculum was used undiluted as a cell
culture supernatant. After inoculation, the dilutions were tested by quantitative RT-
PCR and viral titration in BTY (FMDV) or IB-RS-2 (SVDV) cells to confirm genome
quantity and infectivity.
7.3.2. Experiment minl6
Eleven female Landrace x Large White pigs (UU10 - UU20), between 20 and 30 kg
body weight, were divided into two groups of five pigs and each group placed in an
animal box of a biosecure isolation unit. Blood samples were collected from all the
pigs to serve as control serum samples and the 11th pig (UU20) killed to obtain control
tissue samples. Samples were kept on ice and transported as soon as possible to the
laboratory. One group of pigs was inoculated intravenously into the anterior vena
cava/brachiocephalic vein with 1 ml of SVDV inoculum (10NO TCIDso/animal). The
other group of pigs was inoculated intravenously with 1.0 ml of a 1:10 dilution of
FMDV inoculum (1062 TCIDjo FMDV/animal). Serum samples were collected every
15 minutes for 2 hours. Two pigs from each group were killed 2 hours post
inoculation (UU12/14 and UU17/18) and tissue samples collected. Thereafter,
samples were collected once or twice a day up to 3 days post inoculation and the
remaining pigs killed 2 to 3 days post inoculation and tissue samples collected.
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7.3.3. Experiment min22-rates
Eight female Landrace x Large White pigs (VC80-VC87), between 20 and 30 kg
body weight, were placed in an animal box of a biosecure isolation unit. Control
blood samples were collected from all the pigs. Four of the pigs (VC80 - VC83) were
inoculated by intravenous injection with 0.5 ml of a 1:100 dilution of FMDV (1049
TCID50 FMDV/animal). The remaining four pigs (VC84 - VC87) were inoculated by
intravenous injection with a 1.5 ml mixture consisting of 1.0 ml of SVDV inoculum
(10xo TCID50 SVDV/animal) and 0.5 ml of a 1:100 dilution of FMDV inoculum (1049
TCID50 FMDV/animal). Serum samples were collected every 20 minutes for 2 hours.
All the pigs were killed between 2 and 4 hours post inoculation, with the exception of
pig VC80, which was killed at 4 days post inoculation.
7.3.4. Experiment minl8-blood decay
A female Landrace x Large White pig (UW34) was infected by direct contact with a
FMDV O UKG 34/2001 infected pig for a 2 hour period. Pig UW34 was killed 6 days
after exposure to FMDV and heparinised blood collected from the anterior vena
cava/brachiocephalic vein. The blood sample was transported on ice as soon as
possible to the laboratory where the sample was incubated at 37°C. Aliquots were
removed every hour for 8 hours and again at 12 hour after incubation. Aliquots were
centrifuged at 3000 rpm (1300 g) for 10 min (Denley BR401 Refrigerated Centrifuge;
ThermoQuest, Basingstoke, UK), the plasma aspirated and stored at -80°C for further
analysis.
7.3.5. RNA isolation, reverse transcription, PCR and quantitation
Tissue homogenisation, RNA isolation and RT-PCR were performed as described in
Chapters 2 and 3.
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FMDV concentrations in samples were determined by two different PCR assays:
Samples from Experiment mini6 were analysed with a SA-IR-219-246F/SA-IR-315-
293R primer (Reid et al., 2002) and SAmulti2B-P-288A probe (5'-CCT CAG GGT
ACC TGA AGG GCA TCC-3') set. The SAmulti2B-P-288A probe differed from the
SAmulti2-lR292~269R probe (Reid et al., 2002) used for the detection of all seven
serotypes of FMDV by a base change at position 288. This enabled more sensitive
detection of the FMDV O UKG34/2001 virus. Samples were quantified with a FMDV
O Kaufbeuren (Zhang et al., 2002; Alexandersen et al., 2003c; Zhang &
Alexandersen, 2003) RNA standard.
Samples from Experiment min22-rates were analysed with a SA-UK-IRES-248F/SA-
UK-IRES-308R primer and UK-IRES-271T TaqMan" Minor Groove Binding probe
set and quantified with a FMDV O UKG RNA standard (Quan et al., 2004).
SVDV concentrations in samples were determined by a PCR assay using a 2B-1R
primer and probe set (Reid et al., 2004a and b) and a SVDV RNA standard, kindly
provided by Dr G. Belsham (Institute for Animal Health, UK).
7.3.6. Statistics
To determine whether the rate of removal of virus from the circulation was constant
or increased over time, linear and quadratic regression models were fitted to the virus
concentration in the circulation (log transformed) versus time curves. An F-test of the
regression residuals was used to compare the fit of these regression models
(SigmaPlot 8.0, SPSS Inc, USA).
Analysis of covariance (ANCOVA) was performed in a General Linear Model with
time as a covariate. The homogeneity of slopes was determined by testing for an
interaction between either animal or groups of animals and time (Minitab v. 13,
Minitab, Inc. USA).
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7.3.7. Viral kinetics: definitions and calculations





Integration of Equation 7.1 yields:
V = V ev(0 (1=0)
~krJ
(7.2)
where V(/) = virus concentration in the circulation at time t, V(/=o) = y-intercept of the
linear regression equation (calculated as 10'', Table 7.1), kxy = instantaneous per
m.
capita rate of decrease of virus in the circulation per unit time (calculated as " 1
log e












Figure 7.1 Exponential decay of virus on a) a linear and b) log y-axis. On a log scale (b),
decay is linear and can be described by an equation for a straight line:
logV(() = logV(/=0) - mtt, where m\ is the slope of the straight line.
kxy = instantaneous per capita rate of decrease of virus in the circulation per unit time.
• Clearance: a hypothetical volume of serum cleared of virus per unit time
(volume.time"1), calculated from the intravenous virus dose and the area under the
virus concentration - time curve (AUG):
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• Half-life (%)): the time taken for an amount of virus in the circulation to fall by
• Volume of distribution (VD): a theoretical volume a virus would be diluted in if
the virus dilution was equal to the serum viral concentration (Equation 7.6). The
major determinant of VD is the ratio of virus bound to plasma proteins to virus
bound to tissue components. If a virus is highly tissue bound, most of the virus in
the body will be held in the tissues and very little in the circulation, so the virus
will appear to be dissolved in a large volume and VD will be large. Conversely, if
virus is tightly bound to plasma proteins, the tissue concentration of virus will be
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7.4. Results
The virus concentration in each serum sample is tabulated in Appendix B, Tables B-















































c) FMDV (FMDV inoculation)
d) FMDV (FMDV & SVDV inoculation)




Figure 7.2 Virus concentration in serum samples collected every 15 (Experiments mini 6) to
20 (Experiment min22-rates) min for 2 h.
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Examination of the residuals of log linear regression through data from Experiments
mini6 and min22-rates (not shown) suggested a curvilinear decrease in virus
concentration in the circulation (logio transformed) over time. F-tests of the residuals
of regression lines (SigmaPlot 8.0, SPSS Inc.) suggested an increasing per capita rate
of removal of FMDV from the circulation over time in approximately half (4 out of 9
pigs) of the individuals tested, in which a quadratic regression was found to provide a
significantly better fit to the data than a linear regression (Table 7.1). Of the other
pigs, 3 (out of 5) pigs showed a borderline non-significant result (0.05 < P < 0. 10).
For pigs inoculated with SVDV, F-tests suggested a constant per capita rate of
removal of SVDV in the majority (4 out of 5 pigs) of individuals tested (Table 7.1).
These comparisons were interpreted with caution given the high variance of the data
and the small sample size of animals available in this study.
Table 7.1 Linear (y = ct + mxx) and quadratic (y — c2 + m2x + n2x2) regression analysis of
log-io-transformed data from Experiments mini6 and min22-rates. An F-test (last two columns)
of the regression residuals was used to determine whether the quadratic regression was a
significantly better fit than the linear regression. This would indicate that the decrease of virus
(on a log scale) was curvilinear, rather than linear. Colours were used to highlight non¬
significant (blue) and significant (red) results. The detection assays for FMDV differed
between the two experiments. VC84 - VC87 were given simultaneous inoculations of FMDV
and SVDV.
Virus type: F - FMDV, S - SVDV
f TCID50 BTY cells (FMDV)/IBRS-2 cells (SVDV), given intravenously
not performed
Experiment mini6
y - c\ + mxx T = C2 + m2x -F n2x
2 F-test
ID * Dose* n Cl m, R2 P C2 m2 n2 R2 P F(1) P
UU15 F 106'2 7 5.13 -0.72 94 <0.001 5.17 -0.79 0.03 92 0.003 0.1 0.82
UU16 F 106'2 7 5.43 -0.70 88 0.001 5.06 0.18 -0.40 98 <0.001 31.2 0.01
UU17 F 106'2 7 5.09 -0.34 64 0.019 4.79 0.38 -0.32 83 0.013 6.6 0.06
UU18 F 1062 7 5.06 -0.49 96 <0.001 4.93 -0.17 -0.14 98 <0.001 7.9 0.05
UU19 F 106'2 7 5.25 -0.80 75 0.007 5.02 -0.24 -0.25 72 0.034 0.5 0.52
UU10 S o
a> o
7 6.48 -0.68 88 0.001 6.79 -1.43 0.33 94 0.001 6.9 0.06
UU11 S
o00
O 7 5.80 -0.94 88 0.001 6.13 -1.75 0.36 91 0.004 2.5 0.19
UU12 s 108'° 7 6.50 -0.97 99 <0.001 6.63 -1.29 0.14 99 <0.001 4.1 0.11
UU13 s 108° 7 6.83 -0.77 94 <0.001 6.79 -0.68 -0.04 93 0.002 0.1 0.80
UU14 s 1Q8.0 7 6.26 -1.03 86 0.002 6.81 -2.35 0.59 96 0.001 12.0 0.03
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Experiment min22-rates
y = ct + m^x + m2x + n2x
2 F-test
ID * Dosef n Cl mi R2 P c2 ni2 n2 R2 P F(1) P
VC80 F 104'9 6 5.22 -0.59 93 0.001 5.12 -0.14 -0.27 99 0.001 18.7 0.03
VC81 F 104'9 7 5.13 -0.64 82 0.003 4.92 0.12 -0.38 92 0.003 7.6 0.05
VC82 F 104'9 6 5.35 -1.00 98 <0.001 5.25 -0.55 -0.27 100 <0.001 59.8 0.01
VC83 F 104'9 7 5.12 -0.48 70 0.012 5.11 -0.43 -0.03 62 0.063
VC84 F 1 04 9 7 4.51 -0.29 31 0.115 4.41 0.06 -0.18 21 0.279
S 108° 7 5.63 -0.49 58 0.028 5.65 -0.56 0.03 48 0.120
VC85 F 1049 5 5.17 -0.72 84 0.018 5.17 -0.76 0.03 76 0.120
S 108 o 7 6.84 -1.73 99 <0.001 6.76 -1.44 -0.14 100 <0.001 3.3 0.14
VC86 F 1049 7 5.04 -0.48 61 0.024 5.00 -0.33 -0.08 52 0.104
S 108° 7 6.29 -1.32 93 <0.001 6.38 -1.63 0.16 91 0.003 0.3 0.61
VC87 F 104-9 4 4.90 -0.77 97 0.011 4.94 -1.07 0.30 97 0.093
S 108° 7 6.27 -1.58 96 <0.001 6.41 -2.07 0.24 96 0.001 1.2 0.34
With equivocal evidence of a changing rate of removal of virus from the circulation,
log-linear regression of the experimental data was used in the analysis of the data and
calculation of kinetic parameters (VD and clearance) (Table 7.2).
An ANCOVA showed no significant difference (F(p = 0.14, P - 0.707) in regression
slopes between groups of pigs inoculated with different doses of FMDV (Experiment
mini6 and min22-dose). The per capita rate of decrease of virus in the circulation
ik\y) for FMDV was calculated as the mean of the individual regression slopes for
UU15-19 & VC80-83 (kxv= -1.48 If1 ± 0.29 95% CI, half life = 0.47 h). Likewise, no
significant difference (F(4j = 1.63, P = 0.199) in regression slopes between individual
pigs inoculated with SVDV (Experiment mini6) was detected and kxy for SVDV was
calculated as the mean of the individual regression slopes for UU10-14 (k„= -2.03 h~
1
± 0.30 95% CI, half life = 0.34 h).
An ANCOVA showed a significant difference (F(u = 7.16, P = 0.010) in the y-
intercepts but not in the slopes (F(d = 2.70, P = 0.107) of regression equations of
between groups of pigs inoculated with FMDV alone and in combination with SVDV
(VC80-83 & VC84-87). For SVDV, a significant difference in the slopes (F(i) = 4.51,
P = 0.038) of regression equations was detected between groups of pigs inoculated
with SVDV alone (UU10-14) and in combination with FMDV (VC84-87).
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Table 7.2 FMDV kinetic parameters. Inocula were tested by RT-PCR after each experiment to
determine viral quantities (a-d), which were used in the calculation of VD and clearance. The
detection assays for FMDV differed between the two experiments. VC84 - VC87 were given
simultaneous inoculations of FMDV and SVDV.
V((=o) y-intercept of exponential regression equation
kxy instantaneous per capita rate of decrease of virus in the circulation per unit time
t(\4) time taken for an amount of virus in the circulation to fall by half
VD volume of distribution
1081 FMDV copies/animal dose
b 101° ° SVDV copies/animal dose
1075 FMDV copies/animal dose
d 1010 8 SVDV copies/animal dose
Experiment mini6
ID Virus Dose V(t=ii) kP *<■/.) VD Clearance
(TCID50) (ml"1) (h ) (h) (ml) (ml.h"1)
UU15 FMDV a1062 1.36E+05 1.65 0.42 973 1 604
UU16 FMDV 10® 2 2.67E+05 1.62 0.43 497 806
UU17 FMDV 106'2 1.23E+05 0.79 0.88 1 081 856
UU18 FMDV 106 2 1.16E+05 1.13 0.61 1 144 1 298
UU19 FMDV 1062 1.78E+05 1.84 0.38 744 1 368
Mean 1.64E+05 1.41 0.54 888 1 186
UU10 SVDV b1 o80 3.05E+06 1.57 0.44 3 375 5 296
UU11 SVDV 108° 6.26E+05 2.17 0.32 16 458 35 724
UU12 SVDV 108° 3.17E+06 2.24 0.31 3 246 7 275
UU13 SVDV 1Q8.0 6.75E+06 1.77 0.39 1 526 2 698
UU14 SVDV
oCO
O 1.84E+06 2.38 0.29 5 607 13 345
Mean 3.09E+06 2.03 0.35 6 042 12 868
Experiment min22-rates
ID Virus Dose V(<=H>) kxy *(%) VD Clearance
(TCID50) (ml"1) (h"1) (h) (ml) (ml.h'1)
VC80 FMDV c1049 1.65E+05 1.36 0.51 195 264
VC81 FMDV 1049 1.34E+05 1.47 0.47 239 352
VC82 FMDV 1049 2.22E+05 2.30 0.30 145 333
VC83 FMDV 1049 1.33E+05 1.12 0.62 242 271
Mean 1.64E+05 1.56 0.48 205 305
VC84 FMDV c1049 3.23E+04 0.67 1.03 997 671
SVDV Q. O
CO o
4.28E+05 1.13 0.61 142 610 161 525
VC85 FMDV 1049 1.47E+05 1.66 0.42 219 364
SVDV 108° 6.93E+06 3.98 0.17 8 794 34 962
VC86 FMDV 104-9 1.10E+05 1.12 0.62 292 326
SVDV 108° 1.96E+06 3.04 0.23 31 144 94 680
VC87 FMDV 1049 8.02E+04 1.77 0.39 401 712
SVDV O
CO o
1.85E+06 3.63 0.19 32 902 119 388
Mean FMDV 9.24E+04 1.31 0.61 477 518
SVDV 2.79E+06 2.94 0.30 53 863 102 639
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SVDV could be detected in liver and spleen tissue samples two hours post inoculation
(Tables 7.3 and 7.4). This differed from FMDV where no virus could be detected in
any tissue samples up to 4 hours post inoculation.
Table 7.3 Log SVDV and FMDV copies/g tissue in pigs UU10-14 and UU15-19 respectively
(Experiment mini6). No virus detected in any tissues of control pig (UU20) - results not
shown.
CLN cervical lymph node Hours time post inoculation MLN mandibular lymph node
NVD no virus detected RPLN retropharyngeal lymph S. palate soft palate
node
Viraemia viral concentration (log viral copies/ml serum) at ... pig killed, no sample taken
time of killing
Inoculum SVDV FMDV
Animal UU12 UU14 UU10 UU11 UU13 UU17 UU18 UU15 UU16 UU19
Viraemia 4.62 4.42 3.51 3.34 5.15 4.13 3.89 3.65 7.66 6.62
Hours 2 2 72 72 72 2 2 48 48 48
Liver 5.36 5.58 4.02 NVD 4.20 NVD NVD NVD 4.15 3.65
Spleen 4.02 4.10 4.58 3.69 5.02 NVD NVD NVD 5.56 5.42
CLN NVD NVD NVD NVD 7.86 NVD NVD NVD 4.28 NVD
MLN 4.15 3.52 4.77 NVD 4.80 3.57
RPLN NVD 5.89
S. palate NVD 5.48
Pharynx NVD 5.75
Tonsil NVD 4.93
Tongue NVD 3.62 NVD NVD NVD NVD NVD NVD 4.95 10.67
Skin NVD NVD NVD NVD NVD NVD NVD NVD 7.47 4.93
Table 7.4 Log SVDV and FMDV copies/g tissue in pigs VC84-86, after inoculation with a
combination of 1080 TCID50 SVDV and 104 TCID50 FMDV/animal (Experiment min22-rates).
CLN cervical lymph node Hours time post inoculation MLN mandibular lymph node
NVD no virus detected S. palate soft palate
SVDV FMDV
Animal VC84 VC85 VC86 VC87 VC84 VC85 VC86 VC87
Hours 2 2 2 4 4 2 4 4
Liver NVD 4.31 4.36 3.88 NVD NVD NVD NVD
Spleen 4.69 4.69 4.41 4.05 NVD NVD NVD NVD
CLN NVD NVD NVD 3.59 NVD NVD NVD NVD
MLN NVD NVD NVD NVD NVD NVD NVD NVD
S. palate NVD NVD NVD NVD NVD NVD NVD NVD
Tonsil NVD NVD NVD NVD NVD NVD NVD NVD
Tongue NVD NVD 4.65 NVD NVD NVD NVD NVD
Skin NVD NVD NVD NVD NVD NVD NVD NVD
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Log-linear regression of data from Experiment minl8-blood decay (P = 0.038) was
used to calculate a half-life of FMDV in whole blood of 3.7 hours at 37°C
















0 2 4 6 8 10 12
Time (h)
Figure 7.3 Log-linear regression (solid line) ± 95% CI (dashed lines) of data from Experiment
min18blood-decay.
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7.5. Discussion
Data obtained from quantitative RT-PCR were used to estimate the rate of clearance
and decay of FMDV and SVDV from the circulation in pigs after intravenous
inoculation. Examination of the experimental data and residuals suggested that the
instantaneous per capita rate of clearance (kxy) of FMDV from the circulation over
time was not constant and increased over time. Due to the small numbers of animals
used in this study, equivocal results were obtained when testing whether a curvilinear
regression was a significantly better fit to the log transformed data than a linear
regression. A constant (linear regression) clearance rate was calculated, as a
curvilinear regression (i.e. increasing rate of clearance) would indicate complex
kinetics (such as activation of innate immune responses after inoculation or
inflammation increasing permeability of blood vessels) that would have been difficult
to elucidate in this study.
The instantaneous per capita removal rate of FMDV (-1.48 h"1 ± 0.29 95% CI) from
the circulation was slower than SVDV (-2.03 If1 ± 0.30 95% CI). The former value
compares favourably to the range -0.69 to -1.66 If1 calculated for the per capita rate
of clearance of FMDV in cattle (Sutmoller & McVicar, 1976), in which the
conclusion was made that the clearance of FMDV from the circulation was dose-
related. Below a critical dose, clearance was efficient and the clearance rate (log
pfu/min) directly proportional to the concentration of virus in the blood. Above a
critical dose, clearance was less efficient and not related to dose. At this dosage, virus
decreased exponentially over time and indicated decay of virus, rather than an active
mechanism of clearance. Depletion or saturation of the mononuclear phagocyte
system at higher inoculation doses was suggested as a reason for this dose effect. This
dose effect was not observed in these experiments.
In Experiment min22-rates, groups of pigs were given a single inoculation of FMDV
and simultaneous (dual) inoculations of FMDV and SVDV. By including SVDV in
the inoculations (at a much higher concentration than FMDV), it was hoped that
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SVDV would saturate non-specific binding sites and clearance mechanisms by the
immune system (such as the mononuclear phagocyte system), so that an accurate rate
of infection of epithelial cells by FMDV could be estimated.
No significant differences in the slope, but significant difference in the y-intercept of
regression equations of the FMDV data, were observed between the treatment groups.
The addition of SVDV to the inoculum increased the VD and clearance of FMDV by
lowering the y-intercepts (used in the calculation of VD and clearance) of the
regression equations. The mechanism for this difference in parameter values is due
possibly to occupation of binding sites in the circulation by SVDV. The rate of
clearance (kxy) of FMDV would be expected to decrease as binding sites were
saturated, but clearance was unaffected by the addition of SVDV to the inoculum.
This suggests that binding sites in the circulation and tissue compartments were not
saturated (and only partially occupied) by SVDV. Analysis of tissue samples collected
2 hours post exposure showed SVDV was sequestered in the spleen and liver, which
suggests SVDV has a stronger affinity for heparan sulphate receptors than for non¬
specific binding sites (see later), and therefore the probability that all the binding sites
were saturated by SVDV was low.
A significant difference in the rate of clearance of SVDV between single and dual
inoculation was detected, dual inoculations resulting in an increase in kxy (and VD and
clearance). The reasons for this are not clear, but it is possible that the addition of
FMDV to the inoculum stimulated immune response to a greater degree than SVDV
alone.
There was a large variation in values for VD and clearance (e.g. the VD for SVDV
ranged from 1 526 to 142 610). FMDV concentrations in samples were determined by
two different PCR assays. Although results from a sample analysed using the two
assays would differ quantitatively, the values for the kinetic parameters should be
relatively similar, as they were calculated from terms (serum samples and virus dose)
determined from the same assay. The accuracy of these kinetic parameters, however,
depends on the RT-PCR assay, which may produce results that vary ten-fold (S.
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Alexandersen, personal communication). The calculated values for kinetic parameters
have to be evaluated with this in mind, but what was evident was the large differences
in the values of the parameters between FMDV and SVDV, the VD and clearance for
SVDV much larger than for FMDV.
Differences were also noticed in the analysis of tissue samples. SVDV was detected in
liver and spleen samples as early as two hours post inoculation, while no FMDV was
detected in any tissue samples up to four hours post-inoculation. Possible explanations
for these differences are inoculation dose differences and receptor differences.
The difference in the detection of FMDV and SVDV in tissue samples may be the
result of a lower FMDV inoculation dose compared to SVDV. The low FMDV
inoculation dose may have resulted in viral concentrations below the detection
threshold of the assay used to measure FMDV in tissue (approximately 103'5"4'0
FMDV genomes/g tissue). While this is probably true for Experiment min22-rates,
estimates of the FMDV concentration in liver samples from Experiment mini6 [1043
FMDV genomes/g, calculated for a 25 kg pig, liver weight 2.7% live weight (Collin et
al., 2001) and assuming only 10% of circulating FMDV was removed by the liver and
a homogenous concentration of FMDV in the liver] were above the detection
threshold of the RT-PCR assay.
The ability of SVDV to bind heparan sulphate (Escribano-Romero et al., 2004) most
likely accounts for the detection of SVDV in liver and spleen tissue samples. Heparan
sulphate is a glycosaminoglycan located at the cell surface and in the extracellular
matrix of organs such as the spleen and liver (ten Dam et ah, 2003). In vivo, wild type
FMDV does not use heparan sulphate, but rather integrin receptors to infect a host cell
(Berinstein et ah, 1995; Neff et ah, 1998; Jackson et ah, 2000; Jackson et ah, 2002;
Jackson et ah, 2004). In vitro, culture adapted FMDV can acquire the ability to bind
heparan sulphate but such viruses are attenuated in vivo (Jackson et ah, 1996; Sa-
Carvalho et ah, 1997).
The above results suggested that SVDV inoculated into the circulation was
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sequestered in the liver and spleen by the high concentration of heparan sulphate
receptors in these organs. Due to the high affinity of SVDV for these receptors, the
concentration of virus in the circulation fell rapidly, which resulted in high VD and
clearance values. FMDV, on the other hand, does not utilise heparan sulphate
receptors, was not rapidly sequestered in the liver nor spleen and values for VD and
clearance were therefore much lower.
The overall decrease of FMDV in the circulation (calculated at -1.48 h"1 ± 0.29 95%
CI, half-life = 0.47 h) is due not only to clearance of the virus from the circulation but
also to decay of the virus. A value for the instantaneous per capita decay rate of
FMDV in blood at 37°C was calculated (-0.19 h"1 ± 0.15 95% CI, half life = 3.72 h),
which was considerably smaller than the overall rate of decrease of virus from the
circulation. Also taking into account that the intracellular life cycle of FMDV is very
quick (2.5 - 3.5 hours, Cartwright et a/., 1957) and the virus replicates quickly in vivo
(half-life of 2.4 h, Chapter 4), decay of FMDV at 37°C was thought to not play an
important role in the dynamics of FMDV in vivo and was therefore not included in
mathematical descriptions outlined in Chapter 8.
The calculation of kinetic parameters for FMDV and SVDV has highlighted
differences in virus-host interactions between two structurally similar viruses.
Determination of these parameters will aid in the development of more accurate
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8.1. Summary
• A theoretical framework was developed to explore early viral dynamics of FMDV
in vivo.
• A model using constant parameter values (Model A) could not fully describe
experimental data.
• Modifications to Model A resulted in good agreements between the models and
experimental data. These modifications were:
i. limiting the rate of infection of epithelial cells at low FMDV concentrations
(Model B),
ii. converting the virus removal system in Model A into one of limited
capacity (Model C), or
iii. the addition of a virus removal system of limited capacity (Model D).
• Biological reasons for limiting the infection rate of epithelial cells at low FMDV
concentrations were a minimum infectious dose per cell hypothesis and virus-
virus interactions.
• Biological example of a removal system of limited capacity are the mononuclear
phagocyte system (Model C) and non-specific binding of FMDV to plasma and/or
tissue proteins (competitive and non-competitive).
• Discrepancies between the model and the data could be best explained by a
limited infection rate of epithelial cells at low FMDV concentration or non¬
competitive irreversible tissue binding.
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8.2. Introduction
An important characteristic of FMDV is the highly contagious nature of the virus.
Cattle and sheep can be infected with as little as 10 TCID50 (Gibson & Donaldson,
1986; Donaldson et a/., 1987) from as far as 270 km away from a source of FMDV
under exceptional circumstances (Gloster el al., 1982). Pigs play an important role in
the airborne spread of FMDV as they excrete 1061 TCID5o/24 h (for the FMDV O
UKG strain), 3 000 times more virus than cattle or sheep (Donaldson et al., 1970;
Donaldson, 1983; Alexandersen et al., 2002a; Alexandersen & Donaldson, 2002).
An important aspect in the control of FMD epidemics is the identification and
elimination of infectious animals in the shortest possible time, to reduce the
transmission of the virus from infected to susceptible animal/herd and reduce the
number of affected animals. The ability to quantify and predict the infectiousness of
animals/herds would greatly aid control strategies. To achieve this aim, a thorough
quantitative understanding of the viral dynamics in vivo is needed.
In this chapter, a theoretical framework was developed to explore the early viral
dynamics of FMDV in vivo. The objective was to quantify and describe these
dynamics in mathematical terms, in order to predict the excretion of FMDV and
infectiousness of individual animals.
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8.3. Material and methods
8.3.1. Model A
A model of FMDV replication in vivo (Model A) was considered (Figure 8.1):
Figure 8.1 A model of FMDV replication in vivo (Model A). Variables X and Y represent the
concentrations of FMDV in the central compartment and interstitial space respectively; C and
D represents uninfected and infected cells respectively. The parameters (e.g. kxy) are constant
per capita rates described in Table 8.1.
Virus concentrations in the central compartment and interstitial space were
represented by X [FMDV genomes per ml serum in the central compartment (ml1)]
and Y [FMDV genomes per ml serum in the interstitial space (ml"1)] respectively.
FMDV was lost from the interstitial space through 3 routes: drained by the lymphatic
system to re-enter the central compartment at rate kyx, removed (kyo) or used to infect
epithelial cells (fti). FMDV was added to the interstitial space from the central
compartment (kxy) or from burst infected epithelial cells (b).
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The total numbers of uninfected and infected epithelial cells were represented by
variables C and D respectively. Infected epithelial cells died at rate kd0 and released
virus back into the interstitial space or infected neighbouring uninfected epithelial
cells (ft2). y§2 represented the multifocal spread of FMDV within the epithelium and
was expected to differ from /?]. The basement membrane provides a barrier to
infection of epithelial cells by FMDV and was expected to limit /3\. Once an epithelial
cell was infected, the transmission rate of FMDV from cell to cell {fii) was expected to
be high and significantly greater than f}\.
Figure 8.1 gave rise to the following ordinary differential equations:
ay 1
(8,)
~ =U„X -kj-kj + bkJD (8.2)
^-=-p,YC-hkjx: (8.3)dt
^- = fi,YC + f/,k,„DC~kJ,JD (8.4)dt
The dimensions and the calculation of the parameters used in Model A are described
in Table 8.1.








30.6 mf1 Calculated as burst size of FMDV per infected
cell -r- interstitial volume. The average burst
size of an infected cell was taken to be 1 x 10^
virus (S Alexandersen, personal
communication). The interstitial volume was
calculated at 13.09% of body weight (BW)
(Pond & Houpt, 1978), giving a volume of 3
273 ml for a 25 kg pig. Local viral
concentration at sites of replication is likely to
be different.
Kio Per capita rate
infected cells die
per hour.
0.33 h"1 Calculated as the inverse of the cell attached
and intracellular infection time ofFMDV of
between 2.5 and 3.5 h (Cartwright et al., 1957).
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1.48 h"1 Determined from the mean rate of decrease of
FMDV from the serum of pigs UU15 - UU19
and VC80 - VC83 in samples taken up to 2 h
after intravenous inoculation ofFMDV. The
rate was calculated from log-linear regression
equations fitted through the data (see Chapter
7).





varies h"1 Estimated by fitting the model to the
experimental data.
kyx Per capita rate
FMDV genomes
in interstitial




0.26 h"1 Estimated from the mean rate of increase of
FMDV in the serum of pigs UQI0 - UQ21.
Log-linear regression equations were fitted to
the steepest part of the viraemia curves, using a
minimum of three data points and over a
minimum 24 hour period. In the models
described, the concentrations of virus in the
central compartment and interstitial space were
considered proportional to each other.




per ml serum in
the interstitial
space per hour.
varies mF'.h"1 Estimated by fitting the model to the
experimental data.




varies cell'.h"1 Estimated by fitting the model to the
experimental data.





0.53 Calculated from the volume ofplasma (6.91 %








l .25 x 1010 Estimated from the total surface body area
(BSA) of a pig (25kg), calculated from the
formula BSA cm2 = 734 x (body weight in
kg)066 (Kelley et al., 1973). Average cell size
was estimated to be 20 pm3 (Bacha & Bacha,
2000) and a layer ofepithelial cells 5 to 10
cells thick susceptible to viral infection was
assumed.
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8.3.2. Model B
In Model B, the effect of limiting the per capita infection rate of epithelial cells by
FMDV (/?]) in Model A at low FMDV concentrations was explored, by introducing a
sigmoidal term
f yp ^
Km + Yp j
to Equations 8.3 & 8.4:
dC Yp
^ = 7yc-^dcdt m + Y'
= A YC + P>k-<-DC ' k"D
dt m + Y
(8.5)
(8.6)
The effect of the sigmoidal term on /?i is illustrated in Figure 8.2.
A
m + Y p
(mr1.h"1)
/?, = 6x10"12, m - 0
P1 = 6x10 12, m = 1x10\p = 0.5
P1 = 6x10 12, m = 1x102,p = 0.5
P1 = 6x10 12, m = 1x103,/) = 0.5
P1 = 6x10~12, m = IxlO4,/? = 1
Figure 8.2 The effect of a sigmoidal term
p yp ^
Km + Yr j
on Pi (see Equations 8.5 & 8.6) where
Pi = the per capita rate of infection of epithelial cells by FMDV. Values indicated by the green
line used in Model B.
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8.3.3. Model C
In Model C, the effect of saturating the system that removed FMDV from the
















where W = FMDV genomes per ml serum in the interstitial space removed (mf ) and
K was the saturation capacity [FMDV genomes per ml serum in the interstitial space
i ( W
(ml )] of the removal system. The effect of the term 1
v K J
Figure 8.3.
on kyo is illustrated in
2e+5 4e+5 6e+5 8e+5 1e+6
W
Figure 8.3 The effect of the term
, w^1 on ky0 (see Equations 8.7 and 8.8) where kyo - the
K )
per capita rate FMDV was removed from the interstitial space, W = FMDV genomes in the
interstitial space removed and K = 1x106.
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8.3.4. Model D
FMDV binds to integrin receptors (Berinstein et al, 1995; Neff et a/., 1998; Jackson
et al., 2000; Jackson et al., 2002; Jackson et al., 2004) on epithelial cells. It is likely
that the capsid proteins of FMDV are also bound non-specifically to plasma and tissue
proteins in vivo (Riviere, 1999). We assumed non-specific binding followed the law
of mass action, where the degree of binding was determined by the concentrations of




Figure 8.4 Non-specific binding of FMDV in vivo, where [K| = [free virus], [P] = [available non¬
specific binding sites] and [Q] = [bound virus]. When the concentrations of Y and P are high,
the reaction is favoured to the right. When the concentration of Q is high, the reaction is
favoured to the left. The dissociation constant (Kdiss) = a2la\.
We explored the effect of non-specific tissue binding on viral dynamics in vivo by
modification of Model A (Figure 8.5).
Figure 8.5 Model D. Model A (shown in grey) modified by addition of variables P (available
non-specific binding sites in the interstitial space) and Q (bound virus in the interstitial space).
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The dynamics of FMDV in the interstitial space (Equation 8.2) were changed as
follows:
'dj = AkxrX - kyxY-kyJ-a,rP + a2Q+ (8.9)
Additionally,
- = -alYP + a2Q, and (8.10)
dt
^=- = a,YP - a,Q (8.11)
dt 1
where P = available non-specific binding sites per ml serum in the interstitial space
{P(max) - P(t=o,) (ml1), Q - bound virus per ml serum in the interstitial space (ml"1), oq
= per capita rate of FMDV bound in the interstitial space per available binding site
per hour (mf'.h1) and ai - per capita rate of FMDV lost to the interstitial space per
hour (ml"'.IT1).
The net per capita rate FMDV was bound in the interstitial space [(«i YP-aiQ)IY] over
time in Model D and sensitivity analysis of the parameters that make up this rate are
shown in Figure 8.6.
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Figure 8.6 The net per capita rate FMDV was non-specifically bound in the interstitial space
[(a\YP-aiQ)IY] over time (Model D), and sensitivity of this rate to changes in a) Kdiss (a2/«i) {P(0)
= 2.5x10 and a, = 1.0x10"5), b) a, (P{0) = 2.5x105, a2 = 0) and c) Pm («, = 1.0x10"5, a2 = 0).
Other parameter values are described in Table 8.1.
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8.4. Results
8.4.1. Model A
A typical output from Model A is shown in Figure 8.7. An initial decrease in virus
concentration in the central compartment was followed by an exponential increase. A
maximum concentration was reached, before decreasing when the rate of removal of
virus was greater than the rate of viral replication.
X- FMDV in the central compartment
Y- FMDV in the interstitial space
C - uninfected epithelial cells














Figure 8.7 Model A (X(0) = 1x10 , kyt
described in Table 8.1).
6.0, p{ 3x10"11, fi2 0 and other parameter values
The sensitivity ofModel A to changes in parameter values is shown in Figure 8.8. The
model was sensitive to changes in all parameters, with the exception of kxy and kyx.
The output from Model A was compared to experimental data from Experiment
mini 4 (Quan et al., 2004, Chapter 4) Blood samples were collected three times a day
from pigs inoculated intravenously with different FMDV doses (108"1, 1071 or 1061
genomes/animal) (Figure 8.9).
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Figure 8.8 a) - h) Sensitivity analysis of parameter and variable values used in Model A;
values varied 8-fold. Parameters are instantaneous per capita rates:
kxy FMDV in central compartment lost to kyx
the interstitial space (h_1)
kvo FMDV in the interstitial space lost (h"1) kdo
P\ Uninfected cells infected by FMDV in /?2
the interstitial space (ml"1.h"1)
b Burst size of infected cell (ml"1) Ci0>
FMDV in the interstitial space lost to
the central compartment (h_1)
Death of infected epithelial cells (h"1)
Uninfected cells infected by burst
infected cells
The number of epithelial cells
available for infection at time 0
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Model output for X, when V(0) = 105
Model output for X, when X{0) = 104
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Figure 8.9 An illustrative fit of Model A (km = 6.0, fa = 3x10"11, fa = 0 and other parameter
values described in Table 8.1) to experimental data from Experiment min14. Red, green and
blue symbols indicate different treatments, i.e. 1081, 1071 and 1061 FMDV genomes/animal
intravenous inoculation; shapes indicate individual animals. Box plots show the median time
(and 25th and 75th percentiles) active viraemia was first detected (detection of FMDV below
102"3 genomes/ml serum is not reliable).
Model A reproduced the general shape (decrease, followed by an increase of virus
concentration in the central compartment) of a viraemia curve, but showed much
smaller differences in the timing of viraemia curves between treatment groups than
was indicated by the experimental data. As a result, the model did not accurately
reproduce the experimental data.
The parameters identified in Model A to have a strong influence on the output of the
model (Figure 8.8) were modified in Models B and C to obtain a better agreement
between the models and the experimental data.
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8.4.2. Model B
Model B differed from Model A in the modification of f}\ by the term
Yp
(Equations 8.5 & 8.6). A typical output from Model B (Figure 8.10) was
m+Yp
similar to the output from Model A (Figure 8.7), with the exception that viral growth
was delayed in the early stages of infection, an effect of modifying /?,. Parameter m
determined the virus concentration of Y at which /?, reached maximum (Figure 8.2),
the greater the value ofm, the longer the delay in viral growth (Figure 8.11).
X- FMDV in the central compartment
Y- FMDV in the interstitial space
C - uninfected epithelial cells
D - infected epithelial cells
Figure 8.10 Model B (X(0) = 1x104, kyo = 4.0,/?, = 6x10"12, /?2 = 1x10"10, m = 1x102, p = 0.5 and
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Figure 8.11 Model B. Values for m varied 8-fold (T(0) = 1x104, ky0 = 4.0, /?, = 6x10"12, /?2 = 1x10"
10
and other parameter values described in Table 8.1).
The effect of varying the rate of change of /?i (through p) on different inoculation
doses (X(0)) was explored in Figure 8.12. At constant fi\, tenfold differences in dose
resulted in viraemia curves close together (Figure 8.9). These curves could be
separated from each other by introduction of a variable per capita /3\ (Equations 8.5 &
8.6), sigmoidal in shape (Figure 8.2). Increasing the rate of change of /3\ (through
increase ofp) amplified the dose differences, so that the degree of separation between
the viraemia curves could be controlled though p. The more rapid the increase in /3\
(and the lower the inoculation dose), the greater the degree of separation.
The output from Model B was compared to experimental data from Experiment
mini4 (Quan et al., 2004, Chapter 4) in Figure 8.13 and a good overall fit was
obtained.
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Figure 8.12 Model B. The time taken from inoculation to 1x10 FMDV genomes/ml serum
Y"
(including a minimum), in which p, is modified by the term
m Y'
. Values for p varied 8-fold
























4.0, [11 = 6x10'12,1?2 = 1x10"10, other parameter values described
Model output for X, when X{0) = 10!
Model output for X, when X((j) =10'
Model output for X, when X{0) =10
0 24 48 72 96 120 144 168 192 216 240
Time (hours)
Figure 8.13 An illustrative fit of Model B to experimental data from Experiment mini4 (kyo =
4.0, /?, = 6x10"12, p2 = 1x10"10, m = 1x102, p = 0.5 fitted visually to data; other parameter values
are described in Table 8.1). Red, green and blue symbols indicate different treatments, i.e.
1081, 1071 and 1061 FMDV genomes/animal intravenous inoculation; shapes indicate
individual animals. Box plots show the median time (and 25th and 75th percentile) active
viraemia was first detected (detection of FMDV below 102"3 genomes/ml serum is not reliable).
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8.4.3. Model C
A typical output from Model C is shown in Figure 8.14. Initial viral growth was
limited by the removal term k i-HL
K
The saturation capacity of the removal
system (AT) delayed viral growth, which shifted a viraemia curve to the right with
increasing K (Figure 8.15). Dose differences could be amplified (especially at low
inoculation doses) by varying values of kyo (Figure 8.16). Once the removal system
was saturated, viral growth was rapid and ultimately limited by the depletion of
epithelial cells. At this stage, there was no further removal of virus, due to saturation
of the removal system and the high concentration of virus in the central compartment
and interstitial space were maintained (cf. Model A with Figure 8.14).
1012
X- FMDV in the central compartment
Y- FMDV in the interstitial space
C - uninfected epithelial cells
D - infected epithelial cells
















Figure 8.14 Model C (X{0) = 1x104, kyo = 1.8, fa = 6x10"12, fa = 0, K = 1x106 and other
parameter values described in Table 8.1).
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Figure 8.15 Model C. Values for K varied 8-fold (X(0) = 1x104, kvo = 1.8, /?, = 6x10"12, /T = 0,
other parameter values described in Table 8.1).
103 104 105
Inoculation dose {X{0))
(FMDV genomes/ml serum )
Figure 8.16 Model C. The time taken from inoculation to 1x10 FMDV genomes/ml serum
(including a minimum), in which kyo is modified by the term
other parameter values described in Table 8.1.
W_
~K ; p, = 6x10-12, p2 = 0,
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The output from Model C was compared to experimental data from Experiment
minl4 (Quan et cil, 2004, Chapter 4) in Figure 8.17. While the dose differences were
accurately reproduced (see time active viraemia first detected in Figure 8.17), FMDV
increased exponentially in the serum at a rate {X = 2f(0)e°'66/!) higher than was
calculated from the experimental data ( X - X({])e)Mh). The rate of increase of FMDV
in the central compartment could not be attenuated by adjustment of b, /?i, /T, kyx, kyo
or K without loss of accurate representation of either the dose differences or the start
of active viraemia seen in the experimental data.
Model output for X, when X{0) = 105
Model output for X, when X[0) = 104
Model output for A', when X(0) = 103
Time (hours)
Figure 8.17 An illustrative fit of Model C to experimental data from Experiment min14 (/?, =
6x10"12, /?2 = 0, kvo = 1.8, K = 1x106 fitted visually to data; other parameter values are
described in Table 8.1). Red, green and blue symbols indicate different treatments, i.e. 1081,
107'1 and 1061 FMDV genomes/animal intravenous inoculation; shapes indicate individual
animals. Box plots show the median time (and 25th and 75th percentiles) active viraemia was
first detected (detection of FMDV below 102"3 genomes/ml serum is not reliable).
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8.4.4. Model D
A typical output from Model D is shown in Figure 8.18. Initial viral growth was
limited by the binding of FMDV to non-specific binding sites. The saturation of
binding sites allowed FMDV to increase rapidly in the central compartment to a
maximum concentration. The subsequent decrease of virus resulted in an increase of
available binding sites when binding was competitive (0.2 > 0).
X- FMDV in the central compartment
Y - FMDV in the interstitial space
C- uninfected epithelial cells
D - infected epithelial cells
P - available non-specific binding sites




0 24 48 72 96 120 144 168 192 216 240
Time (hours)
Figure 8.18 Model D 05, = 6x10"12, ft = 5x10"11, kyo = 1.5, a, = 1x10'5, a2 = 1x10"3, Pm =
2.5x10s, other parameter values are described in Table 8.1).
The influence of different Kdiss (dissociation constant a2la\) values on Model D is
shown in Figure 8.19. The smaller the value of Kchss, the greater the limit on viral
growth and the longer the persistence of the virus. Kc/iss also had an influence on the
dose effect and the degree of separation of viraemia curves obtained from different
inoculation doses (X{0))', the smaller the constant, the greater the dose effect and
degree of separation (Figure 8.20).
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X- FMDV in the central compartment
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Figure 8.19 Effect of Kdiss on Model D (/?, = 6x10"12, = 5x10"11, kvo = 1.5, eg = 1x10"5, P(0} =





























(FMDV genomes/ml serum )
Figure 8.20 Model D. The time taken from inoculation to 1x106 FMDV genomes/ml serum
(including a minimum) for different values of Kdiss (cg/cg) (/?i = 6x10"12, = 5x10"11, kyo = 1.5, «i
= 1x10"5, i°(0) = 2.5x105).
Model D was sensitive to changes in og; increasing values of a\ attenuated viral
growth (Figure 8.21). Similar results were obtained for P(oh as it was related to a\
through the mass action term eg YP (Equations 8.9 -8.11).
The output from Model D was compared to experimental data from Experiment
minl4 (Quan et a/., 2004, Chapter 4) in Figure 8.22 and a good overall fit was
obtained.
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a, = 4.0x1CT5or P(0) = 1.0x106
a, - 2.0x10"5or Pm = 5.0x10s
at = 1.0x10'5or Pm = 2.5x10s
at - 5.0x10'6 or Pm) = 1.3x105




Figure 8.21 Model D. Values for a\ (Pm = 2.5x105) or P{0) (a, = 1.0x105) varied 8-fold (X(0) =
1x104, i = 6x10"12, /?2 = 5x10"11, kyo = 1.5, a2 = 0, other parameter values described in Table
8.1). A linear relationship exists between ax and (doubling the value for Pio, has the same















Model output for X, when X(0) = 10:
• Model output for X, when X[a) = 10'









Figure 8.22 An illustrative fit of Model D to experimental data from Experiment min14 (/?,
ky0 = 1.5, a, = 1x10" , «2 = 0, P{o) = 2.5x10 fitted visually to data; other6x10"12, /?2 = 5x10"11
parameter values are described in Table 8.1). Red, green and blue symbols indicate different
treatments, i.e. 108 1, 1071 and 1061 FMDV genomes/animal intravenous inoculation; shapes
indicate individual animals. Box plots show the median time (and 25th and 75th percentiles)
active viraemia was first detected (detection of FMDV below 10
reliable).
,2-3 genomes/ml serum is not
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8.5. Discussion
A theoretical framework was developed to explore the early dynamics of FMDV in
vivo. All the stages of the intra-host life cycle of FMDV, from distribution within the
host, the infection of epithelial cells, replication within the cell, cell death with release
of progeny virus, infection of neighbouring epithelial cells were included in Model A.
The focus of the model was on viral dynamics in the early stages after infection and a
full description of the adaptive immune response in this model was not included.
Virus concentrations in the central compartment and interstitial space were described.
The interstitial space is an important compartment in the body as it the interface
between the central compartment and the epithelial cells. This space contains water,
small solutes, plasma proteins, collagen, elastin, hydrophilic polymers such as
hyaluronate and proteoglycans, fat and cells (Geiger et al., 1984). A large fraction of
the plasma proteins and fluid reservoirs are found in the interstitium of connective
tissues.
Experimental work had shown that FMDV in the central compartment decreased
rapidly (lA life of 28 min) after intravenous inoculation (Exp mini6 and min22-rates,
Chapter 7). The loss of virus from the central compartment may have been due to the
accumulation of the virus in the interstitial space, clearance of FMDV by the immune
system and/or loss of FMDV to epithelial cells. Of the possibilities, the accumulation
of FMDV in the interstitial space was considered the most likely mechanism for the
decrease of the virus from the central compartment.
The immune system as the main mechanism for clearance of FMDV from the central
compartment after an intravenous bolus of FMDV was unlikely based on
experimental evidence that FMDV could not be detected in tissues of the
mononuclear-phagocyte system, such as the liver, spleen and lymph nodes two hours
after an intravenous inoculation of 10x 1 FMDV genomes (Experiment min 16). The
detection threshold of the assay used to measure FMDV in tissue was approximately
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103?-4° FMDV genomes/g tissue. If the same inoculation dose was used and only 10%
of circulating FMDV was removed by the liver, the approximate concentration was
calculated to be 1043 FMDV genomes/g liver in a 25 kg pig [liver weight was
calculated as 2.7% live weight (Collin et al., 2001) and a homogenous concentration
of virus in the liver was assumed], above the detection threshold of the assay. If the
mononuclear-phagocyte system was the main mechanism for clearance of FMDV
from the central compartment, virus should have been detected in these tissues.
The decrease of FMDV from the central compartment may also have been as a result
of loss of virus to epithelial cells. Models describing virus concentrations in the
central compartment and in the epithelial space (not described here) in which the
uptake of virus by epithelial cells was the main mechanism for the loss of virus from
the central compartment, showed a very quick onset of viraemia (for a wide range of
inoculation doses). The loss of virus to epithelial cells was therefore not considered to
be the main reason for the decrease of FMDV from the central compartment.
The dynamics of uninfected epithelial cells were not fully described in the model
because the focus of this research was on the early stages of FMDV infection and only
covered a short time period relative to the normal turnover of epithelial cells
[estimated to be 82 days in guinea pigs (Piatt, 1959)]. In Model B, 74% and in Model
D, 83% of epithelial cells were destroyed by FMDV infection, as no cell turnover was
included in these models. FMDV infection will ultimately increase the rate of
epithelial cell turnover as a result of cell destruction and this effect may be important
during the later stages of infection. A full description of epithelial cell dynamics may
therefore be needed in models that describe the entire infection process.
Model A qualitatively reproduced the general shape of a viraemia curve (Figure 8.7),
but did not accurately reproduce the dose differences seen in the experimental data,
nor capture the delay in time between inoculation and the start of an active viraemia
when virus was undetectable in the central compartment (latent period) (Figure 8.9).
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A comparison between the output from Model A and the experimental data suggested
a non-linear relationship between inoculation dose and onset of active viraemia.
Different non-linear relationships were explored to explain the discrepancies between
the model and the data. Model A was modified by either i) limiting the rate of
infection of epithelial cells at low FMDV concentrations, ii) converting the virus
removal system into one of limited capacity or iii) including a virus removal system
of limited capacity. The modifications focused on the parameters Model A was most
sensitive to: and kyo (along with b) (Figure 8.8).
A better fit to the data could be obtained by limiting the infection rate of epithelial
cells at low FMDV concentrations (Model B and Figure 8.13). In vivo experimental
evidence to support this modification is lacking, but a limited infection rate at low
FMDV concentration has been described in vitro (Thorne, 1962). The FMDV type O
strain and pig kidney cells were used to show that the infection rate was proportional
to virus concentration at low virus concentrations. At higher virus concentrations, the
infection rate levelled off to a constant value, resulting in a curve similar to those seen
in Figure 8.2.
Two biological interpretations of a limited rate of infection at low virus
concentrations are a minimum infectious dose per cell hypothesis and virus-virus
interactions.
The proportion of cells infected from a given virus concentration can be determined
from the multiplicity of infection (Knipe et al., 2001). From a hypothesis in which
cells are able to support viral replication only if they contain a minimum number of
viruses, the effective rate of infection (infection in cells that support replication) can
be calculated and shown to be similar in form to the curves in Figure 8.2. There is no
evidence to show that more than one FMDV is needed to initiate a successful
infection in a cell, but the dose dependent inhibition of host protein synthesis and
stimulation of viral protein synthesis by FMDV strongly suggests that a minimum
infectious dose is likely.
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Infection of cells with FMDV results in the inhibition of host protein synthesis. The
mechanism involves the cleavage of the translation initiation factor elF4G by the
leader (or L) (Devaney et al., 1988; Medina et al., 1993) and 3C protease (Belsham et
al., 2000) of FMDV. eIF4G is part of the eIF4F complex that plays a critical role in
the recognition of the cap structure of cellular mRNA by the translation machinery of
the cell (Prevot et al., 2003). Translation of FMDV RNA is cap-independent and
depends instead on the presence of an internal ribosome entry site (IRES) element
within the 5' noncoding region (Belsham & Brangwyn, 1990). FMDV infection
therefore results in a switch of the cell's translational capacity from cellular to viral
protein synthesis. If only a few virus particles infect a cell, it is possible that the viral
infection may be unable to direct the cell's translational machinery towards viral
protein synthesis because of low L and 3C concentrations and an abortive infection
will be the result.
The primary advantage for a virus to inhibit host protein synthesis may be that the
ability of the cell to mount an anti-viral response is diminished. Interferon production
is induced within FMDV-infected cells, but these interferons are suppressed by
FMDV leader protease (Sellers, 1963; Chinsangaram et al., 1999; Zhang et al, 2002).
Interferons trigger various responses within a cell, including the activation of the
dsRNA-activated protein kinase PKR (Kaufman, 2000). This kinase phosphorylates
the a-subunit of eIF2 and hence blocks the initiation step of both host and viral
protein synthesis, to the obvious detriment of FMDV.
Ohlmann et al., (1995) has shown that the rate of translation of uncapped mRNA in
vitro is dose dependent and a determinant of this rate is the concentration of L
protease. At low L protease concentration, the rate of uncapped mRNA translation
was directly proportional to L protease concentration. The greater the number of
viruses infecting a cell, the higher the L protease concentration within the cell and the
greater the efficiency in directing the cell's translational machinery towards viral
protein synthesis. An inability of FMDV to produce viral proteins at low virus
numbers can therefore be expressed as a minimum infectious dose/cell.
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It has not been shown for FMDV, but virus-virus interactions can enhance the uptake
of virus by target cells. Non-receptor mediated murine mink cell focus-inducing virus
infection could be triggered in trans by the ecotropic virus glycoprotein expressed on
the cell surface in a complex with its receptor. In addition, trans activation increased
the rate of spread of the virus through a population of target cells, indicating that
receptor-dependent and -independent pathways functioned in parallel (Wensel et a/.,
2003). The rate of infection of cells by this virus is therefore not a constant and would
increase with increasing virus concentration up to a maximum rate.
Yp
The term was used to limit P\ at low virus concentrations (Equations 8.5 and
m + Yp
8.6). The equation for calculating the rate of infection was first reported by Michaelis
& Menten, (1913) to describe a saturating reaction rate in enzyme kinetics and has
also been used by Holling, (1959), to describe Type III functional response predator-
prey interactions.
In the Michaelis-Menten equation, the equivalent to m (Model B) is the Michaelis
constant (Km). The Km value is the substrate concentration at which the rate of the
reaction is half the maximum rate and indicates the affinity of an enzyme for
substrate. The effect of m on the model was to shift curve a viraemia curve (Figure
8.11) to the right with increasing values of m. In the context of Model B, m may be
thought of as the affinity of FMDV for its epithelial cell surface receptor.
The Hill equation is a modification of the Michaelis-Menten equation, in which the
substrate concentration (in this case Y) is raised to a power (p). The modification has
been used to describe allosterism, a process in which conformational changes are
induced in the binding sites of an enzyme when a ligand or substrate binds to that
enzyme. The conformational change can either increase (positive cooperativity, p > 1)
or decrease (negative cooperativity, p < 1) the activity or affinity of the enzyme. In
Model B, increasing values of p amplified dose differences by increasing the
separation in time of viraemia curves of different doses (Figure 8.12). In this context,
p is a measure of the influence of the virus receptor complex on other available
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receptors. Negative cooperativity implies the loss of available "bystander" receptors,
in addition to those bound to virus and early endosomal formation as a result of
FMDV attachment to epithelial cell surface receptors would be an example of this
(Miller et al., 2001). The binding of FMDV to epithelial cell surface receptors induces
parts of the cell membrane to pinch off to form early endosomes. These endosomes
decrease the number of available receptors FMDV can bind to, as they contain not
only the virus-receptor complex, but receptors unbound to virus. For the fit of Model
B to experimental data, p - 0.5 was used.
The fit of Model B to the experimental data was an improvement on Model A as the
former reproduced the dose differences, as well as the latent period in the
experimental data, which the latter model did not.
An alternative modification to Model A to better approximate the data was to convert
the virus removal system into one of limited capacity (Model C). An example of such
a system is the mononuclear-phagocyte system (MPS) (van Furth, 1992). The MPS is
a system of phagocytic cells ofwhich the mature functioning form is the macrophage.
All mononuclear phagocytes are considered to share a common origin from the bone
marrow pro-monocytes and to share a common function, i.e. phagocytosis and
digestion of particulate material (Herbert et al., 1985). Monocytes in the circulation
are able to migrate into tissues and body cavities and transform into macrophages.
Monocytes lining the sinusoids of the liver become Kupffer cells; in the epithelium,
they become Langerhans cells.
The MPS can be saturated by high doses of FMDV (Sutmoller & McVicar, 1976). In
( w^
Model B, kyo was modified by the logistic term 1 (Equations 8.7 & 8.8).
v K
Increasing values of K shifted the viraemia curve to the right (Figure 8.15). A dose
effect, visible as the separation in time of the viraemia curves, was strongly amplified
for increasing values of kyo (Figure 8.16).
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Although Model C reproduced the dose effect with the correct separation in time of
the viraemia curves (Figure 8.17), the rate of increase of FMDV in the central
compartment was higher than the data indicated. Viral growth could not be controlled
once the removal system was saturated and as a result, the model could not accurately
describe the data. Viral growth was only controlled when the viral concentration was
high enough to deplete all uninfected epithelial cells. In vivo, it is possible that such a
level would not be reached, due to an adaptive immune response.
A process with limited capacity is non-specific plasma/tissue binding (Model D). For
insoluble substances in the circulation, the primary mechanism of distribution in an
animal appears to be in association with plasma proteins (Riviere, 1999). Substances
that are weak acids are bound to albumin while weak bases often bind to acid
glycoproteins. The four viral proteins (VP1, VP2, VP3 and VP4) that make up the
FMDV capsid confer an overall charge to the virus and the strength of binding of
virus to other proteins is determined by this charge. Bound virus does not play an
important role in early viral dynamics, as the bound virus is unable to bind to
epithelial cells or replicate.
The strength of binding between a substance and plasma protein varies, as substances
may be covalently or noncovalently (i.e. ionic or hydrogen binding, weak
interactions) bound (Riviere, 1999). Covalent binding is a non-competitive
(irreversible) process and noncovalent binding a competitive (reversible) process.
Non-competitive binding occurs when a substance is not released once bound.
Competitive binding occurs when the substance is able to dissociate from the binding
protein, either due to binding to another protein of greater affinity, binding to another
protein of lower affinity but which is at a higher concentration, or changes in the
dissociation constant (Kdiss) as a result of changes in pH or temperature, for example.
Competitive binding follows the law of mass action, where the degree of binding is
determined by the concentrations of free virus, available binding sites and bound virus
(Figure 8.4).
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Non-specific binding sites are limited and thus saturable. A saturable non-specific
binding component has a greater effect at lower inoculation concentrations than at
higher concentrations. This is supported by data from samples taken one to five
minutes after inoculation in Experiments mini3 and mini4 (Chapter 4). The results,
based on an estimate of serum volume, shows that a lower percentage of virus was
recovered from the low dose inoculation groups (21 %), compared to the medium dose
(90%) or high dose (100%) inoculation groups (results were normalised so that the
high dose result was = 100%).
It is likely that FMDV is extensively plasma protein bound and will therefore tend to
remain within the circulation. Data from Experiment mini6 showed a rapid loss of
FMDV from the circulation after intravenous inoculation. This indicated that the
affinity of FMDV for tissue protein (outside the central compartment) is probably
much greater than that of plasma proteins. Alternatively, the affinity of FMDV for
tissue protein may be less than that of plasma proteins, but the density of tissue
binding sites much higher than that of plasma protein binding sites. The accumulation
of FMDV in the interstitial space for other reasons, such as a pH differences should
not be excluded.
Model D was formulated with a non-specific binding component in the interstitial
space. The rate that virus in the interstitial space was bound = o.\P and the rate virus
was unbound = 0.2 (Equations 8.9 - 8.11). Kdiss is the ratio between a2 and oq and Kdiss
- 1 therefore does not mean the rates viruses are bound and unbound are equal; they
are only equal when KdjSS = P. KdiSS was used to explore how the spectrum from non¬
competitive to competitive binding affected viral dynamics. Non-competitive binding
(low values of KdiSS) limited initial viral growth, shifted the viiaemia curve to the light
(Figure 8.19) and amplified a dose effect (Figure 8.20). As binding became more
competitive (increasing Kdiss), the viraemia curve shifted left and tended towards the
curves obtained from Model A.
Model D was sensitive to the rate virus was bound (Figure 8.21) and a value for cq
could be determined that gave a good fit of the model to the data (Figure 8.22). The
best fit of the model was obtained when tissue binding was non-competitive (a2 = 0),
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increasing values of 0.2 decreased the separation in time of the viraemia curves. These
results suggest that in vivo, FMDV is bound irreversibly to non-specific tissue binding
sites.
Model C and D were very similar as they both described a removal/binding system of
limited capacity and the form of the rate of removal/binding was similar (compare
Figure 8.3a & Figure 8.6b). The differences between Model C and D were in the
inclusion of 0.2 and a constant per capita rate of removal of FMDV from the
interstitial space (kyo) in Model D. If an and kyo were both set to zero, the output from
both models was identical for the same parameters values (results not shown).
Model A was kept as simple as possible, so that the underlying principles governing
viral infection and determinants of the early dynamics of FMDV in vivo were clear.
The models presented are not complete descriptions of the early infection process of
FMDV. The form of /?2 has not been fully described. If we assume viral infection of a
single (cuboidal) epithelial cell on the basement membrane and spread of the infection
laterally and superficially to neighbouring cells from the infected cell, we can show
that the rate of infection of uninfected cells decreases exponentially over time and the
form of /?2 as a function of time is 2nd order (results not shown). In this case /6
describes a single focus of infection; how /6 varies with multiple foci at various stages
of infection is not known.
The nature of the burst size (b - the number of FMDV genomes released per ml of
interstitial space per burst infected cell) deserves closer attention. An inverse
relationship between the rate of infection of epithelial cells by infected cells (/fc) and b
is likely. Infection of an epithelial cell by FMDV should initially result in a high rate
of spread of virus between cells (many susceptible cells available) and a low rate of
virus released into the interstitial space. As the infection progresses, /6 is likely to
decrease as susceptible cells become limiting and b is likely to increase, due to an
increasing concentration of replicating FMDV in the epithelial space, as well as the
breakdown of the basement membrane (a membrane that separate the interstitial space
from the epithelial space) as a result of inflammation.
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A full description of the immune system was not included in these models as the focus
of this research was on the early stages of viral infection. The importance of the innate
immune response during this time period was not fully assessed and in the models
was represented by a constant removal rate of virus from the interstitial space.
A more detailed description of the immune response may be warranted as an
interesting hypothesis raised from this modelling exercise is whether the peak in
viraemia is determined by a limitation of uninfected epithelial cells or whether the
immune response removes virus before this can occur, analogous to bottom-up
regulation or top-down regulation respectively (Haydon et a/., 2003).
In this chapter a theoretical framework was developed to explore early viral dynamics
of FMDV in vivo. A model using constant parameter values (Model A) could not fully
describe experimental data and modifications to the model resulted in good
agreements between the models and experimental data. These modifications were i)
limiting the rate of infection of epithelial cells at low FMDV concentrations (Model
B), ii) converting the virus removal system into one of limited capacity (Model C) or
iii) including a virus removal system of limited capacity (Model D).
Model B was supported by more substantial experimental evidence and literature
compared to Model D. Both models provided closer fits to the data than Model C.
Discrepancies between the model and the data could be best explained by a limited
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9.1. General results
9.1.1. Comparison between intravenous and intradermal inoculation
9.1.1.1. Assay differences
Different assays were used to analyse data from pigs inoculated by the intravenous
(Experiments mini3) and intradermal (Experiments minl9/min22-dose) route, and the
data from these experiments were not directly comparable. The former used an 'old'
SA-1R-219-246F/SA-IR-315-293R/SAmulti2-IR292-269R assay quantified against a
FMDV O Kaufbeuren standard and the latter a 'new' SA-UK-IRES-248F/SA-UK-
IRES-308R/UK-1RES-271T assay quantified against a FMDV O UKG standard.
The same FMDV O UKG samples were tested by both assays to compare the
sensitivities of assays. The new assay was approximately 40 times more sensitive than
the old assay, with an average cycle threshold difference of 5.33 (n = 29, 95% CI of
4.74 - 5.93) between the two assays (results not shown).
The two assays were extensively compared with each other in respect of the efficiency
with which the assays detected FMDV O Kaufbeuren and O UKG standards. PCR
efficiency was calculated by the following equation: Efficiency = io("lslope ot standard
curve)
_ j effjcjenCy wjth which the old assay detected FMDV O UKG samples
was 84.8% (n = 3, 95% CI of 76.4 - 93.2%) and the standard (FMDV O Kaufbeuren)
was 86.2% (n = 59, 95% CI of 84.5 - 87.9%). The new assay used a FMDV O UKG
standard for quantitation, which was detected with an efficiency of 98.3% (n = 6, 95%
CI of 94.8 - 101.8%) (results not shown).
The different sensitivities and efficiencies between the two assays resulted in a mean
quantitative 1010-fold difference (n - 29, 95% confidence interval of 10ox - 101'1)
between the two assays, when FMDV O UKG samples were analysed. Data from
Experiments minl9 and min22-dose were therefore scaled (1.0 log subtracted) when
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compared with data from Experiments mini3 (see Figure 9.1). Any result less than
102 FMDV copies/ml of serum after scaling was taken to be zero, as this is the
approximate detection threshold of the 'old' PCR assay.
9.1.1.2. Intravenous and intradermal inoculation
Intravenous inoculation was compared with intradermal inoculation, to determine how
the route of inoculation affected viral dynamics (Figures 9.1 and 9.2). Pigs inoculated
by the intradermal route received a dose half that given to pigs in the same treatment
group but inoculated by the intravenous route. This difference is negligible when
results are compared on a log scale (0.3 log difference in dose). In addition, the
amount of virus given by intradermal inoculation was neither as accurate nor as
precise as that given intravenously, since it was unlikely that the whole inoculum was
injected intradermally. Some virus may be injected into the subcutaneous space or the
circulation, or seep back out of the inoculation site, especially when the area is put
under pressure (e.g. when the foot is weight bearing). As FMDV replicates in
epithelial cells, the effective dose will depend on the proportion of virus that is
injected intradermally. For virus injected into the subcutaneous space or circulation,
the basal membrane of the epithelium provides a barrier that the virus must cross in
order to replicate.
Although similar amounts of inoculum were used for intravenous and intradermal
inoculations, the disease progression was much more rapid in pigs inoculated by the
intradermal/ subcutaneous route than in pigs inoculated intravenously. The start of
active viraemia was reduced (by up to 24 h) in pigs inoculated by the intradermal
route compared to the intravenous route. Intradermal inoculation was a more effective
method than intravenous inoculation for transmitting FMDV to pigs, resulting in
shorter times to the start of active viraemia and clinical scores.
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Figure 9.1 Differences in mean a) viraemia ±SE (solid lines) and b) clinical signs ±SE
(dashed lines) between pigs inoculated by intravenous (blue) and intradermal inoculation
(red). Viraemia data from pigs inoculated by the intradermal route (solid red lines) scaled (1.0
log removed) to make it comparable to data from pigs inoculated by the intravenous route.
Intravenous (i.v) route Intradermal (i/d) route
High dose 1059 TCID50/pig 1056 TCID50/pig
Medium dose 104 9 TCID50/pig 104'6 TCID50/pig
Low dose 103'9TCID50/pig 103 6 TCID50/pig
• High dose i/v inoculation (n = 4)
▼ Medium dose i/v inoculation (r? = 4)
■ Low dose i/v inoculation (n = 4)
• High dose i/d inoculation (n = 4)
▼ Medium dose i/d inoculation (n = 2)
■ Low dose i/d inoculation (n = 5)
0 24 48 72 96 0 24 48 72
Hours post inoculation
o Detection of active viraemia (i/v inoc.) o Onset of clinical signs (i/v inoc.)
O Detection of active viraemia (i/d inoc.) O Onset of clinical signs (i/d inoc.)
23456 72 34567
inoculation dose (Log TCID50)
Figure 9.2 Linear regression of time (±SE) to a) first detection of active viraemia and b) onset
of clinical signs as a function of inoculation dose; i/v inoc. = intravenous inoculation (solid
lines), i/d inoc. = intradermal inoculation (dashed lines).
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9.2. General discussion
FMD is a disease of global importance and plays an important role in the limitation of
trade in livestock and livestock products between FMD free and endemic countries.
Limitations are strict because of the highly contagious nature of the disease. The
consequences of an outbreak of FMD can be devastating, as witnessed by the FMD
outbreak in the United Kingdom in 2001. The risks of an outbreak are so high that no
trade in animal or animal products can take place unless freedom from infection can
be demonstrated. This includes co-called 'carrier' animals, even though no firm
scientific evidence that carrier animals can transmit the disease has been published.
Although the risk of a carrier animal transmitting the disease is likely to be very low,
the consequences of a possible outbreak far outweigh this low risk.
The detection of FMDV is now more rapid and sensitive than traditional techniques,
due to the development of new molecular techniques such as fluorogenic RT-PCR and
it is now possible to obtain fairly accurate quantitative data. This thesis reports on the
quantitative biology and pathogenesis of FMD, as determined by RT-PCR, and uses
these data in the development of mathematical models to describe the viral dynamics
of FMDV in vivo.
The relationship between genome copy number (as determined by RT-PCR) has been
correlated with infectivity and TCID?o (Table 9.1). The FMDV O UKG samples were
analysed using the 'old' primers and probe set (see 9.1.1.1). Using the more sensitive
and accurate 'new' assay, values presented in Table 9.1a would be expected to be
approximately 1 log higher (i.e. the mean genome copy number to TCIDjo ratio would
be 103'25 (1 780) genomes/TCIDjo in pre peak viraemia samples). The ratio of copy
number to TCID5o varied according to the presence of antibodies (assumed in samples
collected after the peak in viraemia). In pigs infected with FMDV O UKG, the ratio of
genome copy number to TCIDso was 12-fold higher in samples collected after the
peak in viraemia. The ratio also varied according to virus type and tissue culture used
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for titration (Table 9.1b). Using Table 9.1, an estimate of infectivity can be obtained
from RT-PCR results presented in this thesis.
Table 9.1 Calculation of the number (log value) of a) FMDV O UKG genomes (measured
using a SA-IR-219-246F/SA-IR-315-293R primer and SAmulti2-IR292-269R probe set) per
TCID50 (measured on BTY cells), and b) FMDV O TAW genomes (measured using primer
probe set described above) per TCID50 (measured on IB-RS-2 cells). A loss of infectivity with
time due to an antibody response was assumed. Samples were therefore divided into those
taken before the peak of viraemia (pre-peak viraemia) and those taken after the peak of
viraemia (post-peak viraemia).
A mean/animal was first calculated from logarithmic values to account for any animal effect.
Includes samples taken at the peak of viraemia.
CI Confidence Interval.
a) b)
Pre peak Post peak All serum Pre peak Post peak
viraemia viraemia samples viraemia viraemia
Mean1" 2.25 3.34 2.87 5.00 5.21
Standard deviation 0.44 0.34 0.21 0.85 0.99
Number of animals 7 7 7 11 9
Number of samples 8 13 28" 20 9







The temporal distribution of FMDV in various tissues of pigs infected by limited
direct contact with FMDV infected pigs was examined. The results demonstrated the
very rapid time-scale of infection: pigs were most likely infected by the oro-nasal
route as high concentrations of FMDV could be detected in tissues of the oro-nasal
pharynx as well as lymph nodes that drain this region two hours after the pigs were
exposed to FMDV-infected pigs. The spread of virus from the site of entry to the
lymph nodes was most likely via the lymphatic system as there was no detectable
viraemia at this time. There was no indication that FMDV replicated in the lymph
nodes as the concentration of FMDV in these lymph nodes was lower at later time
points. Replication of FMDV appeared to take place locally at the site of entry or at a
distant site that the virus reached via the lymphatic or circulatory system. As viraemia
levels increased, virus concentrations in the tissues mirrored levels in the general
circulation. Virus was rapidly cleared from this compartment while the rate of
clearance of FMDV from the tissues was a lot slower.
The next area examined was the influence of inoculation dose and housing conditions
on FMDV dynamics. Exposure to FMDV was by intravenous or intradermal
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inoculation or by the oro-nasal route. Similar results were obtained from pigs infected
with FMDV by the intravenous, intradermal or oro-nasal route:
• A strong relationship between inoculation dose and incubation period was evident:
the higher the inoculation dose, the shorter the incubation period, and vice versa.
• The higher the inoculation dose, the more predictable and consistent was the
incubation period and course of infection. The lower the inoculation dose, the
more variable was the incubation period and the probability of subclinical
infections.
• Housing pigs in a group rather than individually resulted in synchronised
infections and reduced the variance in the incubation period. The onset of clinical
signs occurred earlier in pigs housed as a group than individually. Transmission of
FMDV appeared to be frequency-dependent (transmission is a function of the
number of infected animals) rather than density-dependent (transmission is a
function of the density of animals) over the range of densities used here.
The maximum rate of increase of FMDV in the circulation was shown to be
independent of the inoculation dose. Similar mean values were obtained from pigs
inoculated by the intravenous [0.33 (95% CI 0.24-0.41) for Experiment mini3; 0.26
(95% CI 0.20-0.31) for Experiment mini4] and intradermal [0.28 (95% CI 0.22-0.34)]
routes.
The intradermal route was shown to a more effective route of inoculation than the
intravenous route. The difference in the incubation period between the two routes was
dose dependent. At high inoculation doses, the difference was slight, but increased as
the inoculation dose was decreased. A dose of 103 TCID50 showed a difference of
approximately 4 days (as measured by onset of clinical signs, Figure 9.2) between the
two routes (Figure 9.2).
In the field, the incubation period of FMD in pigs ranges from 24 h (Yang et al.,
1999; Sims et al., 2000) to 14 days (Alexandersen et al., 2003a). This is in close
agreement with values obtained from experimental data (Figure 9.2) and from the
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modelling exercise (see Figures 8.12, 8.16 & 8.19). The results suggest that the
maximum incubation period by the intradermal route is approximately 6 days. An
incubation period of between 6 to 14 days therefore excludes biting, fighting or
scratching as a probable route of infection.
In experimental animals, nasal swabs offer a better alternative to serum samples for
the detection of FMDV, as the virus can be detected for a longer period in the former.
In pigs infected by the direct contact route, FMDV was detected in nasal swabs before
the vims was detected in serum samples, although in pigs inoculated by the
intravenous and intradermal route, viraemia preceded the detection of FMDV in nasal
swabs. In some cases, there was evidence for local replication of FMDV in the upper
respiratory tract without the detection of virus in the circulation, nor clinical signs. As
mentioned earlier, the clearance of virus from the circulation by the immune system
occurs rapidly and FMDV could often be detected in nasal swabs when serum sample
were negative. Whether the same situation exists in the field remains to be seen, but
further research in this area is warranted.
Another area that was explored was the development of mathematical models to help
explain the quantitative data and explore the early viral dynamics of FMDV in vivo.
Initial experimental work focussed on the calculation of the rate FMDV was cleared
from the circulation. SVDV was included in these experiments to, a) provide a
comparison to FMDV, and b) included at a high concentration in dual inoculations
with FMDV to help saturate non-specific binding sites in order that the rate of
clearance of FMDV from the circulation could be accurately determined. Results
indicated that SVDV did not saturate non-specific binding sites as the majority of the
virus was taken up by the spleen, probably as a result of the high affinity of SVDV for
heparan sulphate receptors. This highlighted the differences between the two viruses,
as FMDV does not show as strong an affinity for the spleen.
Initial models of the early viral dynamics of FMDV disagreed with the experimental
data. The models predicted much smaller dose differences (in the temporal
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distribution of the viraemia curves) than was indicated by the experimental data. This
disagreement could be resolved by:
• limiting the rate of infection of epithelial cells at low FMDV concentrations,
• converting the virus removal system into one of limited capacity, or
• the addition of a virus removal system of limited capacity, such as non-specific
binding of FMDV.
A hypothesis in which the rate of infection of epithelial cells was limited at low
FMDV concentration could be supported by the literature and the strongest case could
be made for this modification. For FMDV to successfully infect and replicate within a
cell, host protein synthesis has to be switched off and anti-viral defences inactivated.
The probability of a successful infection increases as the number of infecting viruses
increases, suggesting that the rate of infection of cells at low FMDV concentrations is
indeed limited.
The modelling exercise has highlighted the important determinants of viral dynamics
and focussed on areas that require further research. The exercise has raised more
questions than it has been able to answer, but this should lead to a fuller and deeper
understanding of the dynamics of not only FMDV, but viruses in general.
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Reagents and buffers Appendix A
Glasgow Eagle's Medium (CSU 001 - MED 004)
Sodium chloride (NaCI) 6.4000 g
Potassium chloride (KCI) 0.4000 g
Magnesium sulphate (MgS04.7H20) 0.2000 g
Glucose 4.5000 g
Ferric nitrate (0.1%) 0.1000 ml
Sodium dihydrogen orthophosphate (NaH2P04.H20) 0.1250 g
Glutamine 0.2920 g
Calcium chloride (CaCI2.2H20) 0.2640 g
Sodium hydrogen carbonate (NaHC03) 2.7500 g
Phenol red (0.1%) 15.000 ml
L-Arginine 0.0420 g
L-Cystine 0.0240 g
L-Histidine (HCI.H20) 0.0210 g
L-lsoleucine 0.0524 g
L-Leucine 0.0524 g








Vitamin concentrate 4.0000 ml
Final deionised water volume 1.0000 I
M25 Phosphate Buffer (CSU 001 - MED 008)
Disodium hydrogen phosphate (Na2HP04.2H20)
Potassium dihydrogen phosphate (KH2P04)








Potassium dihydrogen orthophosphate (KH2P04)
Disodium hydrogen orthophosphate (Na2HP04)
Calcium chloride (CaCI2.2H20)


























Reagents and buffers Appendix A
Glucose 1.0000 g
Ferric nitrate (0.1%) 0.0500 ml
Sodium dihydrogen orthophosphate (NaH2P04 H20) 0.1250 g
Glutamine 0.8383 g
Calcium chloride (CaCI2 2H20) 0.2640 g
Sodium hydrogen carbonate (NaHC03) 0.8400 g
Sodium hydroxide 1 pellet




L-Histidine (HCI.H20) 0.0210 g
L-lsoleucine 0.0524 g
L-Leucine 0.0524 g








Vitamin concentrate 4.0000 ml
WRL field antibiotics 6.0000 ml






Table B-1 Experiment DEFRAexp2-Oct-2002. Temperatures of pigs UR91 - UR99, USOO -
US12. Time indicates hours post inoculation (UR91 - UR98) or post exposure (UR99, USOO -
US12).
a morning b afternoon
... animal killed, no sample collected t animal died, no sample collected
0 1a 2a 3a 4a 5a 6a 7a 8a 9a 10a
0.0 23.5 47.5 72.0 96.0 120.0 144.0 168.0 192.0 216.0 240.0
UR91 39.7 39.6 40.6 40.4
UR92 38.8 39.3 39.3 39.6
UR93 39.3 39.2 39.9 t t t t t t t t
UR94 38.3 37.9 39.6 t t t t t t t t
UR95 38.8 38.4 38.4 39.9 39.6
UR96 38.6 38.6 37.9 38.4 38.7 39.3 39.1 39.2 38.6 38.8 38.6
UR97 38.4 38.3 38.6 40.4 39.8 40.2
UR98 39.8 39.6 39.3 40.0 40.5 39.2 40.3 40.3 39.3 39.0 39.2
0 1a 2a 3a 4a 5a
0.0 24.5 48.5 72.5 96.5 120.5
UR99 39.2 39.0 39.1 39.2 40.1 40.4
USOO 38.8 38.7 39.7 39.3 40.0 40.5
US01 39.2 38.8 38.8 39.4 40.8 40.1
US02 38.7 38.8 39.0 39.3 39.9 39.8
US03 39.0 39.1 40.0 39.7 41.0
US04 38.8 39.1 39.6 40.0 40.6
US05 39.3 39.4 40.1 40.4
US06 38.7 39.2 40.0 40.6
US07 38.9 39.3 40.8





Table B-2 Experiment DEFRAexp2-Oct-2002. Clinical score of pigs UR91 - UR99, USOO -
US12. Time indicates hours post inoculation (UR91 - UR98) or post exposure (UR99, USOO -
US12).
a morning b afternoon
animal killed, no sample collected t animal died, no sample collected
0 1a 2a 3a 3b 4a 5a 6a 7a 8a 9a 10a
0.0 23.5 47.5 72.0 78.5 96.0 120.0 144.0 168.0 192.0 216.0 240.0
UR91 0 1 6 6
UR92 0 1 6 6
UR93 0 1 6 t t t t t t t t t
UR94 0 1 6 t t t t t t t t t
UR95 0 0 0 5 5 5
UR96 0 0 0 0 0 0 5 5 6 6 6 6
UR97 0 0 0 6 6 6 6
UR98 0 0 0 0 0 0 2 2 4 5
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0 1a 2a 3a 4a 5a
0.0 24.5 48.5 72.5 96.5 120.5
UR99 0.0 0.0 2.0 5.0 6.0 6.0
USOO 0.0 0.0 3.0 6.0 6.0 6.0
US01 0.0 0.0 3.0 6.0 6.0 6.0
US02 0.0 0.0 0.0 0.0 6.0 6.0
US03 0.0 2.0 6.0 6.0 6.0
US04 0.0 0.0 0.0 4.0 6.0
US05 0.0 0.0 0.0 0.0
US06 0.0 2.0 6.0 6.0
US07 0.0 0.0 6.0


































0 48 96 144 192 240 48 96 144 192 240










Time post exposure (h)
Figure B-1 Experiment DEFRAexp2-Oct-2002. Graphs show time course of viraemia (solid),
temperature (red line), clinical score (blue line) and FMDV concentrations (copies/ml) in nasal
swabs (green line) of pigs inoculated/exposed to FMDV O UKG 34/01. Time indicates hours
post inoculation (UR91 - UR94) or exposure (UR95 - UR99, US00 - US10). Results for
US11 - US14 not shown.
B-6
Mpperiuixt>
TableB-3Experimentmini3.Te peratures(°C)ofigsUP50-61.iindic th uo ti ocula ion,






















































































TableB-4Experim ntmini3.Clin calscoreofgsUP50-61.iindi at sh up si ocul tion,














































































































































FigureB-2Experimentm ni3.Graphsshowt cou sefviraemia(s l d),te peraturel n )clinic ls g s(bi iginoc l d intravenouslywithFMDVOUKG34/01.Timeindicat shourspostocul i n.
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FigureB-3Experimentmin14.Graphsshowt cou sefvi aemia(s lid),te peraturel n )dcl ic ls g s(bi iginoc l ed intravenouslywithFMDVOUKG34/01.Timei dicat shourpostinocul i n.
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Table B-7 Experiment min19. FMDV concentrations in serum samples of pigs infected by
intradermal inoculation. Time indicates hours post inoculation.
a morning ... animal killed, no sample collected NVD no virus detected
0 0a 0b 1a 1b 2a 2b 3a 3b 4a
0.0 0.1 7.0 23.5 31.0 47.5 55.0 71.5 79.0 95.5
UW84 NVD NVD NVD NVD NVD 6.50 7.60 9.38 9.61 9.60
UW85 NVD NVD NVD 8.36 7.88 9.71 9.52 6.98
UW88 NVD 3.80 NVD 7.75 8.04 9.68 9.85 7.89
UW89 NVD NVD NVD 7.49 7.75 9.38 9.48 6.70 5.47 3.38
UW92 NVD 4.15 2.88 6.71 7.57 9.46 9.99 9.83
UW93 NVD 2.76 3.61 8.29 8.94 9.77 9.73 6.77
UW96 NVD 4.05 2.35 6.06 6.84 8.82 9.04 8.82
UW97 NVD 4.00 NVD 7.97 8.17 10.03 9.50 6.34
Table B-8 Experiment min19. Temperatures (°C) of pigs infected by intradermal inoculation.
Time indicates hours post inoculation,
a morning ... animal killed, no sample collected
0 1a 2a 3a 4a
0.0 23.5 47.5 71.5 95.5
UW84 38.8 38.5 38.3 38.6 39.8
UW85 39.0 38.8 40.1 39.7
UW88 38.4 38.3 39.7 40.4
UW89 38.6 38.9 41.1 39.4 39.1
UW92 38.4 38.3 38.9 40.5
UW93 38.8 38.6 39.8 40.3
UW96 38.4 38.7 38.5 40.0
UW97 38.3 38.8 40.5 40.3
Table B-9 Experiment min19. Clinical score of pigs infected by intradermal inoculation. Time
indicates hours post inoculation.
a morning ... animal killed, no sample collected
0 1a 2a 3a
0.0 23.5 47.5 71.5
UW84 0 0 0 6
UW85 0 2 6 6
UW88 0 0 6 6
UW89 0 0 5 5
UW92 0 0 6 6
UW93 0 2 6 6
UW96 0 0 3 5
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Time post inoculation (h)
Figure B-4 Experiment min19. Graphs show time course of viraemia (solid), virus
concentration in nasal swabs (green line), temperature (red line) and clinical signs (blue line)




Table B-10 Experiment min22-dose. FMDV concentrations in serum samples of pigs infected
by intradermal inoculation. Time indicates hours post inoculation.
a morning ... animal killed, no sample collected NVD no virus detected
0 0a 1a 2a 3a 4a 5a 6a 7a 8a 9a 10a 11a
0.0 0.1 24.0 49.0 71.5 97.0 120.0 143.0 167.5 191.5 215.5 239.5 263.5
VC88 NVD NVD NVD NVD NVD 7.58 9.28 8.77 4.96
VC89 NVD NVD NVD NVD NVD 7.30 8.80 9.22 6.35
VC90 NVD NVD 4.45 7.22 9.78 7.22
VC91 NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD NVD
VC92 NVD NVD NVD NVD NVD NVD 3.86 NVD 3.91 NVD NVD NVD NVD
VC93 NVD NVD NVD
VC94 NVD NVD NVD 4.47 7.44 8.84 8.07
VC95 NVD NVD NVD 4.66 7.95 8.83 8.50
VC96 NVD NVD NVD 4.99 7.31 10.03
Table B-11 Experiment min22-dose. Temperatures (°C) of pigs infected by intradermal
inoculation. Time indicates hours post inoculation,
a morning ... animal killed, no sample collected
0 1a 2a 3a 4a 5a 6a 7a 8a 9a 10a 11a
0.0 24.0 49.0 71.5 97.0 120.0 143.0 167.5 191.5 215.5 239.5 263.5
VC88 38.6 38.2 38.0 38.4 38.2 39.3 39.5 38.7
VC89 39.9 38.6 38.4 38.6 38.3 38.1 39.2 38.9
VC90 39.1 38.5 38.2 38.5 39.3
VC91 38.4 38.3 38.1 38.0 37.8 38.0 37.8 38.0 37.8 38.0 37.7 37.9
VC92 38.6 38.1 38.0 37.9 38.0 37.9 38.0 37.7 37.9 38.1 37.9 37.8
VC94 38.5 39.0 38.7 38.3 39.9 41.0
VC95 39.0 39.4 39.0 38.6 39.9 40.5
VC96 38.7 39.1 38.9 38.5 40.1
Table B-12 Experiment min22-dose. Clinical score of pigs; infected by intradermal inoculation.
Time indicates hours post inoculation.
a imorning animal killed, no sample collected
0 1a 2a 3a 4a 5a 6a 7a 8a 9a 10a 11a
0.0 24.0 49.0 71.5 97.0 120.0 143.0 167.5 191.5 215.5 239.5 263.5
VC88 0 0 0 0 0 6 6 6
VC89 0 0 0 0 0 3 6 6
VC90 0 0 0 6 6
VC91 0 0 0 0 0 0 0 0 0 0 0 0
VC92 0 0 0 0 0 0 0 0 0 0 0 0
VC94 0 0 0 0 4 5
VC95 0 0 0 0 3 6
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0 24 48 72 96 120 144 168 192 24 48 72 96 120 144 168 192
Time post inoculation (h)
Figure B-5 Experiment min22-dose. Graphs show time course of viraemia (solid), virus
concentration in nasal swabs (green line), temperature (red line) and clinical signs (blue line)





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































o,0 48 96 144 192 240 0 48 96 144 192 240
° Time post-inoculation (h)
Figure B-6 Experiment mini7 showing FMDV concentration in serum (shaded area) and
nasal swab (green line) samples, temperature (red line) and clinical score (blue line - scaled
to fit the y-axis) of pigs (UU82 - UU99, UVOO - UV01).
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04896144922 012 844922 061 4288 Timepost-inoculation(h)
FigureB-7Experimentm n18showingFMDVconcentratiose um(shad da a)asalsw b( rli mples,temp rature(li edli cal score(bluelin-al dtfithy-axis)ofpigs(UW27-U 48).
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